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Dengue virus (DENV), the causative agent of “breakbone fever”, is the most 
important mosquito-borne human pathogen that put more than half of the world’s 
population to be at risk of infection. As of now, the treatment is mainly supportive 
and there is no licensed vaccine or antiviral drug to limit the infection. The interplay 
between viral and host factors dictates the severity of disease and a good 
understanding of this interplay will help to clarify the roles of these factors in severe 
dengue pathogenesis.  
 
The aim of my thesis is to characterize the interaction of nonstructural protein 5 (NS5) 
with its viral replication partner, NS3 and its host nuclear-trafficking partner, 
importin-α/β1. NS5, the largest and most conserved viral protein, has both 
methyltransferase and RNA-dependent RNA polymerase (RdRP) activities that are 
required for RNA type 1 cap formation and viral RNA replication, respectively. 
Although DENV replicates in the cytoplasm, most of the NS5 is found in the nucleus. 
In the cytoplasm, NS5 interacts with NS3, a protease/helicase viral protein to work in 
concert to synthesize viral genomic RNA. Disruption of this interaction is known to 
be lethal to virus. This study fine mapped the interaction region between NS3 and 
NS5 and investigated its impact on virus replication. The interaction site was 
identified to reside within residues 566-585 of NS3 and residues 320-341 of NS5. 
Further sequence interrogation led to the discovery of a conserved residue in NS3, 
N570 to be crucial for NS3-NS5 interaction. Alanine mutagenesis study of NS3:N570 
within DENV2 cDNA infectious clone, in conjunction with a previously characterized 
NS3-NS5 interaction defective mutant NS5:K330A, led to surprising finding. In 
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agreement with previous study, mutation that disrupts NS3-NS5 interaction is lethal. 
However, with thorough characterization, NS3:N570A behaved slightly differently; 
unlike NS5:K330A, it could undergo low, yet unsustainable viral RNA replication. 
With careful quantification using RT-PCR, we observed an accumulation of negative-
sense RNA synthesis with NS3:N570A mutant. This suggests that optimum protein 
interaction affinity between NS3 and NS5 may be required for long term coordinated 
synthesis of negative- and positive-sense RNA. Hence, this study demonstrates for the 
first time that NS3-NS5 interaction may play an important role in the balanced 
synthesis of positive- and negative-strand RNA for robust viral replication. 
 
For NS5 to traffic into the nucleus, NS5 has to interact with host nuclear import 
transporter, importin-α/β1 via its basic residues of nuclear localization signal (NLS) 
and this has only been demonstrated for NS5 of DENV serotype 2. Therefore, in the 
second part of my PhD study, we investigated the nuclear targeting ability of NS5 
from DENV serotypes 1, 3 and 4 and for the first time, we could show in both 
infected and transfected cells that DENV2 and 3 NS5 were predominately nuclear, 
whereas DENV1 and 4 NS5 were more cytoplasmic. Based on this finding, we 
explored further by focusing on DENV1 and 2 NS5 to determine the region on 
DENV1 NS5 that is responsible for its cytoplasmic retention, despite its ability to 
bind to importin-α/β1. This, however, has led to a discovery of a novel dominant NLS 
that resides at the C-terminal end of DENV2 NS5 via extensive swapping of DENV1 
and 2 NS5 gene fragments. Through alanine mutagenesis analysis of NLS sequence, 
we could disrupt the nuclear targeting ability of DENV2 NS5 by mutating 887KR, 
890RR, 887KR+890RR, and when the same mutations were engineered into DENV2 
cDNA infectious clone, 887KR and 887KR+890RR mutations were found to be lethal to 
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virus. Hence, in this study, we have identified a novel C-terminal NLS in DENV2 
NS5 that is important for NS5 nuclear trafficking and virus replication.  
 
Overall, our findings have unexpectedly converged both NS3-NS5 and NS5-importin-
α/β1 interaction sites on thumb subdomain of NS5 RdRP, which collectively suggests 
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Chapter 1: Introduction 
1.1 Dengue epidemiology 
Globally, dengue is the most prevalent and important mosquito-borne viral disease 
and it is endemic in more than 100 tropical and subtropical countries (Figure 1-1). It is 
estimated that 3.6 billion people (>50% of the world's population) are at risk of 
infection and it is estimated to be causing >390 million human infections that results 
in ~100 million symptomatic dengue cases (Bhatt et al., 2013; Gubler, 2012).  
 
Dengue infection in humans results in a wide-spectrum of clinical symptoms, ranging 
from fully asymptomatic to self-limiting dengue fever (DF) and life-threatening 
severe dengue (dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS)), 
which can be caused by any one of the four distinct, but closely related serotypes 
(DENV1-4) (Halstead, 1988). In the last five decades, the global incidence of dengue 
has increased significantly (Figure 1-2) but the main factors that are responsible for 
the increased transmission of dengue may be multifactorial and remains poorly 
understood. However, there seems to be a close correlation between the increased 
global prevalence of dengue cases and unregulated urbanization together with 
overcrowding (Gubler, 1998).  
 
In Singapore, dengue is endemic and all four serotypes co-circulate continuously - a 
situation that is termed as “hyperendemicity”, with DENV1 and DENV2 being the 
most common serotypes in causing dengue infection (Lee et al., 2010b; NEA, 2014). 
Despite effective vector control program since late 1960s (Ng & Ho, 2013) (Ler et al., 
1 
 
2011), we had still two dengue outbreaks that were caused by DENV1 and one that 
was caused by DENV2 in the last decade. The 2005 epidemic has been suggested to 
be due to the sudden switch of the predominant viral serotype, from DENV2 to 
DENV1 that occurred in 2004; this led to dengue epidemic, with 14,006 cases being 
reported and a total of 27 local deaths were observed (Lee et al., 2010b). Again in 
2007, Singapore experienced a DENV2 outbreak, due to a serotype switch from 
DENV1 to a new strain of DENV2 and this resulted in 8,826 cases and 24 fatalities 
being reported (Ler et al., 2011). Lastly, in 2013, the dengue epidemic was driven by 
a new strain of DENV1, which became dominant in March 2013 and was responsible 
for 85% of all diagnosed cases; a total of 22,318 cases were reported (~55% more 
than 2005 outbreak) and fewer deaths were observed (seven local deaths) when 
compared to 2005 outbreak (NEA, 2014). Taken together, it appears that the interplay 
between the viral and host factors is important in shaping the disease outcome, 




Figure 1-1: Global representation of countries or areas where dengue was reported in 2013 by 





Figure 1-2: Average number of total dengue cases reported to WHO from 1955-2010. The y-axis 
denotes the number of cases in log10 scale whereas the x-axis denotes the year when the cases was 
reported. Figure is adapted from (WHO, 2012).  
 
 
1.2 Transmission cycle of DENV 
DENV is transmitted to humans through the bite of infected female Aedes mosquito - 
Aedes aegypti or Aedes albopictus. Aedes aegypti is the principal vector for DENV 
transmission in urban centers (Gubler, 1998). Once a person is bitten by an infected 
mosquito, the virus undergoes an average incubation period of 4 - 7 days, after which 
the person may experience acute onset of fever, which typically last for 3 - 7 days 
(Figure 1-3) and is accompanied by a variety of non-specific signs and symptoms 
(also see section 1.3, Figure 1-4). During the acute febrile period, virus can be 
detected in the peripheral blood and naïve-mosquito can acquire the virus while 
feeding on the blood of infected individual and transmit to others after 8 - 12 days of 





























Figure 1-3: Disease progression of dengue. Following the incubation period, the disease undergoes 
three phases - febrile, critical and recovery. For DF patients, they usually only experience the febrile 
phase for 3-7 days and after which, enters the recovery phase. For DF patients that progress to severe 
dengue, they are placed under strict observation for timely medical intervention if needed. Figure is 
adopted from (Yacoub et al., 2014). 
 
 
1.3 Clinical manifestations 
As mentioned, most DENV infections are usually asymptomatic and symptomatic 
cases make up 10-50% of total dengue infections (the ratio of 
asymptomatic/symptomatic cases is age-dependent (Guzman & Kouri, 2002)). The 
most commonly reported disease manifestation is DF (Kyle & Harris, 2008), which is 
characterized by sudden onset of self-limiting fever and a variety of nonspeciﬁc signs 
and symptoms, including headache, retro-orbital pain, aches/pains, nausea/vomiting, 
weakness, rash and/or any warning signs (Figure 1-4) (Halstead, 2007; WHO, 2009). 
However, in some DF cases, the disease may progress to severe dengue disease 
(DHF/DSS) at late febrile phase around the time of defervescence, when signs of 
thrombocytopenia (platelet count ≤ 100,000/mm3), common haemorrhagic 
phenomena (eg. petechiae, bleeding gums, gastrointestinal bleeding and etc.) and 
increased vascular permeability with intravascular fluid leakage suddenly develop 
(Figure 1-4) (Halstead, 2007; WHO, 2009) and that can be fatal if not correctly 





Figure 1-4: Classification of dengue and severe dengue. Since 2009, the WHO has simplified 
dengue classification to ease the identification of severe dengue cases. Dengue fever patients with 
warning signs are in danger of experiencing severe dengue and are *placed under strict observation for 
timely medical intervention if needed. Figure is adopted from (WHO, 2009).  
 
 
1.4 Pathogenesis of severe dengue  
The most widely accepted hypothesis for severe dengue pathogenesis is antibody 
dependent enhancement (ADE). This phenomenon is well-documented in several 
clinical studies (reviewed by (Halstead, 2007)). It is known that infection with one 
dengue serotype provides life-long protection to that serotype (homotypic immunity) 
and partial immunity to other serotypes in subsequent infection (heterotypic 
immunity). However, it was also observed in experimental human studies that the 
incubation period during secondary infection with heterologous serotype is shorter 
than primary infection, suggesting that a more efficient infection process during 
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secondary infection (Snow et al., 2014) and this is thought to be mediated by 
homotypic antibodies that are generated during primary infection, which can enhance 
the uptake of opsonized virus particles into Fcγ receptor bearing cells (eg. 
macrophages, monocytes and dendritic cells (DC)) (Figure 1-5) during heterologous 
secondary infection; this results in increased number of infected cells (Gollins & 
Porterfield, 1986), which may lead to higher viral load and increased disease severity 
in dengue infected patients (Libraty et al., 2002a; Simmons et al., 2007; Thomas et 
al., 2008; Wang et al., 2003; Wang et al., 2006).  
 
Another proposed hypothesis for severe dengue phenomenon is “original antigenic 
sin”, which is mediated by activated T cells (Mongkolsapaya et al., 2003). In this 
context, it is thought that during secondary infection with a heterologous serotype, re-
activation of cross-reactive low avidity T cells from the first exposure results in high 
level of proinflammatory cytokine secretion and higher level of viremia due to 
delayed viral clearance (Mongkolsapaya et al., 2003). However, this hypothesis is 
challenged by the observation that heterologous T-cell responses are not always 
required to produce severe dengue in infants because when maternal anti-dengue 
antibody titer drops below the protective level, infants are at increased risk for 
development of severe dengue even though they have never been exposed to DENV 





In both hypothesis, elevated cytokine (eg. TNF-α, IFN-γ, IL-6, IL-8 and IL-10) levels 
may play a direct role in immunopathogenesis of severe dengue in secondary 
infection by increasing vascular permeability (Chakravarti & Kumaria, 2006; Juffrie 
et al., 2001; Nguyen et al., 2005; Pang et al., 2007; Perez et al., 2004; Raghupathy et 
al., 1998). However, these theories cannot explain the occurrence of severe dengue 
during primary infection and other studies have also demonstrated the potential 
occurrence of severe dengue during primary infection with either certain virus 
serotypes (Chau et al., 2008; Duyen et al., 2011; Fried et al., 2010; Tricou et al., 
2011) or strains that are considered more virulent (Kanakaratne et al., 2009; Rabaa et 
al., 2010; Vasilakis & Weaver, 2008b) or among at-risk individuals (eg. age, gender, 
host genetics factors and etc.) (reviewed by (Whitehorn & Simmons, 2011)).  
 
Collectively, there is no clear molecular mechanistic evidence that can specifically 
pinpoint secondary infection, viral virulence factor or host susceptibility as the major 
cause for severe dengue pathogenesis, and instead a complex interplay among these 
factors are probably involved (reviewed by (Acosta et al., 2014; Gubler, 1998; 
Whitehorn & Simmons, 2011)). Nevertheless, there is an urgent need to understand 
how these factors interact with the host immune system to cause severe dengue 
symptoms like increased vascular permeability in order to assist the development of 






Figure 1-5: Antibody-dependent enhancement phenomenon. ADE typically occurs during 
secondary infection with heterologous serotype when homotypic antibodies that are generated during 
primary infection bind to the current infecting DENV particles but cannot neutralize the virus; the 
antibody-virus complex binds to Fcγ receptor of circulating immune cells (eg. macrophages, monocytes 
and DC) and this facilitates the uptake of the virus into immune cells that are not readily infected in the 
absence of antibody. This in turn may lead to higher viral load and increased disease severity in dengue 
infected patients. Figure is adopted from (Whitehead et al., 2007). 
 
 
1.5 Genome organization and taxonomy of DENV  
DENV is a member of the Flavivirus genus, and together with Pestivirus and 
Hepacivirus, and the newly approved Pegivirus genus (Stapleton et al., 2011; Viruses, 
2014), they belong to the Flaviviridae family that share some similarities in virion 
morphology, genome organisation and replication strategy (Lindenbach et al., 2007). 
Genome organisation is similar among the flaviviruses and yet, distinct from 
pestiviruses, hepaciviruses and pegiviruses (Hulo et al., 2011; Kapoor et al., 2013; 
Leyssen et al., 2000; Quan et al., 2013) (Figure 1-6). The flavivirus RNA genome is 
of positive polarity and it is ~11kb long. It contains a type 1 cap structure at the 5’ end 
but lack a poly A tail at the 3’ end. It encodes a single open reading frame that codes 
for three structural (C (capsid), prM (pre-membrane) and E (envelope)) and seven 
nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) and is 
flanked by 5’- and 3’-untranslated regions (UTRs). Both 5′- and 3′-UTRs contain 
highly structured regulatory RNA elements that are crucial for translation and viral 
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RNA replication and they interact extensively to form combined secondary structures 
for efficient replication (also see Figure 1-14, reviewed by (Acosta et al., 2014) and 




Figure 1-6: Genomic organization of members of the Flaviviridae family. The viral genome is a 
single-stranded positive-sense RNA molecule that is either capped in ﬂaviviruses or contains an IRES 
(internal ribosome entry site) in pestiviruses, hepaciviruses and pegiviruses in 5’-UTR, at the N-
terminal end of the genome. 3’-UTR is also present at the C-terminal end of the genome. The genes 
that encoded the structural and nonstructural (NS) proteins are indicated in red and green, respectively. 
The approximate genome size is also indicated. Figure is adapted from (Leyssen et al., 2000), with new 
information incorporated from (Hulo et al., 2011; Kapoor et al., 2013; Quan et al., 2013).  
 
 
The Flavivirus genus contains at least 70 viral species, many of which are transmitted 
by arthropod vectors (eg. mosquitoes and ticks). A number of these flaviviruses are 
medically important human pathogens that are of major global concern, and they 
include DENV (serotype 1-4) (Figure 1-7, boxed in red), Japanese encephalitis virus 
(JEV), Tick-borne encephalitis (TBE), Murray Valley encephalitis virus (MVEV), 
Saint Louis encephalitis virus (SLEV), West Nile virus (WNV) and Yellow fever 
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virus (YFV) (Figure 1-7, boxed in grey), which cause fevers, encephalitis, and 
hemorrhagic fevers (Gubler et al., 2007; Lindenbach et al., 2007; Mackenzie et al., 
2004). Among the flaviviruses, DENV infection causes the highest morbidity and 
mortality (Halstead, 1997), and in recent years, a possible fifth serotype that spilled 
over from a sylvatic cycle has been identified in human, but its impact on public 




Figure 1-7: Phylogenetic tree of Flavivirius genus based on the analysis of partial NS5 amino acid 
sequences that were obtained from Genbank library. The tree was constructed using neighbor 
joining method. The bootstrap value for each major clade is indicated. The four serotypes of DENV are 
boxed in red whereas the other medically important flaviviruses are boxed in grey. Figure is adopted 




Viruses of the Flavivirus genus are further classified into three distinct groups 
depending on their vector association and antigenic relationships: [1] tick-borne, [2] 
mosquito-borne and [3] viruses with no known arthropod vector (Vasilakis & Weaver, 
2008b). DENV is a mosquito-borne flavivirus vectored predominantly by Aedes 
mosquito, contain four antigenically related but genetically distinct dengue viruses, 
termed as DENV serotype 1-4 (Figure 1-7, boxed in red) (Heinz et al., 2000). The 
amino acid conservation among four serotypes is 62-67% (Westaway & Blok, 1997). 
Phylogenetically, DENV1 and 3 are more closely related, whereas DENV4 is the 
most divergent serotype and it is closer to DENV2 than DENV1 and 3. The advent of 
full-length genome sequencing has further subdivided each serotype into ~four 
(DENV 3 & 4) or five (DENV 1 &2) genotypes, where nucleotide sequence 
divergence is not greater than 6% (Rico-Hesse, 1990; Vasilakis & Weaver, 2008b). 
 
 
1.6 Molecular biology of DENV 
1.6.1 Structure of dengue viral particles 
Electron micrographs of mature flavivirus particles showed that these particles have a 
diameter of ~50 nm and they contain an electron dense ribonuclear core of ~30 nm 
(Lindenbach et al., 2007). The nucleocapsid is composed of a single molecule of 
genomic RNA that is associated with ~180 copies of highly basic C protein and it is 
surrounded by host-derived lipid bilayer (Zhang et al., 2007) that contains ~180 
copies of each E and M proteins; the E proteins are organized into 90 tightly packed, 
head-to-tail dimers (Figure 1-8A) that lie flat on the surface of the viral membrane to 
form the external protein shell (Figure 1-8B) (Kuhn et al., 2002). The E protein is the 
major antigenic determinant on virus particles and its role in mediating receptor 
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binding and membrane fusion to facilitate virus entry and that offers a potential target 
for antiviral inhibitors or neutralizing antibodies. The M protein is a small proteolytic 
fragment that is derived from its precursor prM during the maturation of virus 
particles in trans-Golgi network (TGN) and its role in mature virus is unknown.  
 
 
Figure 1-8: DENV envelope protein and its arrangement on mature virion surface. (A) 
Conformation of soluble E homodimers on mature virion surface at neutral pH. The stem and 
transmembrane anchor are not shown in the structure. Figure is adopted from (Modis et al., 2004). (C) 
Packing of E on the surface of a mature virion. 90 E homodimers are arranged on an icosahedral lattice. 







1.6.2 DENV replication cycle 
The infection cycle starts with the attachment of virus particles onto the surface of 
susceptible cells, which include macrophages, monocytes and DCs (Figure 1-9). This 
attachment is mediated by the binding of viral envelope (E) protein to a varied array 
of surface receptors (eg. Fcγ receptor (orange), DC-sign (green), cognate receptor 
(red, ie heparin sulfate, heat shock proteins, CD14 associated proteins, high-affinity 
laminin receptor and etc.), reviewed by (Hidari & Suzuki, 2011)) that allows virus 
entry by receptor-mediated endocytosis. The low pH in late endosome triggers the 
fusion of the viral envelope and host endosome membrane that is mediated by the 
structural rearrangement of E proteins and this leads to the release of the nucleocapsid 
into the cytoplasm. In the cytoplasm, the nucleocapsid dissociates to release viral 
RNA for translation of polyprotein by ribosomes that are located at the membrane of 
rough endoplasmic reticulum (ER). The resulting polyprotein is cleaved by a 
combination of host and viral proteases into three structural proteins (C, prM and E) 
and seven nonstructural (NS; NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) 
proteins. The NS proteins, possibly together with host proteins, induce membrane 
invaginations into the ER lumen to generate vesicles that remain connected to the 
cytoplasm via pore-like openings (Welsch et al., 2009). It is assumed that the vesicle 
interior contains the replication complex (RC) that is responsible for viral RNA 
replication. The virus-encoded NS5 RNA-dependent RNA polymerase (RdRP), 
together with helicase and ATPase activities of NS3, synthesizes a complementary 
negative-strand that is then used as a template for the amplification of genomic RNAs. 
The genomic RNA contains a type 1 cap structure (7meGpppA2′-O-me, see Figure 1-12A 
for cap structure) at the 5’ end, which is generated by methyltransferase (MTase) and 
putative guanylyltransferase (GTase) activities of NS5, in conjunction with RNA 5’-
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triphosphatase (RTPase) activity of NS3. Newly synthesized viral RNA interacts with 
C proteins to form nucleocapsid that bud into the ER lumen, at E- and prM-rich 
microdomains to form immature virions. The immature virions are transported from 
the ER to TGN via the typical secretory pathway. While passing through the TGN, the 
host protease furin cleaves prM protein into the pr peptide that remains bound to 
virion surface under acidic pH to prevent pre-mature fusion before virus release. The 
secretion of virion into extracellular milieu is accompanied by the release of pr 
peptide when exposed to neutral pH and this gives rise to mature infectious virions 





Figure 1-9: Schematic representation of the DENV replication cycle. The virus enters the cell by 
receptor mediated endocytosis. Membrane fusion between viral envelope and host endosome 
membrane leads to the release of the nucleocapsid into the cytoplasm. In the cytoplasm, the 
nucleocapsid dissociates to release viral RNA for translation. The viral RNA is translated by ribosomes 
to produce a single polyprotein that is being cleaved by viral and host proteases into three structural 
proteins (C, prM and E) and seven nonstructural (NS; NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS5) proteins. Replication takes place in RCs that reside in virus-induced vesicles. Newly synthesized 
viral RNA interacts with C proteins to form nucleocapsid that bud into the ER lumen, at E- and prM-
rich microdomains to form immature virions. These immature virions are released from the cell via 
secretory pathway. Virus maturation occurs in TGN where host protease furin cleaves prM protein into 
the pr peptide. Mature virions are secreted into the extracellular milieu.  
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1.6.3 Translation and polyprotein processing 
Following the uncoating of nucleocapsid in cytoplasm, the 5’ capped RNA genome 
serves as mRNA for translation of viral proteins. Translation from a single ORF 
produces a ~3300 amino acids long polyprotein that is processed co- and post-
translationally by both host and viral proteases into 10 individual proteins. The N-
terminal region of the polyprotein encodes structural proteins (C-prM-E) that are 
involved in the formation of virions whereas the C-terminal region of the polyprotein 
encodes seven NS proteins (NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) that form the 
RC for genome replication (Lindenbach et al., 2007). The NS3, together with its co-
factor, NS2B forms the viral protease that cleaves the protein junctions between 
C/prM, NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4A/NS4B and NS4B/NS5 whereas 
signalase, an ER resident host protease, cleaves the protein junctions between C/prM, 
prM/E, E/NS1 and NS4A/NS4B (Figure 1-10). Furin, a Golgi-resident endoprotease is 
involved in virion maturation by cleaving prM to pr peptide and M protein during the 
transit of the immature virion prior to release. The protease cleaving NS1/2A junction 





Figure 1-10: Proposed topologies of the viral proteins with respect to the ER membrane and the 
enzymes that are involved in processing the polyprotein. Structural proteins are shown in red and 
NS proteins are shown in green. The viral and host proteases that are involved in polyprotein 
processing are indicated. The NS3, together with its co-factor, NS2B forms the viral protease that 
cleaves the protein junctions between C/prM, NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4A/NS4B and 
NS4B/NS5 whereas signalase, an ER resident host protease, cleaves the protein junctions between 
C/prM, prM/E, E/NS1 and NS4A/NS4B (Figure 1-10). Furin, a Golgi-resident endoprotease is involved 
in virion maturation by cleaving prM to pr peptide and M protein during the transit of the immature 
virion prior to release. The protease cleaving NS1/2A junction remains to be determined.  
 
 
1.6.4 Functions of dengue viral proteins 
Following polyprotein processing, three structural proteins (C, prM and E) and seven 
NS (NS; NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins are released to 
perform their functions, such as formation of virions and RC, respectively 


























































































































































































































































































































































1.6.4.1 Structural proteins 
a) Capsid protein 
Capsid is a ~11 kDa (114 amino acids) highly basic protein that together with the viral 
RNA genome, forms the nucleocapsid. It can bind viral RNA with high affinity and 
has RNA chaperone activity (Pong et al., 2011). The capsid protein exists as dimers in 
solution and each monomer comprises of four alpha helices (Jones et al., 2003). 
Through nuclear magnetic resonance study, the dimer revealed an asymmetric 
distribution of basic residues on protein surface; about half of the basic residues lie on 
one side of the dimer to interact with viral RNA, while the conserved hydrophobic 
residues form an extensive apolar surface on the opposite side of the dimer to interact 
with viral membrane (Figure 1-11) (Ma et al., 2004). In infected cells, the protein 
localizes to the nucleus and nucleoli (Makino et al., 1989; Wang et al., 2002) and it is 
mediated by two monopartite nuclear localization signals (NLS) (within residues 6-9 
and 73-76) and one bipartite NLS (within residues 85-100); mutagenesis study 
showed that 73KK and 85RK are important for its nuclear localization, interaction with 
DAXX (Death domain-associated protein 6) and induction of apoptosis (Netsawang et 
al., 2010). Intriguingly, the protein also localizes to the surface of cytoplasmic lipid 
droplets and through mutagenesis study, disrupting its lipid droplet targeting ability 




b) Membrane protein  
Precursor of membrane (prM) protein is ~26 kDa and it plays an important regulatory 
role during virus entry and exit (Hsieh et al., 2011). Uncleaved prM is 166 amino long 
and the first 91 amino constitutes the pr peptide. Cleavage of prM into soluble pr 
peptide and membrane-associated M protein is mediated by Golgi-resident 
endoprotease furin that recognizes the highly conserved RR(D/E)KR sequence in pr 
domain (Keelapang et al., 2004). The role of pr peptide is thought to prevent the pre-
mature fusion of E protein before virus release (Lindenbach et al., 2007) and this is 
supported by the crystal structure of prM-E protein complex that showed the binding 
of pr peptide to the fusion loop of E protein (Figure 1-11) (Li et al., 2008). In 
agreement to that, virus preparations derived from furin-deficient cells contained high 
numbers of prM-containing viral particles and they were unable to infect (Zybert et 
al., 2008), which further supports the proposed function of pr peptide. Intriguingly, 
these immature particles became infective when complexed with anti-prM , which 
might be Fc receptor mediated (Dejnirattisai et al., 2010; Richter et al., 2014; 
Rodenhuis-Zybert et al., 2010) and this poses a concern for vaccine development 
because prM protein is present in DENV vaccine (eg. live attenuated, recombinant or 
inactivated virus) (Whitehead et al., 2007) and this may increase the risk of ADE in 




c) Envelope protein  
Envelope (E) is a 56 kDa (495 amino acids) membrane-associated glycoprotein and it 
is the major component of the virion surface. It is involved in virion assembly, 
receptor binding, membrane fusion and induction of protective anti-DENV antibody. 
The E protein is synthesized as a type I membrane protein containing twelve 
conserved cysteines that form six disulphide bonds and it is N-glycosylated (Deubel et 
al., 1991; Men et al., 1991). The proper folding of E requires co-synthesis with prM 
(Lindenbach et al., 2007). The N-terminal ectodomain of E contains three β-barrel 
domains, domain I, II and III (EDI, EDII and EDIII, coloured in red, yellow and blue, 
respectively (Figure 1-8A and 11). Domain II is involved in the dimerization of E 
protein, whereas domain III is responsible for receptor binding. The fusion loop is 
found at the tip of domain II and its role is to interact with host endosomal membrane 
during fusion (Modis et al., 2005). The C-terminal domain has a stem region 
containing two α-helices that are connected by a stretch of conserved sequences and 
an anchor region containing two TM domains (Lin et al., 2011). The glycosylation of 
E protein has been shown to be important for production of viral particles and 
infection of DC-SIGN expressing cells (Alen et al., 2012; Bryant et al., 2007; Lee et 




1.6.4.2 Nonstructural proteins 
a) NS1  
NS1 is a 46 kDa (352 amino acids) glycoprotein that plays an essential yet unclear 
role in viral replication. In mammalian cells, it exists in two major forms: membrane-
associated and secreted forms (Muller & Young, 2013). NS1 monomeric form is 
water-soluble and it becomes membrane-associated once it dimerizes (Winkler et al., 
1989; Winkler et al., 1988). It resides in ER lumen and it co-localizes with double-
stranded RNA (dsRNA) in both insect (Mackenzie et al., 1996) and mammalian 
(Welsch et al., 2009) cells. When NS1 was expressed together with the first 26 amino 
acids of NS2A, NS1 localized to the plasma membrane via 
glycosylphosphatidylinositol (GPI) anchor; this is in line with the report that ~20% of 
surface-expressed NS1 in infected cells were GPI-linked and this linkage may 
associate NS1 to lipid raft to mediate signaling cascade common to GPI-anchored 
proteins when specific antibodies are present (Jacobs et al., 2000; Noisakran et al., 
2008a; Noisakran et al., 2007). Recently, the crystal structure of NS1 was solved and 
NS1 was shown to have three domains: β-roll dimerization domain, wing domain and 
β-ladder domain; the β-roll dimerization domain enables NS1 dimerization and it also 
forms a hydrophobic protrusion with the connector subdomain of wing domain, which 
is thought to mediate the interaction of dimeric NS1 with the ER membrane and the 





Secreted NS1 is hexametric and inhibition of glycosylation affects the secretion of 
hexameric form (Flamand et al., 1999; Somnuke et al., 2011). Cryo-electron 
microscopy study revealed that the secreted NS1 hexamer forms a lipoprotein particle 
with open-barrel protein shell and a central channel rich of lipids, predominantly 
triglycerides; interestingly, the composition of these lipids highly resembled high-
density lipoprotein and inhibiting lipid biosynthesis reduced NS1 secretion, implying 
that host lipids may play an essential role in NS1 secretion (Gutsche et al., 2011). The 
amount of secreted NS1 appears to be significantly higher in sera of patients with 
DHF rather than DF (Libraty et al., 2002b), which can be a cause or consequence of 
plasma leakage. In addition, both secreted and surface-expressed NS1 are capable of 
modulating complement activation pathways through binding to proteins of 
complement system or the formation of immune complexes (Avirutnan et al., 2010; 
Avirutnan et al., 2006; Chung et al., 2006; Kurosu et al., 2007). 
 
b) NS2A 
NS2A is a 22 kDa (218 amino acids) integral membrane protein that plays an 
important role in viral RNA replication. According to proposed topology model, 
NS2A contains five TM helices; the N- and C-terminal faces the ER lumen and 
cytoplasm, respectively (Xie et al., 2013). Based on nuclear magnetic resonance 
study, the first TM domain was solved and it was shown to contain two helices that is 
connected by “helix breaker” (Pro85) (Figure 1-11) (Xie et al., 2013). Through 
mutagenesis study, NS2A was shown to be important for viral RNA synthesis and 
virus assembly/maturation (Xie et al., 2013; Xie et al., 2015) but the underlying 




NS2B is a 14 kDa (130 amino acids) integral membrane protein that serves as an 
essential cofactor for NS3 serine protease activity and it recruits NS3 to ER 
membrane. It was predicted to have two N-terminal TM helices and a membrane-
associated C-terminal domain that is connected by hydrophilic cytoplasmic domain; 
the hydrophilic domain contains a 47 amino acids long region (residues 49-95) that is 
essential for NS3 folding and activity (Clum et al., 1997; Erbel et al., 2006; Falgout et 
al., 1991; Luo et al., 2008a). NS2B-NS3 protease interaction via the 47 amino acids 
long region induces structural remodeling of the protease domain to facilitate 
cleavage sequence recognition and substrate binding (Zuo et al., 2009). It was 
suggested that NS2B may play the main role in anchoring NS3 and NS5 to NS2A, 
NS2B and NS4B in RC (Yu et al., 2013) and this has been evidenced by the co-
localization of NS2B with dsRNA in RC (Welsch et al., 2009).  
 
d) NS3 
NS3 is a multifunctional protein and it is the second largest (69 kDa, 618 amino acids) 
viral protein (Lindenbach et al., 2007). It contains a N-terminal protease domain (Li et 
al., 1999b), and a C-terminal domain that has helicase, RNA-stimulated nucleoside 
triphosphatase (NTPase), and RNA 5’-triphosphatase (RTPase) activities (Benarroch 
et al., 2004; Cui et al., 1998; Preugschat et al., 1990; Wengler, 1993; Xu et al., 
2005b). The protease domain, works in concert with its NS2B cofactor, is responsible 
for cleaving the viral polyprotein (see section 1.6.3). On the contrary, its helicase 
domain, together with NS5 RdRP and MTase activities, is involved in viral RNA 
replication and type 1 cap formation, respectively. During viral RNA replication, the 
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helicase activity is thought to be required for unwinding of duplex RNA and/or 
secondary structure of single-stranded RNA whereas the NTPase activity provides the 
energy for helicase unwinding activity. During type 1 cap structure formation, the 
RTPase activity is responsible for removing the γ-phosphate from 5’triphosphorylated 
RNA, which has to occur before NS5 MTase can catalyze the subsequent reaction 
(also see Figure 1-12B) (Wang et al., 2009a; Xu et al., 2005b). In infected cells, NS3 
co-localises with dsRNA and NS4B proteins in perinuclear region (Welsch et al., 
2009) and it was shown to interact with both NS4B (Umareddy et al., 2006a) and 
hypophorylated NS5 (Kapoor et al., 1995); these findings are consistent with the role 
of NS3 in viral RNA replication in RC. Apart from its interaction with viral proteins, 
NS3 has also been shown to interact with the host protein fatty acid synthase (FAS); 
this interaction is mediated by the protease domain and through this interaction, it 
enhances the activity of FAS and recruits FAS to areas of viral replication to possibly 
establish or expand the membranous replication vesicles (Heaton et al., 2010).  
 
The N-terminal of NS3 (residues 1-168) encodes a trypsin-like serine protease that 
contains the typical catalytic triad of His-53, Asp-77 and Ser-138 in its active site. For 
it to function as an active protease, it has to interact with the hydrophilic region of 
NS2B (residues 49-95) (Leung et al., 2001). Without NS2B49-95, NS3 is known to be 
insoluble and hence, in order to obtain soluble active form of NS3 protease for 
crystallization, NS3 protease was expressed as a fusion construct with NS2B49-95 that 
was connected by flexible glycine linker (G4SG4) (Leung et al., 2001; Li et al., 2005). 
The crystal structure of DENV protease revealed a chymotrypsin-like fold with two β-
barrels and each barrel is formed by six β-strands; the barrel interface contains the 
catalytic triad. In the presence of inhibitor, the C-terminal region of NS2B (residues 
25 
 
67-95) form a conserved β-turn hairpin that wraps around the C-terminal β-barrel of 
NS3 to form a “closed” conformation and this allows the β-turn hairpin to bind to 
hydrophobic S2 and S3 pockets in the substrate binding site to interact directly with 
inhibitor (Aleshin et al., 2007; Erbel et al., 2006; Noble et al., 2012). Hence, this 
collectively implies that residues 67-95 is needed for NS3 proper folding and catalytic 
activity.  
 
The C-terminal domain of NS3 is a multifunctional protein (residues 180-618) and it 
is a member of the superfamily 2 (SF2) that contains the DEAH sequence motif 
(Gorbalenya et al., 1989). NS3 helicase contains three domains and the crystal 
structure revealed the RecA-like fold of domain I and II, which is composed of six β-
strands that are surrounded by four and three α-helices, respectively (Xu et al., 
2005b). For domain III, it is composed of two β-strands and approximately five α-
helices. The ATPase and RTPase activities are found in domains I and II whereas the 
single-stranded RNA binding groove is found at the interface of the three domains. 
NS3 helicase activity was shown to be ATP- and Mg2+-dependent (Benarroch et al., 
2004) and its interaction with NS4B promotes its dissociation from single-stranded 
RNA, which subsequently enhances its helicase activity (Umareddy et al., 2006a). Its 
NTPase and RTPase activities were also found to Mg2+-dependent and both activities 
could be stimulated by NS5 (Cui et al., 1998; Yon et al., 2005); through biochemical 
and mutagenesis studies, it was suggested that NTPase and RTPase may share a 
common active site (Bartelma & Padmanabhan, 2002). Similarity, mutations affecting 
helicase activity also reduced RTPase activity (Benarroch et al., 2004), suggesting 
that the helicase, NTPase and RTPase activities may be functionally coupled.  
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The structure of DENV4 full-length NS3 revealed an elongated conformation with 
protease domain sits underneath the ATP binding site of helicase (Luo et al., 2008a); 
the protein can also adopt a different relative orientation of the protease and helicase 
(protease domain rotated by ~161° with reference to the helicase domain) domains 
due to flexibility of the two domains that is mediated by linker region (residues 169-
179) and it appears that the linker region has evolved to an optimum length to confer 
flexibility to full-length NS3 protein that is required for both polyprotein processing 
and RNA replication.(Luo et al., 2010). The two conformations of NS3 protein 
probably reflect the different conformations that are being adopted by the protein to 
perform its various functions during virus life cycle.  
 
e) NS4A 
NS4A is a 16 kDa (150 amino acids) integral membrane protein that plays an 
important role in viral replication. It was shown to co-localize with dsRNA, NS3 and 
NS4B in RC (Miller et al., 2007; Welsch et al., 2009; Zou et al., 2015b). It is only 
viral protein that was demonstrated to have membrane curvature-inducing activity 
when expressed on its own, suggesting that NS4A may play a major role in 
replication vesicle formation; biochemical study suggests that NS4A contains three α-
helical segments that give rise to its peculiar membrane topology, which may explain 
its membrane curvature-inducing activity (Miller et al., 2007). A recent study 
suggests that NS4A contains an N-terminal amphipathic α-helix (residues 3-20) and 
mutations affecting this helix have reduced ability to oligomerize and have 
impairment in RNA replication, implying that NS4A self-oligomerization may be 




NS4B is a 30 kDa (248 amino acids) integral membrane protein that plays an 
important role in viral replication. It was shown to co-localize with dsRNA, NS3 and 
NS4A proteins in RC (Umareddy et al., 2006b; Welsch et al., 2009; Zou et al., 
2015b). NS4B exists as dimers in transfected and infected cells (Zou et al., 2014) and 
it contains three TM segments, as well as N- and C-terminal segments that face ER 
lumen and cytoplasm (Miller et al., 2007). Mutational studies on NS4B showed that it 
is crucial for virus replication in cell culture and animal models (Grant et al., 2011; 
Kelly et al., 2010; Orozco et al., 2012) (Zou et al., 2014). NS4B might be a key 
determinant of cytokine secretion like TNF-α, IFN-γ, IP-10, IL6 and IL-8 in infected 
cells (Kelley et al., 2011). 
 
g) NS5 
NS5 is the largest (103 kDa, 900 amino acids) and most conserved protein among all 
viral proteins (Lindenbach et al., 2007). Its N-terminal domain contains MTase 
(Egloff et al., 2002; Egloff et al., 2007; Kroschewski et al., 2008) and putative GTase 
activities (Issur et al., 2009) that are involved in type 1 cap formation, whereas its C-
terminal harbors RdRP activity that is responsible for viral RNA replication with NS3 
(Yap et al., 2007). In infected cell, DENV2 NS5 is known to interact with NS3 
(Kapoor et al., 1995) and to also, shuttle between the cytoplasm and nucleus (see 
section 1.9 for more information) (Brooks et al., 2002; Kumar et al., 2013; Pryor et 
al., 2007; Rawlinson et al., 2009). NS5 was shown to be a potent TNF-α, IL-6 and IL-
8 inducer (Kelley et al., 2011; Medin et al., 2005), and its IL-8 inducing ability seems 
to correlate with NS5 nuclear localization and infectious virus production (Pryor et 
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al., 2007; Rawlinson et al., 2009). It was demonstrated that DENV2 NS5 can bind to 
STAT2 to promote UBR4-mediated STAT2 degradation by bridging STAT2 and 
UBR4, an E3 ligase that recognizes and degrades proteins and this results in inhibition 
of type I interferon signaling (Ashour et al., 2009; Mazzon et al., 2009; Morrison et 
al., 2013). 
 
NS5 MTase has two binding sites: a S-adenosyl-L-methionine (SAM) binding site 
and a RNA cap site for binding to guanosine of the cap structure (Egloff et al., 2007). 
Its MTase domain possesses two methylation activities: guanine-N7 (Kroschewski et 
al., 2008) and nucleoside 2'-O methylation (Egloff et al., 2002). The current model for 
the formation of type 1 cap structure assumes four sequential steps: [1] the RTPase 
activity of NS3 removes 5′ γ-phosphate from newly synthesized RNA (Benarroch et 
al., 2004; Xu et al., 2005a), [2] the newly identified GTPase activity of NS5 may cap 
the RNA 5′-diphosphate end with guanosine monophosphate (GMP) through a 5′ to 5′ 
phosphodiester bond (Issur et al., 2009), [3] the guanine-N7 methylation activity of 
NS5 transfers a methyl group to the N7 position of the guanine moiety to form a cap 0 
structure (7meGpppA-RNA) (Zhou et al., 2007) and [4] lastly, the 2'-O methylation 
activity of NS5 catalyzes methylation at the ribose 2′-O position of adenosine to form 
type 1 cap structure (7meGpppA2′-O-me-RNA) (Egloff et al., 2002) (Figure 1-12B). Time 
course experiment showed that N7-methyltion occurs before 2’O-methylation 
(Selisko et al., 2010) and both use SAM as methyl donor for methylation (Noble et 
al., 2010). Through mutagenesis study, N7-methyaltion was found to be important for 
virus replication (Zhou et al., 2007). Recently, a 2’-O MTase mutant virus (216EA 
in DENV1 and 217EA in DENV2) that was shown to replicate like WT in cell 
culture but poorly in mice and rhesus monkeys were able to induce protection in 
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rhesus monkeys during homologous challenge, hence demonstrating the potential of 




Figure 1-12: Type 1 cap formation by NS5 MTase and NS3 RTPase activities. A) The mRNA cap 
structure. The cap structure consists of an N-7 methylguanosine, a triphosphate bridge and one or two 
2′-O methylnucleotide(s). The N-7 and 2′-O methyl groups are indicated in blue. B) Four enzymatic 
activities are required for type 1 cap formation: 5′ RTPase, GTase, N-7 MTase and 2′-O MTase. 5′ 
RTPase activity (blue) is performed by NS3. N-7 MTase (red) and 2′-O MTase (green) activities are 
performed by NS5 and GTase (orange) acitivty is thought to be performed by NS5 too. SAM is the 




The RdRP domain of DENV3 has the classical “cupped right hand” architecture with 
fingers, palm and thumb subdomains that have been described for various flaviviruses 
(Lim et al., 2013b; Lu & Gong, 2013; Malet et al., 2007; Yap et al., 2007). The βNLS 
and α/βNLS (reside in residues 320-405), which was originally thought to be an 
interdomain linker region between MTase and RdRP were found to be an integral part 
of RdRP domain and is distributed between the fingers and thumb subdomains. The 
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highly conserved palm domain contains four out of the six conserved sequence motifs 
that are important for NTP binding and catalysis, including the GDD catalytic active 
site. Its active site is encircled by several loops to form a tunnel that can direct the 
RNA template strand to the active site (Yap et al., 2007). The thumb subdomain 
contains the most structurally variable elements among the known polymerase 
structures that help to shape the RNA template tunnel and possibly regulate the entry 
and exit of template into active site, and also the priming loop that is involved in de 
novo initiation (Yap et al., 2007). Functional mutagenesis study of two conserved 
cavities of thumb subdomain led to the identification of residues K328, Y859 and 
I863 that are crucial for de novo initiation but not elongation, and also residue K330 
that is involved in NS3-NS5 interaction (Zou et al., 2011).  
 
Recently, the structure of compact form of DENV3 full-length NS5 was solved and it 
revealed a different relative orientation of the MTase and RdRP (MTase domain 
rotated by 105° with reference to the RdRP domain) (Zhao et al., 2015) when 
compared to extended form JEV full-length NS5 structure (Lu & Gong, 2013), despite 
the similarity in the overall shape of DENV3 and JEV NS5s.The differences in the 
length, sequence and structure of linker, as well as the molecular nature of MTase-
RdRP binding interface between DENV3 and JEV NS5s led to two NS5 
conformations that may reflect the different conformations that are being adopted by 




1.6.5 RNA replication in flavivirus replication complex  
DENV replication presumably occurs in perinuclear virus-induced vesicles that 
contain the RC, where viral RNA, viral proteins and host proteins participate in many 
important RNA-RNA, RNA-protein and protein-protein interactions to ensure 
efficient viral RNA replication (Chen et al., 1997; Uchil & Satchidanandam, 2003). 
By electron microscopy and tomography, virus-induced vesicles are shown to be 
derived from the invagination of ER membrane (Welsch et al., 2009) and they are 
demonstrated to contain all NS proteins and dsRNA by immuno-electron microscopy 
and light microscopy (Chen et al., 1997; Uchil & Satchidanandam, 2003; Welsch et 
al., 2009). 
 
The replication of viral genome starts at the 3’end of the positive-strand genome to 
synthesize negative-strand RNA that in turn acts as template for additional positive-
strand RNA in 10-100 fold excess of negative-strand (Tomassini et al., 2003). Three 
major species of labeled DENV RNA have been described, including genomic RNA 
that is RNase sensitive, a double-stranded replicative form (RF) that is RNase 
resistant and, a heterogeneous population of replicative intermediate (RI) that is 
partially RNase resistant. RF is composed of genome-length positive- and negative-
strand RNAs and it serves as the recycling template for positive-strand production. RI 
is essentially RF that contains an additional positive-strand RNA molecule and its 
synthesis is necessary for the progression of replication cycle (Chu & Westaway, 




1.6.6 NS protein-protein interactions within replication complex 
Protein-protein interaction between several viral NS proteins of RC have been 
described, including that of DENV NS2B and NS3 (Phong et al., 2011), NS4A and 
NS4B (Zou et al., 2015b), and NS1 and NS4B self-dimerization (Figure 1-13) (Akey 
et al., 2014; Zou et al., 2014) by pulldown assay, NS3 and NS4B (Umareddy et al., 
2006b; Zou et al., 2015a), and NS3 and NS5 by yeast two-hybrid (Y2H) and protein-
complex immunoprecipitation (co-IP) studies (Brooks et al., 2002; Kapoor et al., 
1995; Mairiang et al., 2013; Moreland et al., 2012). In vitro binding studies on Kunjin 
virus proteins showed that NS2A could bind strongly to 3’UTR, NS3 and NS5, while 
NS4A could bind strongly to itself, NS3 and NS5 strongly and bind weakly to 3’UTR 
(Mackenzie et al., 1998). Studies on YFV and DENV proteins demonstrated a genetic 
interaction between NS4A with NS1 and NS4B, respectively (Lindenbach & Rice, 
1999; Tajima et al., 2011). A recent study on WNV proteins showed that only four NS 
proteins, namely the transmembrane proteins, NS2A, NS2B, NS4A and NS4B co-
localized with ER membrane protein calnexin, but NS1, NS3 and NS5 did not when 
these proteins were expressed singly (Yu et al., 2013), which is consistent with the 
role the NS2A, NS2B, NS4A and NS4B as intergral membrane protein in RC. 
Through confocal microscopy, ﬂuorescence resonance energy transfer and biologic 
ﬂuorescence complementation, the authors showed that there were two-way 
interactions between (1) NS2A and NS4A, (2) NS2B and three other transmembrane 
proteins (NS2A, NS4A and NS4B), (3) NS2B and NS3, and (4) NS3 and NS5, and 
three-way interactions between three other transmembrane proteins (NS2A, NS4A 
and NS4B) and NS3 occurred only when NS2B was present (Yu et al., 2013). This 
suggests that NS2B may be playing the main role in bringing the three transmembrane 
proteins together in the RC and in recruiting the key replicative enzymes, NS3 and 
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NS5 to the replication site. No protein-protein interaction was found between NS1 and 
the other NS proteins, but ﬂuorescence resonance energy transfer data suggested the 
formation of NS1 homodimer (Yu et al., 2013), which is the consistent with the 
observation that intracellular NS1 is predominately dimeric (Akey et al., 2014; 
Gutsche et al., 2011; Muller et al., 2012; Muller & Young, 2013). Further functional 
evidence that supports interaction between NS proteins has been demonstrated by the 
modulation of NS3 enzymatic/functional activity by NS4A (Shiryaev et al., 2009), 
NS4B (Umareddy et al., 2006a) and NS5 (Cui et al., 1998; Yon et al., 2005). 
 
 
Figure 1-13: Proposed model of flavivirus replication complex in ER. This model was 
proposed as reviewed in section 1.6.6 and was based on study by (Yu et al., 2013) and reviews 
by (Muller & Young, 2013; Shi, 2014). The four transmembrane proteins NS2A, NS2B, 
NS4A and NS4B are proposed to form a transmembrane complex in the ER. NS3 and NS5 are 
not ER-bound but they are tethered to the ER, together with viral RNAs (yellow line: parental 
strand that serves as template, green line: unwound parental strand; red line: complementary 
daughter strand) via interaction between NS2B and NS3. NS3 has been reported to interact 
with NS4B and NS5. NS1, NS4A and NS4B have the capability to form dimers. The 
hydrophobic nature of a protrusion that is located at the N-terminal of NS1 is suggested to be 





1.6.7 Role of 5’ and 3’ untranslated regions in DENV life cycle 
Efficient viral RNA replication, translation and viral pathogenicity are regulated by 
structural elements and conserved sequences in the 5’UTR, capsid-coding region and 
3’UTR. It has been shown that DENV genome is a dynamic molecule that adopts at 
least two different conformations during viral replication - linear and circular (Figure 
1-14B); it has also been demonstrated that only the circular forms are capable of viral 
RNA replication in infected cells (Filomatori et al., 2006) and maintaining a balance 
between linear and circular forms of the genome is essential for replication, possibly 
as a control mechanism to limit negative-sense RNA synthesis so as to maintain a 
1:10-100 ratio of negative- versus positive-sense RNA found in infected cells 
(Tomassini et al., 2003; Villordo et al., 2010; Villordo & Gamarnik, 2009). It is 
known that viral proteins (eg. NS3 and NS5) and host proteins do bind to 5’- and/or 
3’-UTR (Anwar et al., 2009; De Nova-Ocampo et al., 2002; Garcia-Montalvo et al., 
2004b; Gomila et al., 2011; Paranjape & Harris, 2007; Polacek et al., 2009; Vashist et 
al., 2009; Vashist et al., 2011; Yocupicio-Monroy et al., 2003) (also see Table 3-5 for 
the list of these host proteins) and some of the host proteins are shown to modulate 
viral RNA replication (eg. polypyrimidine tract-binding protein (PTB); (Anwar et al., 
2009), Interleukin enhancer-binding factor 3 (ILF3) (Gomila et al., 2011) and Y box-
binding protein-1 (YB-1) (Paranjape & Harris, 2007)) but it remains to be determined 
if viral proteins and host proteins can mediate the switch between linear and circular 







DENV has short 5’UTR (96 nucleotides for DENV2) (Figure 1-14A) consisting of 
two stem loops (SLA and SLB) that is connected by an oligoU spacer. NS5 RdRP 
domain specifically binds to the genome by SLA, which functions as the promoter 
element for NS5 RdRP (Villordo & Gamarnik, 2009). SLA alone is inadequate in 
inducing RdRP activity, and specific nucleotides in SLA are necessary to form an 
active promoter-polymerase complex for RNA synthesis (Filomatori et al., 2006). 
SLB contains 5’UAR that interacts with 3’UAR in 3’-UTR (connected by blue line in 
Figure 1-14A), and together with another two pairs of long range 5’-3’ RNA-RNA 
interactions (5’-3’CS and 5’-3’DAR, connected by orange and grey lines, 
respectively, in Figure 1-14A), they are required for the circularization of viral 
genome (Figure 1-14B) to place NS5 to the 3’end of the genome for initiation of 
negative-strand synthesis (Alvarez et al., 2005b). In addition, the composition of the 
sequence downstream of 5’CS also influences genome circularization (Friebe et al., 
2012). Apart from the crucial role of 5’-UTR in replication, it is also known that the 
5’-UTR contains a capsid-coding region hairpin element (cHP) (Figure 1-14B) that is 
needed for viral RNA synthesis and translation initiation codon selection (Clyde et al., 





Figure 1-14: Schematic representation of DENV genome circularization and proposed model for 
negative-sense RNA synthesis. (A) In DENV genome, the 5′- and 3′-UTRs are approximately 100 and 
500 nucleotides in length, respectively, and they contain highly structured regulatory RNA elements 
that are crucial for translation, viral RNA replication and pathogenicity. The 5′- and 3′-UTRs contain 
sequences, namely 5’ and 3’UAR (connected by blue dotted line), 5’ and 3’DAR (connected by grey 
dotted line), and 5’ and 3’CS (connected by orange dotted line) that can participate in long-range RNA-
RNA interactions to circularize the genome for negative-strand synthesis. (B) Proposed model for 
negative-sense RNA synthesis. In this model, NS5 binds to 5’ SLA to from promoter-polymerase 
complex that is far from the 3’ initiation site. Through genome circulation that is mediated by long-
range 5’-3’ RNA-RNA interactions, the promoter-polymerase complex is placed in close proximity to 
the 3’ end of the genome, which the promoter-polymerase complex can use it as a template to initiate 
negative-strand synthesis. SL = stem loop, VR = variable region, DAR = downstream AUG region, 
UAR = upstream AUG region, CS = cyclization sequence, DB = dumbbell, UTR = untranslated region 
and cHP = capsid hairpin. Refer to main text for more information. Figure is adapted from (Acosta et 




b) 3’UTR  
DENV has a long 3’UTR (454 nucleotides for DENV2) (Figure 1-14A) that contains 
several important RNA structures/sequences in addition to the three complementary 
regions (3’CS, 3’UAR and 3’DAR), which are required for genome circularization. 
The variable region (VR) that is located at the 5’end of 3’UTR contains five stem 
loop structures (SL-I to V). SL-II forms a pseudo-knot structure in to stall the cellular 
5’-3’ exonuclease XRN1 to form subgenomic flaviviral RNA (sfRNA) (Chapman et 
al., 2014); sfRNA has been shown to inhibit XRN1 activity and dysregulate host 
mRNA stability (Moon et al., 2012), and also to sequester multifunctional RNA-
binding proteins G3BP1, G3BP2 and CAPRIN1 to inhibit interferon stimulated genes 
mRNA translation (Bidet et al., 2014). The middle part of 3’UTR forms two dumb-
bell structures that are required for optimal translation (Alvarez et al., 2005a). Finally, 
the highly conserved 3’SL is crucial for RNA replication and translation (Holden et 




1.7 Nuclear-cytoplasmic transport of dengue viral proteins  
In DENV life cycle, it is known that DENV2 NS5 protein can undergo nuclear-
cytoplasmic trafficking that is mediated through interaction of NS5 with components 
of host import and export machinery.  
 
For protein to be transported into the nucleus, heterodimer of importin-α and β1 binds 
specifically to NLS on its respective cargo protein to facilitate the passage of protein 
across the nuclear pore complex (NPC) (Figure 1-15); importin-α acts as an adaptor 
molecule that binds cargo protein directly via NLS to form trimeric cargo-importin-
α/β1 complex for trafficking (Marfori et al., 2012). Two classical NLSs have been 
reported that are characterized by the presence of either one (monopartite) or two 
(bipartite) basic amino acid clusters (Dingwall & Laskey, 1991). The consensus 
sequences for monopartite and bipartite NLSs are K-K/R-X-K/R and K-R-X10-12K-R-
R-K respectively (X represents any amino acids) (Arnold et al., 2006; Matsuura et al., 
2003; Moore & Blobel, 1993; Waldmann et al., 2007). 
 
For nuclear-resident proteins to be transported out of the nucleus, CRM1/exportin-1, a 
member of the importin-β superfamily, binds specifically to nuclear export signal 
(NES) on its respective cargo protein to facilities the export of protein to the 
cytoplasm (Figure 1-15). The NES sequence is generally characterized by the 
presence of regularly spaced, large hydrophobic amino acids (leucine or isoleucine), 
with intervening amino acids that are small, polar or negatively charged (Fornerod & 
Ohno, 2002; la Cour et al., 2004). The consensus sequence for NES is ФX2-3ФX2-
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3ФXФ (Ф represents hydrophobic amino acids valine, leucine, isoleucine, 




Figure 1-15: Mechanism of nuclear-cytoplasmic trafficking of proteins across nuclear pore 
complex. The cargo protein that contains NLS is recognized by importin-β alone or importin-α/β 
heterodimer; the cargo protein that contains NES binds to exportin when complexed with Ran-GTP. 
The passage of transport complex through the nuclear pore is facilitated by transient interaction of 
importin-β with Nups. In the cytoplasm, a NLS-containing cargo-importin complex traffics into the 
nucleus by transient interaction with phenylalanine-glycine-repeat (FG-repeat) domains on Nups of 
NPC (Pyhtila & Rexach, 2003). After trafficking of cargo protein into the nucleus, the binding of GTP-
bound form of Ran (Ran-GTP) to importin-β causes a conformation change in importin-β that 
dissociates it from cargo-importin complex. The released cargo protein is free to perform its function in 
the nucleus, and the importins are recycled to the cytoplasm by its export receptor, cellular apoptosis 
susceptibility (CAS), for next round of transport (Kutay et al., 1997). In the nucleus, a NES-containing 
cargo-exportin complex forms a trimetric complex with Ran-GTP and traffics out of the nucleus by 
transient interaction with FG-repeat domains on Nups (Kutay & Guttinger, 2005). In the cytoplasm, the 
conversion of Ran-GTP to Ran-GDP by guanine nucleotide exchange factor RCC1 to trigger the 
dissociation of the export complex (Melchior & Gerace, 1998). The relative position of several Nups 





1.8 Identification of DENV host factors via viral-protein interaction 
screens 
The analysis of viral-protein interaction network in DENV is being intensively 
investigated as a means to identify both human and mosquito host factors that are 
involved in mediating replication and pathogenesis. The two approaches that are 
commonly used for such screen are high-throughput Y2H assay (Bhuvanakantham et 
al., 2010; Brault et al., 2011; Chua et al., 2004; Duan et al., 2008; Folly et al., 2011; 
Gao et al., 2010; Jiang et al., 2009; Khadka et al., 2011; Le Breton et al., 2011; Li et 
al., 2012; Limjindaporn et al., 2007; Limjindaporn et al., 2009; Mairiang et al., 2013; 
Silva et al., 2013), or co-affinity purification or co-IP that is coupled to mass 
spectrometry (MS) (Colpitts et al., 2011a; Colpitts et al., 2011b; Kurosu et al., 2007; 
Noisakran et al., 2008b).  
 
The first genome-wide analysis of viral-protein interactions between DENV and 
human proteins was reported by Khadka and colleagues via Y2H screening with 
human liver cDNA library (Khadka et al., 2011). They identified a total of 139 
interactions between 105 human proteins and 8 dengue viral proteins (M protein and 
all NS proteins). Among the 105 human proteins, six were previously implicated in 
DENV infection whereas 45 were associated with replication of other viruses. The 
authors found enrichment among human proteins that are related to cell/centrosome, 
coagulation cascade, Golgi apparatus, complement and cytoskeleton (Khadka et al., 
2011). In the same year, two additional Y2H screens were published to identify 
interactions between structural or NS proteins of DENV with human proteins (Folly et 
al., 2011; Le Breton et al., 2011). Folly et al. identified 31 human proteins to be 
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interacting with E, prM or C and these proteins are involved in distinct biological 
process that are related to immune response and homeostatic balance (Folly et al., 
2011). Similarly, Le Breton and coworkers identified 108 human proteins to be 
interacting with NS3, NS5 or both and host proteins related to the regulation of innate 
immune response, transcription regulation, RNA binding and vesicular transport. 
Topological analysis of this interaction network revealed that NS3 and NS5 have a 
strong tendency to interact with human proteins that highly connected within the 
human interactome and this further support Khadka et al’s conclusion (Le Breton et 
al., 2011).  
 
The first genome-wide analysis of viral-protein interactions between DENV and 
human or mosquitoes proteins was reported by Mairiang and coworkers via Y2H 
screening with human peripheral blood leukocytes or Aedes aegypti cDNA library 
(Mairiang et al., 2013). They have identified 102 interactions between 93 mosquito 
proteins and four dengue viral proteins (C, prM, NS3 and NS5) and 46 interactions 
between 35 human proteins and three dengue viral proteins (C, NS3 and NS5). Out of 
93 mosquito proteins, 54 were identified to have human orthologs but only four of 
these proteins were observed to have conserved interactions among mosquito and 
human with same dengue proteins. NS3-mosquito protein-protein interactions were 
enriched by proteins that are implicated in response to heat shock and stress, whereas 




A recent co-IP experiment coupled with MS study with GFP-NS3 and GFP-NS5 
transfected cells that were also infected with DENV2 by Carpp et al has identified 41 
and 53 host proteins to be interacting with GFP-NS3 and GFP-NS5, respectively, and 
13 of them were common to both. Analysis of interaction network revealed biological 
processes or cellular components like viral infectious cycle, reproductive process, 
major histocompatibility complex class I protein binding, protein folding and 
unfolded protein response to be enriched in GFP-NS3 interaction network, whereas 
nuclear pore, nuclear envelope and Golgi-to-ER retrograde vesicle-mediated transport 
to be enriched in GFP-NS5 interaction network. Lastly, lipid metabolism and 
transmembrane transporter activity for organic acids and carboxylic acids were 
enriched in both GFP-NS3 and GFP-NS5 interaction networks (Carpp et al., 2014).  
 
1.9 Dengue control  
Currently, there is no licensed vaccine and antiviral drug that can be used to prevent 
or treat dengue infection and vector control remains the cornerstone in preventing 
transmission. The current treatment for dengue infection is mainly supportive. 
Patients with DF are encouraged to take oral fluids to replace losses from vomiting 
and fever and antipyretics (eg. paracetamol) is given for fever. The treatment for DHF 
requires timely fluid support to prevent the progression to DSS and this involves 
prompt diagnosis, monitoring for warning signs, providing supportive care and fluid 




1.9.1 Vector control 
Traditional -based vector control methods rely on surveillance, public education and 
removal of mosquito breeding habitats to control the abundance of mosquito (NEA, 
2015; Ooi et al., 2006). However, in recent years, there has been increased interest in 
the use of Wolbachia-infected mosquito in natural setting as a population replacement 
strategy to biologically control DENV transmission by targeting mosquito longevity 
(Hancock et al., 2011). As of current, there have been several Wolbachia field trials in 
Australia and Vietnam and its impact on DENV transmission in natural setting is 
currently being evaluated.  
 
1.9.2 Dengue vaccine 
Vaccine research and development for DENV have been ongoing since the 1940s 
(Mahoney et al., 2011) and yet, there is still no approved vaccine against DENV 
infection because of the difficulty in mounting sufficient tetravalent protection against 
all four DENV serotypes to deal with the ADE phenomenon (Figure 1-5) where the 
major risk is that presence of subneutralizing concentrations of neutralizing antibodies 
may increase the risk of ADE (Thisyakorn & Thisyakorn, 2014). At present, several 
vaccine candidates are under development and they include live attenuated vaccine, 
recombinant chimeric vaccine, inactivated virus vaccine, recombinant protein vaccine 
and DNA vaccine (reviewed by (Murrell et al., 2011). Among them, only the 





1.9.3 Antiviral development  
In recent years, a greater molecular understanding of viral protein roles in replication 
and pathogenies enables a new range of targets to be identified for potential 
therapeutic intervention. Extensive effort has been invested to discover new small-
molecule antiviral drug against DENV. 
 
1.9.3.1 Discovery of new antiviral agents 
Searching for anti-dengue inhibitors against viral and host proteins that are implicated 
in viral replication or pathogenesis and obtaining crystal structures of viral proteins 
(Figure 1-11, representative crystal structures of DENV proteins) are the general 
approaches that have been taken to identify potential targets for antiviral therapy and 
obtaining key information for rational design of novel anti-dengue agents. Various 
strategies have been frequently used to identify such inhibitors and they include (1) 
high-throughput cell-based infection assays, (2) high-throughput cell-based infection 
assays coupled with viral enzyme assay or functional characterization assay, (3) 
structure-based in silico docking and rational design, and (4) repurposing of HCV 
inhibitors for DENV (reviewed comprehensively by (Lim et al., 2013c).  
 
For the viral proteins, the receptor binding property of E and the enzymatic functions 
of NS3 (protease/helicase) and NS5 (MTase/RdRP) (refer to section 1.6.4 on details 
of functions) have always been attractive antiviral targets and several compounds 
have been identified via the above strategies; however, in recent years, new antiviral 
targets that include NS3 RTPase activity, NS5 RNA binding and viral-viral protein 
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interaction (both structural and NS, refer to section 1.6.6 for known NS protein-
protein interactions) have also been proposed to be promising new targets and they 
remained to be further explored (Geiss et al., 2009). For the host proteins, those that 
are involved in viral protein trafficking, viral glycoprotein modification, viral 
replication (eg. pyrimidine biosynthesis) and severe dengue pathogenesis are worth to 
be further pursued. Collectively, among the identified compounds, very few inhibitors 
have advanced to the point of clinical trial (see 1.8.3.1) because of their poor 
selectivity, physiochemical or pharmacokinetic properties (Lim et al., 2013c).  
 
1.9.3.2 Therapeutic trial of small molecules  
As of now, several clinical studies have been conducted to test the efficacy of small 
inhibitors that are either targeting the NS5 protein (eg. balapiravir) or host protein (eg. 
celgosivir, chloroquine and prednisolone) in conventional randomized controlled trial 
(Low et al., 2014; Nguyen et al., 2013a; Tam et al., 2012; Tricou et al., 2010; 
Whitehorn et al., 2012).  
 
Balapiravir is a prodrug of a nucleoside analogue that was initially developed for 
treatment of chronic HCV infection; despite its antiviral potential in vitro, balapiravir 
was unable to improve clinical outcome when tested in a trial (Nguyen et al., 2013a). 
Celgosivir is a prodrug of castanospermine that inhibits host alpha-glucosidase I. It 
was shown in vitro to be effective against all four serotypes and further in vivo study 
with mouse model shown antiviral activity against DENV2 (Rathore et al., 2011b). 
Celgosivir was demonstrated to be safe and well tolerated but there was no clear 
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evidence to suggest protection at recommended doses (Low et al., 2014). Chloroquine 
was evaluated for both its anti-dengue properties and its ability to potentially 
modulate immune response during infection; however, the trial did not show any 
obvious antiviral or clinical benefits (Tricou et al., 2010). Prednisolone was tested for 
its ability to modulate immune-mediated response with the hope that through early 
administration of prednisolone, severe dengue could be prevented; the trial was safe 
but it was not effective (Tam et al., 2012) and there were very little evidence to 
suggest the attenuation of host immune response (Nguyen et al., 2013b).  
 
1.10  Dual faces of NS5 in DENV life cycle 
In DENV infected cells, NS5 exists in two forms; a hypo- and hyper-phosphorylated 
forms. The hypo-phosphorylated form is localized to the cytoplasm where it interacts 
with NS3; the hyper-phosphorylated form is predominately localized to nucleus and is 
thought not to interact with NS3 (Kapoor et al., 1995; Welsch et al., 2009).  
 
1.10.1 Cytoplasmic NS5  
Among the NS proteins, NS3 and NS5 contain the enzymatic activities, namely 
NTPase/RTPase/helicase and MTase/RdRP activities, respectively, which are crucial 
for viral RNA replication in cytoplasmic RC. Further evidence for the roles of NS3 
and NS5 proteins in the RC have been demonstrated by the specific interactions of 
NS3 and NS5 with flavivirus 5’ and 3’UTR (Chen et al., 1997; Cui et al., 1998; 
Garcia-Montalvo et al., 2004b; Khromykh et al., 1996; Mackenzie et al., 1998; You et 
al., 2001), the stimulation of NS3 NTPase and RTPase activities by NS5 (Cui et al., 
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1998; Yon et al., 2005) and the addition of anti-NS3 and anti-NS5 inhibited the 
reaction that converts RF to RI (Bartholomeusz & Wright, 1993); these findings are 
consistent with the functional roles of both proteins in the RC.  
 
NS3 and NS5 have been demonstrated to co-localized at RC in infected cells (Kapoor 
et al., 1995; Uchil et al., 2006; Welsch et al., 2009; Westaway et al., 1997). There 
have been several reports on NS3-NS5 interaction that include co-IP assays from 
infected cell extracts (Chen et al., 1997; Garcia-Montalvo et al., 2004b; Kapoor et al., 
1995; Moreland et al., 2012), in vitro direct-binding assays (Moreland et al., 2012; 
Takahashi et al., 2012) and Y2H studies (Brooks et al., 2002; Johansson et al., 2001a; 
Mairiang et al., 2013). Through Y2H studies, their interaction has been mapped to C-
terminal region of NS3 helicase (residues 303-618) and the N-terminal region of NS5 
RdRP (residues 320-368) (Figure 1-16) (Brooks et al., 2002; Johansson et al., 2001b). 
Interestingly, the region of NS5 also binds to importin-β1 and hence, known as βNLS 
(Brooks et al., 2002). The binding site on NS5 seems to be centered on residue K330 
because the mutation of this residue to alanine reduced its interaction with NS3 and 
abolished infectious virus particle production, although the in vitro de novo RdRP 
activity remained unaffected (Zou et al., 2011). Based on structure-guided mutational 
analysis of two cavities in DENV NS5, it was hypothesized that the cavity occupied 
by K330 may be a potential target for antiviral drug design by blocking NS3-NS5 




1.10.2 Nuclear NS5 
During infection, DENV2 NS5 accumulates in the nucleus (Kapoor et al., 1995). The 
functional bipartite NLS (α/βNLS) that is responsible for mediating NS5 nuclear-
localization is found within residues 369-405 (Figure 1-16) (Brooks et al., 2002; 
Forwood et al., 1999) and it has been shown experimentally that the α/βNLS is 
capable of targeting β-galactosidase into the nucleus by interacting with importin-α/β1 
complex (Forwood et al., 1999). Mutations in NS5 α/βNLS (387KKKAAA and 
371KKAA+387KKKAAA) reduced NS5 nuclear accumulation and virus release 
and this correlates well with increased IL-8 secretion (Pryor et al., 2007). Apart from 
a well-characterized NLS, a consensus casein kinase 2 (CK2) site (395TREE) was also 
identified in this region and in vitro phosphorylation of site by CK2, possibly at T395, 
was shown to be negatively regulating DENV2 NS5 nuclear import (Forwood et al., 
1999). Subsequently, a NES sequence (residues 327-343) was identified to be 
responsible for shuttling DENV2 NS5 into cytoplasm and it was shown to bind to 
CRM-1 (Rawlinson et al., 2009). Blocking nuclear export with CRM-1 inhibitor 
leptomycin B (LMB) increased NS5 nuclear accumulation and virus release and this 
also correlates with decreased IL-8 secretion (Rawlinson et al., 2009), which 
collectively implies that nuclear NS5 is important for efficient virus production. 
Recently, it was demonstrated that NS5 residues 529-740 interacts with DAXX in the 
nucleus to modulate RANTES (CCL5) production, which is a DHF-associated 
cytokine (Khunchai et al., 2012). Taken together, it seems to suggests that the role of 
nuclear NS5 is to modulate host transcription to create a permissive environment for 





1.11  Aim of the thesis  
Given the worldwide re-emergence of epidemic dengue, there is an urgent need for 
the development of prophylactic vaccine or effective antiviral agent to control dengue 
infection. Knowledge of dengue pathogenesis, especially in the molecular aspects of 
virus-virus protein and virus-host protein interactions that are important for virus 
replication and pathogenesis will contribute to the identification of potential targets 
for antiviral therapy and obtainment of key information for rational design of novel 
anti-dengue agents. The enzymatic activities of two major replicative proteins of 
DENV, NS3 and NS5 proteins, and the membrane fusion ability of E have formed 
important targets for anti-dengue drug design (Geiss et al., 2009; Lim et al., 2013c). 
However, in recent years, virus-virus protein interaction between the two major 
replicative proteins of DENV, NS3 and NS5, as well as virus-host protein interaction 
between DENV NS5 and its nuclear importer, importin α/β1 have also become 
attractive targets for antiviral drug development (also see section 1.9.3.1) (Caly et al., 
2012b; Geiss et al., 2009). In order to facilitate the drug discovery process, an in-
depth understanding of their molecular interactions and the consequence of their 
interactions on viral replication is needed; the quest of such knowledge constitutes the 
basis of this thesis, with specific aims that are directed at dissecting the details of 





The specific aims of this thesis are: 
1. To fine map the interaction region between NS3 and NS5 and investigate its 
impact on virus replication 
We set out to investigate the details of molecular interaction between NS3 and NS5, 
with more emphasis from the NS3 perspective as it was not fully characterized. 
Biochemical pull-down assays from infected cell lysates have demonstrated the 
existence of NS3-NS5 interaction (Chen et al., 1997; Kapoor et al., 1995). Previous 
Y2H studies have narrowed down the region on NS3 and NS5 to residues 303-618 
and residues 320-368 respectively (Figure 1-16) (Brooks et al., 2002; Johansson et al., 
2001a; Vasudevan et al., 2001). Reverse genetics study with mutation in NS5, residue 
K330 to alanine abolished viral replication via reducing NS3-NS5 interaction, while 
the RdRP activity of NS5 remained unaffected, suggesting that interaction between 
NS3 and NS5 may be a potential antiviral target (Zou et al., 2011). These studies 










































































































































































































































































































































































































































































































































































































































































































2. To investigate the subcellular localization pattern of NS5 for DENV1-4 serotypes 
and its impact on virus replication  
Flavivirus NS5 subcellular localization has been reported for DENV2, YFV, JEV and 
WNV. In the case of DENV, it was only formally shown for DENV2 NS5 that its 
nuclear-cytoplasmic trafficking ability was mediated by both well-characterized NLS 
and NES sequences that also reside within residues 320-405 (Figure 1-16) (Brooks et 
al., 2002; Pryor et al., 2007; Rawlinson et al., 2009; Vasudevan et al., 2001). In order 
to determine if similar nuclear-cytoplasmic trafficking ability was observed in NS5 in 
infected cells of other serotypes, anti-NS5 antibodies that could cross-react with all 
serotypes were developed in-house as such antibody was unavailable commercially. 
Using a uniquely available anti-NS5 antibody, we found that DENV2 and 3 NS5 are 
predominately nuclear while DENV1 and DENV4 NS5 are mostly cytoplasmic. A 
small molecule screen based on interaction of NS5 with importin-α/β1 identified 
ivermectin as a potential inhibitor. In spite of the differences in the NS5 subcellular 




3. To identify potential nuclear or cytoplasmic binding partners that are unique to 
DENV1 and 2 NS5 by co-immunoprecipitation coupled to mass spectrometry 
Even though it has been known for two decades that DENV2 NS5 localizes to the 
nucleus of infected cell, the significance of NS5 protein nuclear localization remains 
poorly understood. In comparison to DENV capsid protein, which is also known to 
nuclear-localized, research in recent years has shed some light on its possible 
functions in nucleus (Colpitts et al., 2011a; Netsawang et al., 2010). Apart from that, 
several proteomics screens were performed to identify host proteins that physically 
interact with DENV capsid protein, either by Y2H (Li et al., 2012) (Bhuvanakantham 
et al., 2010; Bhuvanakantham & Ng, 2013; Limjindaporn et al., 2007) or tandem 
affinity purification-MS (Colpitts et al., 2011a), and all of them have successfully led 
to the identification of several host proteins that interact with capsid and are 
implicated in DENV life cycle. With this notion, we set out to isolate and identify 
binding partners to DENV1 and 2 NS5 by co-IP coupled to MS.  
 
4. To characterize a newly discovered C-terminal NLS of DENV2 NS5 and study its 
importance in virus replication 
While searching for a cytoplasmic retention signal (CRS) in DENV1 NS5 through 
gene shuffling with DENV2 NS5, we unexpectedly discovered a new C-terminal NLS 
in DENV2 NS5. This finding was studied comprehensively to prove the functionality 
of this NLS in targeting NS5 and unrelated protein into nucleus. The implication of 




Chapter 2: Methods and Materials 
2.1 Materials 
2.1.1 Antibodies 
Table 2-1: Primary antibodies used in the course of this work 
Antibody  Name From (Organism)  Type Source 
Anti-dsRNA  J2 Mouse Monoclonal Scicons, Hungary 
Anti-E 4G2 Mouse Monoclonal HB-112, ATCC, USA 
Anti-NS2B 3F10 Human Monoclonal This work; (Moreland et al., 2012) 
Anti-NS3 3F7 Human Monoclonal This work; (Moreland et al., 2012) 
Anti-NS3  3F8 Human Monoclonal This work; (Moreland et al., 2012) 
Anti-NS5 5M1 Human Monoclonal This work; (Zhao et al., 2014) 
Anti-NS5  5R3 Human Monoclonal This work; (Zhao et al., 2014) 
Anti-actin  A2066 Rabbit Polyclonal Sigma-Aldrich, USA 
Anti-STAT2 4594 Rabbit Polyclonal Cell Signaling Technology, USA  
Anti-DDX3X A300-474A Rabbit Polyclonal Bethyl Laboratories Inc, USA  
Anti-DDX5 A300-523A Rabbit Polyclonal  Bethyl Laboratories Inc, USA 
Anti-MATR3 A300-591A Rabbit Polyclonal Bethyl Laboratories Inc, USA 
Anti-GFP ab6556 Rabbit Polyclonal  Abcam, USA 
Anti-M13 HRP 27942101 Mouse Monoclonal GE Healthcare, USA 
 
Table 2-2: Secondary antibodies used in the course of this work 
Antibody  From (Organism)  Source 
Anti-human Alexa Fluor 488 Goat Invitrogen, USA 
Anti-mouse Alexa Fluor 488 Goat Invitrogen, USA 
Anti-rabbit Alexa Fluor 488 Goat Invitrogen, USA 
Anti-human Alexa Fluor 594 Goat Invitrogen, USA 
Anti-mouse Alexa Fluor 594 Goat Invitrogen, USA 
Anti-mouse IgG HRP Goat Dako, USA 
Anti-rabbit IgG HRP Goat GE Healthcare, USA 
Anti-human IgG HRP Goat MyBiosource, USA 
 
 
2.1.2 Bacterial strains 
Table 2-3: Bacterial strains used in the course of this work 
E. coli strain Genotype Source 
XL1-blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 




F- ompT hsdS(rB- mB-) dcm+ Tetr gal l (DE3) endA Hte 





2.1.3 DNA oligonucleotides 
The DNA oligonucleotides that were used in this work were synthesized by Integrated 
DNA Technologies (IDT; Singapore). The oligonucleotides were provided as 
lyophilized powder, which were resuspended in DNase/RNase-free distilled water 
prior to use. The sequences of all synthesized DNA oligonucleotides were listed in the 
respective tables.  
 
2.1.4 Cloning vectors 
Table 2-4: Cloning vectors used in the course of this work 
Vector Tag Cleavage site Type  Source 
pEGFP-C1  N-terminal GFP  - Mammalian  Clontech, Japan 
pET14b N-terminal His6 Thrombin Bacterial  Novagen, Germany 
pET15b N-terminal His Thrombin Bacterial  Novagen, Germany 
pET32b N-terminal His and thioredoxin Thrombin Bacterial  Novagen, Germany 
pGEX-4T-1 N-terminal GST Thrombin Bacterial  GE Healthcare, USA 
pPROEX 
HTb B N-terminal His TEV Bacterial 
Invitrogen, Thermo 
Fisher Scientific, USA  
 
 
2.1.5 Enzymes, kits and other reagents  
Table 2-5: List of kits, enzymes and other reagents used in the course of this work 
Product Manufacturer  
Protein expression and purification 
IPTG Thermo Fisher Scientific, USA 
Protein G-Sepharose 4B Sigma-Aldrich, USA 
HisTrap HP column GE Healthcare, UK 
Amicon® Ultra-15 Centrifugal Filters Millipore, Merck, USA 
DNA cloning and purification  
T4 DNA-Ligase NEB, USA 
PfuUltra II Fusion HS DNA Polymerase Agilent Technologies, USA 
QuikChange II Site-Directed Mutagenesis Kit Agilent Technologies, USA 
dNTPs Promega, USA 
QIAGEN Plasmid Mini Kit Qiagen, Germany 
QIAquick Gel Extraction Kit Qiagen, Germany 
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UltraPure Phenol:Chloroform:Isoamyl Alcohol 
(25:24:1, v/v) Life Technologies, Thermo Fisher Scientific, USA  
Transfection reagent 
jetPRIME transfection reagent  Polyplus-transfection SA, France 
Lipofectamine 2000 Invitrogen, Thermo Fisher Scientific, USA 
In vitro transcription  
m7G(5')ppp(5')A RNA Cap Structure Analog NEB, USA 
mMESSAGE mMACHINE T7 Transcription Kit Ambion, Thermo Fisher Scientific, USA 
Improm II reverse transcription system Promega, USA 
Real time RT-PCR 
iQ SYBR Green supermix Biorad, USA  
iTaq Universal SYBR Green One-Step Kit  Biorad, USA 
SDS-PAGE and western blot 
Prestained SDS-PAGE standards Biorad, USA 
Silver Stain kit  Thermo Fisher Scientific Pierce, USA 
Nitrocellulose transfer membrane Milipore, Merck, USA 
Amersham Hybond-P polyvinylidene fluoride 
(PVDF) transfer membrane  GE Healthcare, UK 
WesternBright Sirius HRP substrate  Advansta, USA 
Immunoprecipitation  
Protease Inhibitor Cocktail (Complete) Roche, Switzerland 
GFP-Trap_A resin Chromotek, Germany  
Protein A/G agarose Thermo Fisher Scientific Pierce, USA 
RapiGest SR surfactant reagent  Waters, USA 
RNA extraction and purification  
QIAamp Viral RNA Mini kit Qiagen, Germany 
TRIzol reagent  Life Technologies, Thermo Fisher Scientific, USA 
Immunofluorescence assay 
ProLong Gold antifade reagent with DAPI  Life Technologies, Thermo Fisher Scientific, USA 
Restriction enzymes  
Acc65I, BamHI, BspEI, EagI, NaeI, NdeI, SalI, 
SphI, XhoI and XmaI NEB, USA 
Others 
Ph.D.™ Peptide Display Cloning System NEB, USA 
Fab-phage display library  Humanyx Pte Ltd, Singapore 
Malachite Green Phosphate Assay Kit BioAssay Systems,  
 
 
2.1.6 Buffers and solutions  
Table 2-6: Buffers and solutions used in the course of this work 
DNA and RNA work 
3M Sodium Acetate 3 M Sodium Acetate (pH 5.2)  
6× DNA loading dye  
0.4% orange G, 0.03% bromophenol blue, 0.03% xylene 
cyanol FF, 15% Ficoll® 400, 10 mM Tris-HCl (pH 7.5) 
and 50 mM EDTA (pH 8.0) (Promega, USA) 
NEB buffer 4 (NEB, USA) 20 mM Tris-acetate, 10 mM magnesium acetate, 50  
mM potassium acetate and 1 mM DTT (pH 7.9)  
10× T4-DNA Ligase Buffer (NEB, 
USA) 
500 mM Tris-HCl, 100 mM MgCl2, 10 mM ATP and 100 
mM DTT (pH 7.5) 




SDS page and western blot 
30% acrylamide/bis Solution 29:1  30% acrylamide/bis-acrylamide (29:1) solution with 3.3% cross-linker concentration (Biorad, USA) 
Western blot blocking and antibody 
binding buffers (PBST-M) 
PBS pH 7.2 with 0.1% (v/v) of Tween 20, and 3% (w/v) 
milk powder 
Coomassie blue staining solution 0.25% (w/v) Coomassie Brilliant Blue R-250, 50% (v/v) 
Methanol, 10% Glacial Acetic acid 
Destaining solution  5% (v/v) Methanol, 5% (v/v) Glacial acetic acid 
4× SDS-PAGE sample loading buffer  
200 mM Tris-HCl pH 6.8 , 8% (w/v) SDS, 40% (v/v) 
glycerol, 4% β-mercaptoethanol (v/v), and 0.08 % 
bromophenol blue 
Stacking gel buffer  1M Tris-HCl (pH 6.8) 
Resolving gel buffer 1.5M Tris-HCl (pH 8.8) 
Western blot stripping buffer  2% (v/v) SDS, 62.5 mM Tris HCl pH 6.8 and 0.8% (v/v) 
β-mercaptoethanol 
Western blot wash buffer (PBST) PBS pH 7.2 with 0.1% (v/v) of Tween 20 
Immunofluorescence assay 
4% paraformaldehyde  
 
PBS pH 7.4 with 4% (w/v) paraformaldehyde. Heat to 
60°C, with continuous stirring to promote dissolution. 
Filter sterilized and stored at -20°C. 
Blocking and antibody binding buffers PBS pH 7.4 with 2% (w/v) bovine serum albumin (BSA)  
Antibiotics and bacterial culture medium 
1000× ampicillin stock 100mg/ml in double distilled water, filter sterilized and stored at -20°C (Sigma-Aldrich, USA) 
1000× kanamycin stock 50mg/ml in double distilled water, filter sterilized and stored at -20°C (Sigma-Aldrich, USA) 
1000× chloramphenicol 34mg/ml in 100% ethanol and stored at -20°C (Sigma-Aldrich, USA) 
Luria Broth (LB) medium  BD, USA 
LB-agar BD, USA 
Cell culture medium (Gibco, Thermo Fisher Scientific, USA) 
Dulbecco’s Modified Minimal Eagle 
Medium (DMEM), high glucose  L-Glutamine DMEM with 4.5g/L glucose.  
Roswell Park Memorial Institute 
(RPMI) 1640 Medium L-Glutamine RMPI. 
RPMI 1640 Medium, HEPES RPMI 1640 medium with 5.958g/L Hepes. 
100× penicillin-streptomycin (P/S) 
(10,000U/ml)  Used at a final concentration of 100U/ml. 
Fetal bovin serum (FBS)  Heat-inactivated at 56°C for 30 minutes. Used to 
supplement cell culture medium at 2, 5 or 10%.  
Opti-MEM Reduced serum medium that was derived from modification of DMEM for transfection use. 
Other solutions/buffers 
ATPase assay buffer  50 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 1.5 mM 
dithiothreitol, 0.05% Tween 20 and 0.25 μg/ml BSA 
BSA (Sigma-Aldrich, USA)  5% (w/v) BSA in PBS pH 7.2. Filter sterilized and stored at -20°C. 
Carboxymethyl cellulose 
0.8% (w/v) aqualite II dissolved in RPMI media 
supplemented with 2% FBS, 1% P/S , 0.0375% (v/v) 
NaHCO3 and 25 mM HEPES 
Crystal violet solution 1% (w/v) crystal violet dissolved in 20% (v/v) ethanol  
CCMB80 buffer (modified)  
80 mM CaCl2, 10 mmMgCl2. 10% (v/v) glycerol and 10 
mM potassium acetate pH 7.0. Adjusted pH to 6.4 with 
HCl. Filter sterilized and stored at 4°C. 
Lysis buffer with 1% triton X-100 50 mM Tris pH 7.4, 150 mM NaCl, 1mM EDTA, 1% 
(v/v) triton X-100 
PBS pH 7.2 137 mM NaCl, 2.7mM KCl, 10 mM Na2HPO4 and 1.8 mM and KH2PO4  
NP-40 AnalytiCon Discovery, Germany 
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2.1.7 Cell lines 
All cell lines were obtained from ATCC.  
Table 2-7: Cell lines used in the course of this work 
Cell lines Description  
BHK-21  Baby hamster kidney cell (Fraser & Gharpure, 1962; Stoker, 1962) 
Huh-7 Human hepatoma cell (Nakabayashi et al., 1982) 
Vero African green monkey kidney cell (Mosca & Pitha, 1986) 
HEK293T Human embryonic kidney cells expressing the SV40 large T-antigen (Graham et al., 
1977) 




DENV1-4 of GenBank accession number: EU081230, EU081177, EU081190 and 
GQ398256 respectively were grown in C6/36 cells, and titered in BHK-21 cells 
before storage at -80°C (Christenbury et al., 2010; Schreiber et al., 2009a). These 
viruses were isolated during a local dengue outbreak that occurred in 2005 as part of 
Early Dengue infection and outcome (EDEN) study in Singapore (Schreiber et al., 
2009a). 
 
2.2 Methods  
Standard molecular cloning techniques, and protein expression and purification 
methods were carried out as described in reference manuals, namely “Molecular 
Cloning: A Laboratory Manual” (Sambrook, 2001) and “Current Protocols: Molecular 
Biology” (Ausubel, 2010), and references that were cited in this work. Unless 
mentioned otherwise, all routine practises like DNA and RNA purification, restriction 
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enzyme digestion, ligation, transfection and etc. were carried out according to the 
protocol provided by the respective manufacturers.  
 
All centrifugation steps mentioned in this work were done in bench top or floor 
standing refrigerated centrifuge at specified temperatures.  
 
2.2.1 Cell culture and viruses 
2.2.1.1 Cell culture 
Huh-7 cells were cultured in DMEM high glucose medium supplemented with 
10%FBS and 1% penicillin-streptomycin (P/S). Vero and HEK293T cells were MEM 
high glucose medium supplemented with 10%FBS. BHK-21 cells were maintained in 
RPMI 1640 medium supplemented with 10% FBS and 1% P/S. These cells were 
maintained at 37°C with 5% CO2.  
 
C6/36 cells were maintained in RPMI 1640 medium, supplemented with 25 mM 
HEPES, 10% FBS and 1% P/S at 28°C in the absence of CO2. 
 
Depending on the cell types, these cells were re-plated every 3 to 4 days, and with a 





2.2.1.2 Transfection of eukaryotic cells with plasmid DNA 
One day prior to transfection, 1.6×105 Vero cells were seeded into 12-well plate, with 
glass cover slips, and incubated overnight at 37oC with 5% CO2. On the following day, 
Vero cells were transfected using Lipofectamine 2000 with 2 μg of plasmid per well 
respectively, according to the manufacturer’s recommendations.  
 
2.2.1.3 Passaging viruses 
The virus supernatants from C6/36 cells that were infected with DENV (serotypes 1-4) 
were harvested either on day 7 post-infection, or when infected cells showed ~75% 
cytopathic effect under a microscope, whichever came first. The harvested virus 
supernatants were filtered through a 0.22µm pore size filter and stored at -80ºC as 
small aliquots. Plaque assays of virus stocks were carried on BHK-21 cells to 
determine viral titer prior to use.  
 
2.2.1.4 Plaque assay 
One day prior to experiment, 2×105 BHK-21 cells were seeded in a 24-well plate. On 
the day of experiment, medium was aspirated and 10-fold serial dilutions of virus in 
RPMI medium were added to BHK-21 cells. After 1 hour incubation at 37°C, virus 
inoculum was removed and replaced with 0.8% methyl-cellulose in maintenance 
medium (RPMI 1640 medium supplemented with 2% FCS and 1% P/S). The plate 
was kept at 37°C for at least 4 days (typically 5 days but not more than 7 days) and 
fixed with 4% formaldehyde at RT for 20 minutes when the plaque was visible to 
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eyes. After fixing, the plate was washed thoroughly with water, and 0.5 ml of 1% 
(w/v) crystal violet was added to stain fixed cells for 20 minutes. After staining, the 
plate was washed, dried and the plaque forming units per ml (pfu/ml) was calculated. 
 
2.2.1.5 Immunofluorescence assay 
At an appropriate time post-transfection/infection, cells that were either transfected 
with mammalian expression plasmids, infected with DENV, or mock-
transfected/infected were fixed with ice-cold methanol: acetone (1:1) for 15 minutes 
at -20ºC. Following fixation, cells were washed once by PBS and analyzed by IFA, 
using primary antibodies against GFP (ab6556, 1:1000; Abcam), dsRNA (J2, 1:300; 
Scicons), E (4G2, 1:1000; HB-112, ATCC) or NS5 (5M1, 20 nM and 5R3, 30 nM 
(Zhao et al., 2014)), and secondary antibodies coupled to Alexa-Fluor 488 or Alexa-
Fluor 594 (Invitrogen). Coverslips were mounted using ProLong Gold antifade 
reagent with DAPI (Invitrogen).  
 
2.2.1.6 Fluorescence microscopy and confocal laser scanning microscopy 
Digitized images were captured on inverted ﬂuorescence microscope (Olympus IX71, 
USA) and Zeiss LSM 710 upright confocal microscope (Carl Zeiss, Germany) at 20× 
and 40/64× magniﬁcation, respectively. Image processing was performed with ImageJ 






2.2.1.7 Computation of nuclear to cytoplasmic fluorescence ratio (Fn/c) 
Image analysis was performed on digitized images with ImageJ software (Collins, 
2007) to determine nuclear to cytoplasmic fluorescence ratio (Fn/c) of each cell using 
the following formula: Fn/c = (Fn-Fb)/(Fc-Fb), where Fn is the nuclear fluorescence, Fc 
is the cytoplasmic fluorescence and Fb is the background fluorescence (Kumar et al., 
2013; Pryor et al., 2007; Rawlinson et al., 2009; Tay et al., 2013). The mean Fn/c ± 
SEM was calculated for ≥ 25 cells.  
 
2.2.2 Working with DNA and RNA 
2.2.2.1 Site-directed mutagenesis  
Site-directed mutagenesis (SDM) was carried out using with QuikChange II SDM Kit 
with appropriate forward and reverse primers, according to manufacturer’s 
instructions. Sequencing was done to confirm the presence of mutation.  
 
2.2.2.2 Polymerase chain reaction  
The polymerase chain reaction (PCR) for generating DNA fragments for cloning 
contained of 30-50 ng template DNA, 200 nM forward and reverse primer, 300 μm 
dNTPs, 1×PCR buffer and 1 μl PfuUltra II Fusion HS DNA Polymerase in a reaction 
volume of 50μl. The PCR cycling conditions were: 1 cycle of 95°C 2 minutes, 
followed by 30 cycles of 95°C 20 seconds, 55-58°C 20 seconds, 72°C 15 seconds per 
kb and a last cycle of 72°C for 10 minutes.  
 
2.2.2.3 Overlap extension polymerase chain reaction  
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The first step involved two independent PCRs that generated two PCR products that 
were subjected for joint in the second PCR (Figure 2-1; primers a and b for first 
fragment, and primers c and d for second fragment). Primers for the joining position 
(primer b and c) were designed in a way that they overlapped with each other by at 
least 30 base pairs. Following purification of both fragments, 1:1 molar ratio of 
purified fragments were mixed together and heated at 95°C in a heat block for 5 
minutes. The mixture was allowed to cool to RT to promote annealing of both 
fragments. Following annealing, the mixture underwent extension at 72°C for 30 
minutes by adding polymerase and dNTPs. After extension, 1/3rd of the extension mix 
was used for the last PCR, with the addition of primer a and d and fresh polymerase 
and dNTPs for amplification of more overlapped products.  
 
 
Figure 2-1: Schematic representation of the PCR products that were generated for overlap 
extension PCR. AB: segment synthesized by primers a + b; CD: segment synthesized by primers c + 




2.2.2.4 DNA extraction from agarose gel 
Following DNA gel electrophoresis, gel slides containing DNA were cut and 
subjected to DNA purification by QIAquick Gel Extraction Kit, following supplier’s 
protocol.  
 
2.2.2.5 Transformation of competent bacteria 
Competent E.coli XL1-blue and BL21-Codon Plus(DE3)-RIL were made in CCMB80 
buffer (Table 2-6) (Sambrook, 2001). DNA plasmid (≥50 ng/μl) or ligation reaction 
was mixed with 100 μl of competent bacteria and incubated on ice for 5 minutes. 
Afterwards, the cells were heat-shocked at 42°C for 1.5 minutes and incubated on ice 
for 2 minutes. The bacteria was resuspended in 500 μl LB and incubated at 37°C with 
shaking for 1 h. After 1 h, the cells were pelleted and plated on LB-agar plates 
containing appropriate antibiotics and grown overnight at 30 or 37°C for colony 
development.  
 
2.2.2.6 DNA plasmid purification 
Plasmids were prepared from 5-10ml (high copy plasmids) or 100 ml (low copy 
plasmids) overnight cultures that were inoculated with a single colony in LB medium, 
which contained the appropriate antibiotics. The plasmids were extracted with 
QIAGEN Plasmid Mini Kit according to manufacturer’s instructions. The reagent 
volumes were adjusted according to the volume of overnight culture. DNA was eluted 
in nuclease-free water and the concentration was quantified by NanoDrop 2000 UV-
Vis Spectrophotometer (Thermo Fisher Scientific, USA). 
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2.2.2.7 DNA sequencing 
Purified DNA plasmids or fragments were sent to First Base (Singapore) for 
sequencing. The sequencing results were analysed by ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Thompson et al., 1994). 
 
2.2.2.8 Quantitative real time RT-PCR  
For intracellular viral RNA quantification, total cellular RNA was extracted from 
infected cells by TRIzol reagent according to supplier’s protocol. 500 ng of viral RNA 
was used for cDNA synthesis with Improm II reverse transcription system with 
random primer in a 10 μl reaction according to manufacturer’s instructions. Following 
cDNA synthesis, 40 ng of cDNA was used for quantitative real time RT-PCR analysis 
of viral RNA with the use of iQ SYBR Green supermix and NS1 gene primers 
DENV2 NS1 (forward: 5’- CCGCTGACATGAGTTTTGAGTC-3; and reverse: 5’-
CATGACAGGAGACAT CAAAGGA-3’ (Paradkar et al., 2011a). Absolute copy 
numbers of viral RNA was calculated based on DENV2 standard curve and 
normalized to actin level that was also quantified (forward: 5’-
CAGGGGAACCGCTCATTGC CAATGG-3’ and reverse: 5’- 
TCACCACACACTGTGCCCATCTACGA’-3) and reported as absolute copy 
numbers of viral RNA per μg of RNA used for real-time RT-PCR.  
 
For extracellular viral RNA quantification, viral RNA from supernatant was extracted 
by QIAamp Viral RNA Mini kit according to manufacturer’s instructions and for its 
quantification, a SYBR green one-step real-time RT-PCR (Bio-Rad) was conducted 
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using the same PCR conditions as cellular RNA quantification, with primers that bind 
to NS1 gene (as mentioned above). Absolute copy numbers of viral RNA was 
calculated based on DENV2 standard curve and reported as absolute copy numbers of 
viral RNA in log scale per ml of supernatant used for real-time RT-PCR.  
 
2.2.3 Working with proteins 
2.2.3.1 Standard SDS-PAGE 
Protein samples were mixed with sample loading dye and were heated at 95ºC for 5 
minutes. The polyacrylamide gels were prepared according to standard protocols 
(Sambrook, 2001) and gel electrophoresis was carried out at a constant voltage of 
100-120 for 1-2 hours (10×7.5 cm). Prestained SDS-PAGE standard was used as 
molecular size marker. 
 
2.2.3.2 Western blot analysis 
Following gel electrophoresis, the proteins were transferred to Amersham Hybond-P 
PVDF transfer membrane with wet transfer apparatus (Biorad, USA) for 2 hours at a 
constant voltage of 80. The membrane was blocked with PBST-M for 1 hour at RT 
and was incubated overnight with the primary antibody diluted in PBST-M at 4°C. 
Following overnight incubation, the membrane was washed 3× for 10 minutes with 
PBST. Afterwards, the appropriate secondary antibody was diluted in PBST-M and 
incubated for 1-2 hours at RT with membrane. Following incubation, the membrane 
was washed 3× with PBST and WesternBright Sirius HRP substrate was added for 
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signal development. Image was acquired using an ImageQuant LAS 4000 (GE 
Healthcare, UK).  
 
2.2.4 Working with DENV2 cDNA infectious clone 
DENV2 of cosmopolitan genotype (GenBank™ accession number: EU081177, as 
mentioned in section 2.1.8) was selected to be the template for generation of cDNA 
infectious clone (developed in collaboration between Dr Subhash G. Vasudevan and 
Dr Eng Eong Ooi; clone was generated by Dr Yuwen Chong) because of its well-
documented patient’s history (Schreiber et al., 2009a). The overall schematic 
representation of cloning strategy is shown in Figure 2-2A. The infectious clone was 
divided into three separate fragments (fragment 1: nucleotide position 1-4,498, 
fragment 2: nucleotide position 4,493-6008 and fragment 3: nucleotide position 
6,003-10,723) and each fragment was maintained as a subclone in low-copy plasmid 
pWSK29 (Wang & Kushner, 1991) (pWSK29 D2 fragment 1, 2 and 3 respectively). 
These three fragments were also assembled into full-length clone, which was 
maintained in the same plasmid (Tay et al., 2014b). Depending on the site the 
mutation, the respective subclone was selected for SDM. 
 
2.2.4.1 Generation of mutant virus 
In the course of this work, all mutations were made in pWSK29 D2 fragment 3 




After transformation of DpnI digested site-directed mutagenesis reaction mix into E. 
coli XL-1 blue chemically competent cell, the cells were grown at 30°C for at least 20 
hours. Colonies were picked to inoculate 100ml Luria Broth (LB) culture for 
overnight growth at 30°C. On the next day, cells were harvested and lysed with 
QIAprep Spin Miniprep Kit (Qiagen) for isolating dengue cDNA plasmid. The 
plasmid was sent for automated DNA sequencing (1st BASE DNA Sequencing 
Services [Singapore]) to confirm the presence of mutation. Once the mutation was 
confirmed, fragment 3 was cut from the plasmid by XbaI and SacI and inserted into 
subclone pWSK29 D2 fragment 1+2 that were similarly cut with XbaI and SacI to 
generate full-length DENV2 cDNA infectious clone, which contained the intended 
mutation. All enzymes were purchased from NEB. 
 
2.2.4.2 Linearization and purification of linearized infectious clone plasmid  
10 μg of full-length DENV2 cDNA infectious clone plasmid was digested by SacI 
(NEB) in the presence of BSA and buffer 4 in a 100µl reaction for 2 hours at 37°C for 
linearization. After digestion, 100µ1 of phenol/chloroform/isoamylalcohol (25:24:1) 
was added and mixed thoroughly. The mixture was spun at 13,200 rounds per minute 
(rpm) for 2 minutes and 100µl was transferred to a new eppendorf tube. 100µl of 
chloroform was added to the supernatant and mixed thoroughly. The mixture was 
spun at 13,200rpm for 2 minutes and 60µl of supernatant was transferred to a new 
eppendorf tube. The remaining 40ul of supernatant was mixed thoroughly with 140µl 
of water and allowed to spin at 13,200 rpm for 2 minutes. 140µl of diluted supernatant 
was removed and combined with the initial 60µl of supernatant to give 200µl. 20µl of 
3M sodium acetate pH 5.2 (1/10th volume of combined supernatant) and 500µl of 100% 
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ethanol (2.5×volume of combined supernatant) were added to precipitated DNA at -
80°C for at least 1 hour. The mixture was spun at 13,200 rpm at 4°C for 10 minutes 
and the supernatant was discarded. The DNA pellet was washed with 1ml of 70% 
ethanol and the mixture was spun at 13,200 rpm at 4°C for 10 minutes. The 70% 
ethanol was removed and the DNA pellet was allowed to air-dry at RT. The dried 
DNA pellet was resuspended in RNase-free water and the concentration was 
measured by NanoDrop 2000 Spectrophotometer.  
 
2.2.4.3 In vitro transcription 
Linearized full-length DENV2 cDNA infectious clone plasmid that was purified was 
used as template for in vitro transcription by Ambion MEGAscript® T7 Transcription 
Kit. The reaction mix contained 5.6 µl of linearized DNA (≤3 µg), 2 µl of rGTP, rCTP 
and rUTP, 0.4 µ1 of rATP, 3 µl of m7G(5')ppp(5')A RNA Cap Structure Analog (total 
2.5 units), 1 µ1 RNAse inhibitor, 2 µ1 T7 RNA polymerase and 2 µ110× reaction 
buffer. The reaction mix was incubated at 37°C for 30 minutes. Following 30 minutes 
incubation, the reaction was spiked with additional 1.8 µl rATP and 0.2 µl 10× buffer 
and allowed to incubate for another 2 hours at 37°C. 1 µl of TURBO DNase was 
added and the reaction was incubated at 37°C for 15 minutes to remove DNA 
template. Following the addition of 27 µL Nuclease-free water and 30 µL lithium 
chloride, RNA was allowed to precipitate overnight at -80°C. After overnight 
incubation, the reaction mix was spun at 13,200 rpm at 4°C for 15 minutes to pellet 
RNA. The supernatant was removed carefully and the RNA pellet was resuspended in 
1 ml of 70% ethanol. The mixture was spun at 13,200 rpm at 4°C for 10 minutes to 
pellet RNA and the 70% ethanol was removed. The RNA pellet was allowed to air-
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dry at RT. The dried RNA pellet was resuspended in RNase-free water and the 
concentration was measured by NanoDrop 2000 UV-Vis Spectrophotometer. 0.6% 
DNA agarose gel was used to check RNA integrity.  
 
2.2.4.4 Electroporation of DENV RNAs into mammalian cells  
BHK-21 or C6/36 cells cells in the log phase of growth were trypsinized and washed 
2× with cold PBS pH 7.4. The cells were resuspended in Opti-MEM® (Gibco) to a 
cell density of 1×107 cells/ml. 10 µg of in vitro transcribed RNA was mixed with 800 
µl of the cell suspension and was transferred into a pre-chilled 4mm curvette (Bio-rad, 
Germany). The cells were electroporated with a Gene Pulser Xcell system (Bio-rad) at 
850V and 25µF, for 2 pluses at an interval of 3 seconds. The cells were allowed to 
recover at RT for 10 minutes.  
 
For BHK-21 cells, cells were diluted to a cell density of 3×105 cells/ml in RPMI 1640 
medium supplemented with 10% FBS and 1% P/S, and 1ml of cells were seeded into 
each well of a 12-well plate. The medium was changed 6 hours post-seeding to RPMI 
1640 medium supplemented with 2% FBS and 1% P/S, and the supernatants and cells 
were harvested at 24, 48, 72, 96 and 120 hours.  
 
For C6/36 cells, cells were diluted to a cell density of 1×105 cells/ml in RPMI 1640 
medium supplemented with 25 mM HEPES, 10% FBS and 1% P/S and 10 ml of cells 
were seeded into a T25 flask. The medium was changed 24 hours post-seeding to 
RPMI 1640 medium supplemented with 25 mM HEPES, 2% FBS and 1% P/S, and 
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the supernatants were harvested at 7 days post-seeding. The harvested samples were 
kept at -80oC till further processing.  
 
2.2.5 Statistical analysis  
Two-tailed unpaired Student t-test was used to determine if the difference in mean 
observed was statistically significant. P values < 0.05 were considered as signiﬁcant. 
All calculations were done using GraphPad Prism v5.0 (GraphPad Software Inc). 
 
2.3 Material and Methods that were used in section 3.1  
2.3.1 Peptide synthesis 
DENV3 and 4 NS3 and NS5 peptides (Table 2-8) that were used for SPR assay, 
competitive NS3-NS5 interaction ELISA and viral inhibition assay were synthesized 
by NTU peptide synthesis core facility (Singapore).  
Table 2-8: List of peptides used in SPR assay, competitive NS3-NS5 interaction ELISA and viral 
inhibition assay. The residue numbers in peptide name indicate the region on NS3 or NS5 that was 
synthesized. The peptides were synthesized with either biotin or NH2 group at N-terminal and CONH2 
group at C-terminal. “s” indicates scrambled sequence.  
 
























2.3.1 NS5 peptide-phage clone construction 
DENV3 NS5 peptide-phage clones were constructed using Ph.D.™ Peptide Display 
Cloning System (NEB) according to the manufacturer’s instructions. Templates 
encoding the sequence of DENV3 NS5320-368, 320-341 and 342-368 (Table 2-9) were 
synthesized by IDT. Transformant with NS5 insert was confirmed by sequencing, and 
was used to prepare NS5 peptide-phage stock as instructed by NEB for peptide-phage 
ELISA. The phage titre was determined prior to ELISA.  
Table 2-9: Sequences of NS5 template used in cloning of NS5 peptide-phage clones for NS5 
peptide-phage ELISA. The residue numbers in template name indicate the region on NS5 that was 
cloned. Underlined nucleotides within primers indicate Acc65I and EagI sites respectively.  
 














2.3.2 NS3 bacterial expression plasmid construction  
Plasmids for the expression of DENV3 NS5 RdRP (residues 273-900), DENV3 and 4 
NS3 full-length protein (NS2B49-66NS3FL; residues 49-66 of NS2B and 1-618 of NS3 
connected by a flexible glycine linker G4SG4), DENV 3 protease domain (NS2B49-
95NS31-185; residues 49-95 of NS2B and 1-185 of NS3 connected by a flexible glycine 
linker G4SG4) and DENV4 NS3 helicase domain (NS3172-618) had been described 
previously (Li et al., 2005; Luo et al., 2008a; Yap et al., 2007) (Table 2-10).  
73 
 
DENV3 NS2B49-66NS3FL construct (as mentioned above) was used as template to 
amplify the PCR fragments of DENV3 NS3172-618, 482-618 and 566-618 by primers in 
Table 2-10. DENV3 NS3172-618 and 482-618 fragments were digested with NdeI and 
BamHI, and ligated into pET14b vector that was pre-cut with NdeI and BamHI. 
NS3482-618 and 566-618 fragments were digested with BamHI and XhoI, and ligated into 
pGEX-4T-1 vector that was pre-cut with BamHI and XhoI.  
 
DENV4 NS2B49-66NS3FL construct (Luo et al., 2008a) was used as template to 
amplify the PCR fragment that encoded helicase of DENV4 NS3172-618-NS5320-341 
(connected by a flexible glycine linker G4SG4) (Figure 3-6A) by primers in Table 2-
10. The flexible linker sequence and NS5320-341 sequence were then added by two 
separate PCR reactions to the helicase fragment, and the full-length fragment was cut 
by NaeI and SalI and ligated into pProEx HTb vector that was pre-cut with NaeI and 
SalI.  
 
Mutation of NS3 N570 to alanine in DENV3 NS2B49-66NS3FL protein was done using 
using QuikChange II SDM kit, according to manufacturer’s instruction. The following 
primers were used: NS3_N570A_forward (5’-GATGGGCAACGCAATGCTCAAA 
TTTTAGAGGAG-3’) and _reverse (5’-CTCCTCTAA AATTTGAGCATTGCGTTG 
CCCATC-3’). The underlined nucleotide corresponds to the mutation that was being 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.3.3 E. coli protein expression and purification  
All NS3 and NS5 bacterial expression constructs (Table 2-3) were transformed into E. 
coli BL21 CodonPlus (DE3)-RIL cells for protein expression and were purified as 
previously published (Li et al., 2005; Luo et al., 2008a; Moreland et al., 2010; Tay et 
al., 2014b; Yap et al., 2007). 
 
2.3.4 Competitive NS3-NS5 interaction ELISA 
Maxisorp 96-well Immunoplate (Thermo Scientific Nunc) was coated with 100 μl of 
NS5 RdRP (5 μg/mL) in PBS (pH 7.2) overnight at 4ºC (Figure 3-2A). Prior to 
blocking of each well by 300 μl of 5% skim milk in PBST for 1 hour at 37ºC, the 
plate was washed 2× with PBS. After blocking, the plate was washed 3× with PBST 
and 35 μl of either DENV3 NS2B49-66NS3FL or NS2B47NS31-185 protein (control) that 
was diluted in PBST with 0.5% BSA was added for 1 hour incubation at 37ºC. After 
which, the plate was washed 4× with PBST and bound NS3 proteins were detected by 
1 hour incubation at 37ºC with 50 μl of 3F10 IgG (1 nmol/L) that was diluted in 
PBST-M. Plates were again washed 5× with PBST and incubated with 100 μl of anti-
human IgG HRP conjugate (1:1000 in PBST-M) for 1 hour at RT. Prior to colour 
development with 35 μl of colorimetric substrate TMB (3,3′,5,5′-
tetramethylbenzidine; Sigma), the plate was washed with 2×PBST and 1×PBS. 
Colour development was stopped with addition of 12.5 μl of 3M HCl and the plate 





For competitive NS3-NS5 interaction ELISA, the concentration of NS2B49-66NS3FL 
was fixed at either 60 nM when NS3 peptide was added (starting from 60 to 480 μM) 
or 80 nM when NS3 protein was added (starting from 1 to 20 μM). The concentration 
of NS3 peptide or protein at which 50% inhibition of NS2B49-66NS3FL protein binding 
occurs corresponds to the Kd. Data was subjected to nonlinear regression analysis by 
GraphPad Prism 5 software and an apparent Kd was obtained. 
 
2.3.5 ATPase assay 
The assay was carried out as described (Xu et al., 2005a), with slight modification. 
2.5 nM of purified NS2B49-66NS3FL WT or N570A protein was pre-incubated at 37°C 
with poly U (10 μg/ml) in 40 μl ATPase assay buffer (section 2.1.6) for 5 minutes. 
The reaction was initiated by the addition of 10 μl of increasing ATP concentrations 
(2-fold serial dilution, starting from 2000 μM) and carried out for 10 minutes at 37°C. 
10 μl of Malachite green reagent was added to stop the reaction. Absorbance was read 
at 635 nm after 30 minutes at RT. The Km of the protein was determined with 





2.3.6 Surface plasmon resonance assay (did in collaboration with Drs Luo 
Dahai and Julien Lescar in NTU) 
Surface plasmon resonance (SPR) measurements were performed on ProteOn XPR36 
instrument (Bio-Rad Laboratories, Inc). All experiments were carried out with a 
constant flow rate of 25µl/minutes (20 mM Tris-HCl pH 7.4, 0.2 M NaCl, 1 mM 
dithiothreitol, 5% glycerol, 0.005% NP-20). Both DENV4 NS2B49-66NS3FL and 
NS3172-618 were amine-coupled to a carboxylated sensor surface (GLM sensor chip) to 
a final immobilized level of 10000 and 15000RU respectively. A 2-fold serially 
diluted biotinylated NS5 peptides (starting from 120 μM) was injected in duplicate 
across the chip for four minutes and dissociation was monitored for ten minutes. Data 
were analyzed in ProteOn Manager version 2.0. 
 
2.3.7 NS5 peptide-phage ELISA 
The ELISA binding assay was performed as instructed by NEB. In brief, Maxisorp 
96-well Immunoplate was coated with either 100 μl of DENV3 NS2B49-66NS3FL, 
NS3172-618, NS3482-618, NS2B49-95NS31-185 or BSA (control) protein (5 μg/mL) in PBS 
(pH 7.2) overnight at 4°C. Prior to blocking of each well by 300 μl of 5% skim milk 
in PBST (PBS pH 7.2 supplemented with 0.1% Tween 20; PBST-M) for 1 hour at RT, 
the plate was washed 2× with PBS. After blocking, the plate was washed 3× with 
PBST and 100 μl (5×109 phage particles) of either DENV3 NS5320-368 , NS5320-341, 
NS5342-368 peptide-phage or WT phage (control) that was diluted in PBST-M was 
added for 2 hours incubation at RT. After which, the plate was washed 5× with PBST 
and bound phages were detected by 1 hour incubation at RT with 100 μl of anti-M13 
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HRP conjugate polyclonal antibody (1:1000; PBST-M) for 1 hour at RT. Prior to 
colour development with 35 μl of colorimetric substrate TMB, the plate was washed 
with 2×PBST and 1×PBS. Colour development was stopped with addition of 12.5 μl 
of 3M HCl and the plate was read at 450 nm on an optical density plate reader.  
 
 
2.3.8 Small angle X-ray scattering data collection and processing (did in 
collaboration with Saw Wuan Geok and Dr Gerhard Grüber from 
NTU) 
Small angle X-ray scattering (SAXS) data of the NS3172-618 and NS3172-618-NS5320-341 
were collected and analysed as described (Tay et al., 2014b). Briefly, SAXS 
experiments for both NS3172-618 and NS3172-618-NS5320-341 proteins were collected with 
a NANOSTAR instrument (Bruker AXS, USA) that was equipped with a Metaljet X-
ray source and a 2D Vantee-2000 detector. Data was collected at 15°C, a wavelength 
of λ = 1.34 Å and a source-to-sample and sample-to-detector distance of 145 and 67 
cm, respectively. To exclude concentration-dependence effect, 3 different 
concentrations of each protein, namely 1.2, 2.2 and 4 mg/ml, were prepared. Nine 
measurements were recorded for each sample with a 5 minutes interval. The data were 
flood-field, spatially corrected and processed using the in-built SAXS software. No 
radiation damage was detected as comparison of all datasets revealed no changes in 
data. The scattering intensity of the buffer was subtracted from the scattering intensity 
of each protein solution. All the data processing steps were performed automatically 
using the program package PRIMUS (Svergun, 1993). The radius of gyration Rg and 
forward scattering I(0) were evaluated using the Guinier approximation (Lipson, 
1956). These parameters were also computed by the indirect transform package 
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GNOM (Svergun, 1992), which also provide the distance distribution function p(r). 
Ten low-resolution models of NS3172-618 or NS3172-618-NS5320-341 were independently 
built by the program GASBOR (Svergun et al., 2001). The normalized spatial 
discrepancy (NSD), which is a measure of similarity between sets of 3D points was 
computed for all ten reconstructions using the DAMAVER program (Kozin & 
Svergun, 2001); the reconstruction with the least NSD was selected for both proteins. 
Ensemble Optimization Method (EOM) suite was employed to select an ensemble of 
conformations that best fits the experimental data, and the dimensions of selected 
conformations were compared with the random pool to evaluate the compactness and 
flexibility of NS3172-618-NS5320-341 (Bernado et al., 2007; Petoukhov et al., 2012). 
 
2.3.9 Viral inhibition assay  
One day before infection, Huh-7 cells were seeded in 12 well plates at a density of 
2×105 cells/well. On the following day, cells were infected with DENV2 (MOI = 1) 
for 1 hour at 37°C, and after which, virus inoculums were removed and replaced with 
5% FBS DMEM media. At 6 hours post-infection, the infected cells were treated with 
7.5 μM NS3 peptides complexed with 22.5 μM penetratin (molar ratio = 1:3) or 7.5 
μM NS5-penetratin fusion peptides. At 24 hour post-infection, cells were washed 
once with PBS pH 7.4 prior to lysis by TRIzol for extraction of total cellular RNA for 
viral RNA quantification by real-time RT-PCR analysis with primers that binds NS1 
gene (see section 2.2.2.8). Absolute copy numbers of viral RNA was calculated based 
on DENV2 standard curve and normalized to actin level that was also quantified. The 




2.3.10 NS3-NS5 co-IP from infected cells 
One day prior to infection, 2.4×106 Huh-7 cells were seeded in a 10-cm plate. On the 
following day, medium was removed and cells were infected with either DENV1 or 2 
at a multiplicity of infection (MOI) of 10 (2 plates per serotype). After 1 hour 
incubation at 37°C, virus inoculum was removed and replaced with 5% FBS DMEM 
medium. The plates were kept at 37°C with 5% CO2 for 24 hours. After 24 hours, the 
medium was removed and the cells were harvested by trypsinization. The cells were 
washed 2× with 5ml cold PBS pH 7.4 and the cell pellet was resuspended in 600 μl of 
lysis buffer with 1% triton X-100 that was supplemented with protease inhibitor). The 
cells were allowed to lyse on ice for 30 minutes with occasional mixing. The lysed 
cells were centrifuged at 13,200 rpm for 10 minutes in a 1.5ml eppendorf tube, and 
supernatant was transferred to new eppendorf tube. 2µg of each dengue antibody 
(mouse anti-E 4G2, human anti-NS3 3F7 (Moreland et al., 2012), anti-NS3 3F8 
(Moreland et al., 2012) or anti-NS5 5R3 (Zhao et al., 2014)) was incubated with 135 
µl of supernatant overnight at 4°C with continuous rotation. Following overnight 
incubation, 10µl of equilibrated protein A/G resin (washed 3× with lysis buffer) was 
added to each antibody-supernatant mixture and allowed to incubate for at least 2 
hours at 4°C with continuous rotation. After incubation, the resin was washed with 3× 
with 1ml TBST (25 mM Tris pH 7.2, 100 mM NaCl and 0.1% Tween 20). Bound 
proteins were eluted from resin by boiling at 95ºC for 5 minutes with 45 μl of 2× 





2.3.11 Generation of NS3:N570A and NS5:K330A mutant viruses 
For NS3:N570A and NS5:K330A, mutation was done in pWSK29 D2 fragment 3 
subclone. SDM was performed with QuikChange II SDM Kit, according to the 
manufacturer's instructions. The following primers were used for the generation of 
both mutants: NS3:N570A_forward (5’-CTTTGATGGAGTCAAGAACGCCCAAA 
TCTTGGAAGAAAATG-3’) and _reverse (5’-CATTTTCTTCCAAGATTTGGGCG 
TTCTTGACTCCATCAAAG-3’) and NS5:K330A_forward (5’-GTGGTTAGGCTG 
CTAACAGCACCTTGGGATGTCATCCCC-3’) and _reverse (5’- GGGGATGACA 
TCCCAAGGTGCTGTTAGCAGCCTAACCAC-3’). The underlined nucleotide 
corresponds to the mutation that was being made.  
 
2.3.12 Strand-specific quantitative RT-PCR assay  
For intracellular viral RNA quantification of both negative- and positive-strand, 5’-
tagged primers (Plaskon et al., 2009) that bind to E gene (Johnson et al., 2005) were 
used for transcribing cDNAs of both polarities (Table 2-11). Forward primer 
(Eden2_E_FP_RT) was used to transcribe cDNA from negative-strand RNA, while 
reverse primer (Eden2_E_RP_RT) was used to transcribe cDNA from positive-strand 
RNA by using Improm II reverse transcription system. 40 ng of cDNA was used for 
real-time RT-PCR analysis of viral RNA with the use of iQ SYBR Green supermix 
and the appropriate primer pair for either negative-strand (Eden2_E_RP_qPCR and 
Tag_S_qPCR) or positive-strand (Eden2_E_FP_qPCR and Tag_S_qPCR) for 
detection. Absolute negative- and positive-strand copy numbers were quantitated with 
DENV2 standard curve that used in vitro RNA transcripts (nucleotide number 1450 to 
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1739 of DENV2 genome) that were synthesized by T7 RNA polymerase, and reported 
as described in section 2.2.2.8.  
Table 2-11: Primers used for intracellular viral RNA quantification of both negative- and 
positive-strand by real-time RT-PCR. The underlined sequence corresponds to unique tag sequence 
that was incorporated into cDNA and was responsible for binding to tag primer during real-time RT-
PCR.  
 
Primer name Sequence (5’3’) Reference 
Eden2_E_FP_RT  GGCCGTCATGGTGGCGAATAACAGGCTATGGCACTGTCACGAT 
This study 






2.4 Materials and Methods that were used in section 3.2 
2.4.1 Biopanning of naïve human Fab-phage display library 
The biopanning was performed as described previously (Moreland et al., 2010; Tay et 
al., 2014a) (Figure 2-2). Briefly, Fab-phage display library (Humanyx Pte Ltd, 
Singapore) was biopanned against either biotinylated DENV2 or 3 NS5 MTase and 
RdRP proteins for four rounds, with increased stringency after each round, by 
reducing the amount of biotinylated protein and increasing the number of washes. 
After the last round of panning, individual phage colony was picked to produce phage 
particles for screening of positive phage clone that could bind to unbiotinylated 
DENV2 or 3 NS5 MTase and RdRP by ELISA. Upon confirmation of positive phage 
clone that bound NS5, the Fab-phage clone was converted to human IgG by cloning 
the variable light and heavy chain sequences into an IgG vector containing human 
constant region sequences via ApaL1 and BsmB1 sites as previously described (Lim 
et al., 2008). IgG was produced by transfection of full-length IgG vector via 
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jetPRIME reagent (Polyplus) into HEK293T cells as previously described (Moreland 
et al., 2012).  
 
Figure 2-2: Schematic representation of biopanning against Fab-phage display library. Humanyx 
library was constructed by introducing cloned Fab fragment into phagemid that fused the cloned Fab 
fragment to gene III. Fabs are displayed on surface of M13 phage as Fab-protein III fusion protein. 
During biopanning, Fab-phage are mixed with biotinylated target to allow binding and unbound phage 
are removed by washing. Bound phage are eluted by a short exposure to extreme pH and amplified 
overnight for subsequent rounds of biopanning. Figure is modified from (Smothers et al., 2002).  
 
 
2.4.2 Characterization of anti-NS5 by ELISA and dot blot 
The ELISA was performed as described previously (Moreland et al., 2012). Briefly, 
either DENV2 or 3 NS5 MTase or RdRP protein was coated overnight in PBS pH 7.5, 
5 μg/ml, at 4ºC. On the following day, the plate was washed and blocked in PBST-M 
for 1 hour at RT. After blocking, 2-fold serially diluted anti-NS5 Fab or IgG in PBST-
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M (starting from 200 nM; 5M1 or 5R3) was added and incubated for 1 hour at RT. 
After primary antibody incubation, plate was washed with PBST and incubated with 
an anti-human HRP conjugate (MyBiosource, USA) for detection. 
 
The dot blot was performed as described previously (Zhao et al., 2014). Briefly, either 
boiled or native DENV3 NS5 protein was spotted onto nitrocellulose western blot 
membrane at various amounts (2-fold serially diluted, starting from 2.5 μg). The 
membrane was allowed to dry prior to blocking in PBST-M. After blocking, the blot 
was incubated with 10 nM of anti-NS5 IgG for 1 hour at RT. After primary antibody 
incubation, bolt was washed with PBST and incubated with an anti-human HRP 
conjugate for detection.  
 
2.4.3 Mammalian expression plasmid construction  
2.4.3.1 DENV1-4 GFP-NS5 constructs 
DENV1-4 NS5 genes were amplified by PCR from DENV1-4 cDNA clones 
(GenBank accession numbers for the relevant sequences are: DENV1 (EU081230), 
DENV2 (EU081177), DENV3 (EU081190) and DENV4 (GQ398256)) (Christenbury 
et al., 2010; Schreiber et al., 2009b) with the primer pairs listed in Table 2-12 for each 
construct. The PCR products were digested with XhoI and XmaI and cloned in 




Table 2-12: Primers used to clone NS5 full-length proteins of DENV1-4 into pEGFP-C1 vector, 
which is an N-terminal GFP tag mammalian expression vector. FP indicates forward primer; RP 
indicates reverse primer; CTCGAG in FP indicates XhoI site; CCCGGG indicates XmaI site; CC 
indicates extra nucleotide added for in-frame cloning. 
Construct name Primer name Primer sequence  
D1 NS5 D1NS5_FP CAAGTCCGGACTCAGATCTCGAGCCGGTACGGGAGCCCAAGGGG 
D1NS5_RP CTAGATCCGGTGGATCCCGGGTCACCAGAGTGCCCCTTCGGG 
D2 NS5 D2NS5_FP CAAGTCCGGACTCAGATCTCGAGCCGGAACTGGCAACACAGGAGAG 
D2NS5_RP CTAGATCCGGTGGATCCCGGGCTACCACAAGACTCCTGCCTC 
D3 NS5 D3NS5_FP CAAGTCCGGACTCAGATCTCGAGCCGGAACAGGCTCACAAGGTG 
D3NS5_RP CTAGATCCGGTGGATCCCGGGTTACCAAATGGCTCCCTCCAAC 




2.4.3.2 DENV1 and 2 GFP-NS5 domain-swapped constructs 
DENV1 and 2 GFP-NS5 domain-swapped genes were generated by overlap extension 
PCR with the primer pairs listed in Table 2-12 and 2-13. DENV1 and 2 GFP-NS5 
constructs (mentioned above) were used as templates for overlap extension PCR. The 
PCR products were digested and cloned in pEGFP-C1 vector as described in section 
3.2.5.1.  
Table 2-13: Primers used to clone NS5 full-length proteins that were domain-swapped between 
DENV1 and 2 into pEGFP-C1vector (together with those primers listed in Table 2-12). The residue 
numbers in construct name indicate the region on DENV1 and 2 NS5 that were being swapped. FP 
indicates forward primer; RP indicates reverse primer.  
Construct name Primer 
name 
Sequence  
D2 1-319 D1 320-405 
D2 406-900  
D2_320_D1 FP CAGACTGGATCAGCATCATCCATGGTCAATGGTGTGGTGAAAC 
D2_320_D1 RP GTTTCACCACACCATTGACCATGGATGATGCTGATCCAGTCTG 
D1_405_D2 FP GGAGTTCACAAGAAAAGTTAGGTCAAATGCAGCCTTAGGTGCC 
D1_405_D2 RP GGCACCTAAGGCTGCATTTGACCTAACTTTTCTTGTGAACTCC 
D1 1-319 D2 320-405 
D1 406-900 
D1_320_D2 FP GCCATCAGGATCAGCCTCATCCATGGTGAACGGAGTGGTTAGGC 
D1_320_D2 RP GCCTAACCACTCCGTTCACCATGGATGAGGCTGATCCTGATGGC 
D2_405_D1 FP GAATTCACAAGAAAGGTGAGAAGCAACGCAGCCATTGGAGCAGTG 






2.4.3.3 DENV1 and 2 GFP-NS3 constructs 
DENV1 and 2 NS3 genes were amplified by PCR from pET32b plasmids that 
encoded DENV1 and 2 NS2B49-66NS3 (GenBank accession numbers for the relevant 
sequences are: DENV1 Hawaii strain (EU848545) and DENV2 TSV01 strain 
(AY037116)) (Moreland et al., 2010) with the primer pairs listed in table 2-14. The 
PCR products were digested and cloned in pEGFP-C1 vector as described in section 
3.2.5.1. 
Table 2-14: Primers used to clone NS3 full-length proteins of DENV1 and 2 into pEGFP-C1 
vector. FP indicates forward primer; RP indicates reverse primer; CTCGAG in FP indicates XhoI site; 




name Sequence  
D1 NS3 D1NS3_FP CAAGTCCGGACTCAGATCTCGAGCCGCCGATTTATCACTGGAGAAAGC 
D1NS3_RP CTAGATCCGGTGGATCCCGGGTTATCTTCTTCCTGCTGCAAACTC 
D2 NS3  D2NS3_FP CAAGTCCGGACTCAGATCTCGAGCCGCTGATTTGGAACTGGAGAGAG 
D2NS3_RP CTAGATCCGGTGGATCCCGGGTTACTTTCTTCCAGCTGCGAATTCCTTG 
 
All plasmids produced in the study were verified by sequencing (First Base, 
Singapore) before use. 
 
2.4.4 Virus infection in Huh-7 cells  
One day prior to infection, 7.5×104 Huh-7 cells were seeded into 24-well plate, with 
glass cover slips, and incubated overnight at 37oC with 5% CO2. On the following day, 
the cells were infected with either DENV1, 2, 3 or 4 at a MOI of 10 for 1 hour and 





2.4.5 Cell-based flavivirus immunodetection assay 
The cell-based flavivirus immunodetection (CFI) assay was carried out essentially as 
described elsewhere (Tan et al., 2014). Briefly, one day before the experiment, 
1.3×104 BHK-21 cells were seeded into 96-well plate and incubated overnight at 37oC 
with 5% CO2. On the following day, the cells were infected with DENV2 at a MOI of 
0.3, in the presence of different concentrations of the test compounds for 1 hour at 
37°C. The virus inoculums were removed and replaced with fresh 2% FBS RMPI 
media containing the test compounds, and the cells were incubated for 48 hours, at 
37°C with 5% CO2. The cells were washed once with phosphate-buffered saline 
(PBS) and fixed with ice-cold methanol for 15 minutes at -20ºC. Following fixation, 
cells were washed 2× by PBS and blocked for 1 hour at RT in PBS that contained 1% 
FBS and 0.1%Tween 20. After blocking, fixed cells were analyzed by IFA by using 
primary antibody against E (4G2) and secondary antibody coupled to Alexa-Fluor 488 
(Invitrogen). Cells were counterstained with DAPI prior to high-content ﬂuorescence 
microscopy by imaging at channels that detected both DAPI and Alexa Fluor 488 at 
4× magnification. Dose-response curves were plotted (log concentration of test 
compound versus mean percentage infection) by nonlinear regression analysis in 
GraphPad Prism 5 software and the concentration of the test compound that decreased 






2.5 Material and Methods that were used in section 3.3  
2.5.1 NS3- or NS5-host protein co-IP from transfected cells 
One day prior to transfection, 5×106 HEK293T cells were seeded into 10-cm plate and 
incubated overnight at 37oC with 5% CO2. On the following day, cells were 
transfected using jetPRIME reagent (Polyplus) with 10 μg of plasmid per plate (2 
plates per GFP construct), according to the manufacturer’s recommendations. After 
24 hours, the medium was removed and the cells were harvested by trypsinization. 
The cells were washed 2× with 5ml cold PBS pH 7.4 and the cell pellet was 
resuspended in 200 μl of lysis buffer (10 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM 
EDTA, 0.5% (v/v) NP-40) in the presence of protease inhibitor (Sigma)). The cells 
were allowed to lyse on ice for 30 minutes with occasional mixing. The lysed cells 
were centrifuged at 13,200 rpm for 10 minutes in a 1.5ml eppendorf tube, and 
supernatant was transferred to new eppendorf tube. The supernatant was diluted with 
dilution buffer (10 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA) to achieve a final 
concentration of 0.2% NP-40. 15 μl of equilibrated GFP-Trap_A resin (washed 3× 
with lysis buffer) was incubated with diluted supernatant overnight at 4°C with 
continuous rotation. Following overnight incubation, the resin was washed with 2× 
with 500 μl of lysis buffer and once with 500 μl of 50 mM ammonium bicarbonate. 
Bound proteins were eluted from resin by 70 μl of 0.2% (w/v) RapiGest SR surfactant 
reagent (Waters) that was made up in 50 mM ammonium bicarbonate via vigorous 
vortexing for 5 minutes at RT. The elutant was removed and fresh 70 μl of 0.2% 
RapiGest SR reagent was added to elute the remaining bound proteins via heating at 




2.5.2 Silver staining and western blot analysis  
Elutants from co-IP experiment were nanodropped to quantify the amount of protein 
present. After quantification, appropriate amount of elutants were mixed with 4×LD 
and boiled, prior to loading on two 8% SDS PAGE for silver staining (Thermo 
Scientific Pierce) and western blot analysis. Western blot was performed as described 
using primary antibodies against GFP, STAT2, DDX3X, DDX5 and MATR3 and the 
respective HRP conjugated secondary antibodies were added for detection.  
 
2.5.3 LC/ESI/MS/MS analysis and MS data analysis 
Elutants were quantified by BCA assay (protein total amount is listed in Table 3-2) 
prior to mass spectrometry (MS) analysis to ensure that a fixed percentage (≤ 1 μg) of 
each elutant was injected for analysis. After BCA quantification, elutants were 
digested with trypsin and digested peptides were subjected to liquid chromatography 
(LC)/electrospray ionization (ESI)/MS/MS for host protein identification; this service 
was provided by Proteomics and Metabolomics Shared Resource of Duke University 
(http://www.genome.duke.edu/cores/proteomics/).  
 
For MS data analysis, trypsin-digested peptides were searched against the Swiss-Prot 
2013× database using the ‘Mascot’ database search algorithm. Search parameters in 
Mascot were as follows: an initial MS tolerance of 10 ppm and an MS/MS tolerance 
at 0.04 Da, full tryspin specificity and allowing at most 2 missed cleavages. 
Carbamidomethylation of cysteine was included as a fixed modification, and 
oxidation of methionines and deamidation of asparagine and glutamine were included 
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as variable modifications. Scaffold Proteome software (version 4.3.4) was used to 
validate MS/MS-based peptide and protein identification (available from 
http://www.proteomesoftware.com/products/free-viewer/). Peptide and protein 
identifications were validated with the PeptideProphet algorithm with decoy database 
validation, and the final database set was curated based on the following parameters: 
peptide thresholds: 95.0% minimum, protein thresholds: 99.0% minimum and at least 
two exclusive unique peptide count (the number of different amino acid sequences, 
regardless of any modification that are associated with a single protein group).  
 
2.5.4 Enrichment of annotation terms and pathways 
The set of human proteins that bound to either GFP-NS2B18NS3 (DENV1 or 2) or 
GFP-NS5 (DENV1 or 2) was submitted to GeneMANIA (Warde-Farley et al., 2010) 
with the following parameters: (1) all networks enabled, (2) equal weighting by 
network, and (3) 20 related genes displayed. GeneMANIA performed a false 
discovery rate-corrected hypergeometric test to test for enrichment of gene ontology 
(GO) features in the query/input dataset by comparing with the entire database of GO 
terms in the Homo sapiens proteome. Significantly enriched GO features, together 
with their associated q-values are reported. For each enriched GO feature that is 
associated with the generated interaction network, the number of proteins in the 
interaction network listed in that group, as well as the number of total proteins in the 





2.6 Materials and Methods that were used in section 3.4 
2.6.1 Mammalian expression plasmid construction  
Two types of mammalian expression plasmids were used for cloning: [1] pEGFP-C1 
vector (Clontech) and [2] pEGFP-C1 vector with additional GFP gene cloned in 
(2×GFP vector) that was generated in this study (see below for details). Gene 
fragments were generated either by PCR or overlap extension PCR (see below for 
details) and were digested by XhoI and XmaI prior to ligation into pre-cut vectors. 
 
2.6.2 DENV1 and 2 GFP-NS5 domain-swapped constructs 
DENV1 and 2 GFP-NS5 domain-swapped genes were generated by overlap extension 
PCR with the primer pairs listed in Table 2-12 and 2-15. DENV1 and 2 GFP-NS5 
constructs (mentioned above) were used as templates for overlap extension PCR. The 
PCR products were digested and cloned in pEGFP-C1 vector as described in section 
2.4.3.1.  
Table 2-15: Primers used to clone NS5 full-length proteins that were domain-swapped between 
DENV1 and 2 into pEGFP-C1vector (together with those primers listed in Table 2-12). The 
residue numbers in construct name indicate the region on DENV1 and 2 NS5 that were being swapped. 
FP indicates forward primer; RP indicates reverse primer.  
Construct name Primer name Sequence  
D2 1-272 D1 273-900 D2_272_D1 FP CGGAATTGAAAGTGAGACACCAAACCTAGATATCATTGGCCAG 
D2_272_D1 RP CTGGCCAATGATATCTAGGTTTGGTGTCTCACTTTCAATTCCG 
D2 1-319 D1 320-900 D2_320_D1 FP CAGACTGGATCAGCATCATCCATGGTCAATGGTGTGGTGAAAC 
D2_320_D1 RP GTTTCACCACACCATTGACCATGGATGATGCTGATCCAGTCTG 
D2 1-405 D1 406-900 D2_405_D1 FP GAATTCACAAGAAAGGTGAGAAGCAACGCAGCCATTGGAGCAGTG 
D2_405_D1 RP CACTGCTCCAATGGCTGCGTTGCTTCTCACCTTTCTTGTGAATTC 
D1 1-272 D2 273-900 D1_272_D2 FP GCAGTGGAACCAGAGGTAGCCAATTTAGACATAATTGGGAAAAG 
D1_272_D2 RP CTTTTCCCAATTATGTCTAAATTGGCTACCTCTGGTTCCACTGC 
D1 1-319 D2 320-900 D1_320_D2 FP GCCATCAGGATCAGCCTCATCCATGGTGAACGGAGTGGTTAGGC 
D1_320_D2 RP GCCTAACCACTCCGTTCACCATGGATGAGGCTGATCCTGATGGC 
D1 1-405 D2 406-900 D1_405_D2 FP GGAGTTCACAAGAAAAGTTAGGTCAAATGCAGCCTTAGGTGCC 





2.6.2.1 DENV1 and 2 GFP-NS5 motif-swapped constructs 
DENV1 and 2 GFP-NS5 motif-swapped genes were generated by overlap extension 
PCR with the primer pairs listed in Table 2-12 and 2-16. DENV1 and 2 GFP-NS5 
constructs (mentioned above) were used as templates for overlap extension PCR. The 
PCR products were digested and cloned in pEGFP-C1 vector as described in section 
2.4.3.1. 
Table 2-16: Primers used to clone NS5 full-length proteins that were motif-swapped between 
DENV1 and 2 into pEGFP-C1 vector (together with those primers listed in Table 2-12). The 
residue numbers in construct name indicate the region on DENV1 and 2 NS5 that were being swapped. 
FP indicates forward primer; RP indicates reverse primer.  
Construct name Primer name Sequence  
D2 1-361 D1 362-393 D2 
394-900 
D2_362_D1 FP CAAAGAGAAGGTGGACACGAGAACACCAAAAGCAAAACGAGG 
D2_362_D1 RP CCTCGTTTTGCTTTTGGTGTTCTCGTGTCCACCTTCTCTTTG 
D1_393_D2 FP GAAACAAGAAGCCAAGAATTTGTACCAGAGAAGAATTCACAAG 
D1_393_D2 RP CTTGTGAATTCTTCTCTGGTACAAATTCTTGGCTTCTTGTTTC 
D2 1-393 D1 394-496 D2 
497-900 
D2_394_D1 FP GAAAAAGACACCTAGGATGTGCACAAGAGAGGAGTTCACAAG 
D2_394_D1 RP CTTGTGAACTCCTCTCTTGTGCACATCCTAGGTGTCTTTTTC 
D1_496_D2 FP CATGAACGAAGACCACTGGTTTTCCAGAGAGAACTCCC 
D1_496_D2 RP GGGAGTTCTCTCTGGAAAACCAGTGGTCTTCGTTCATG 
D2 1-507 D1 508-536 D2 
537-900 
D2_508_D1 FP CCCTGAGTGGAGTGGAAGGAGAAGGACTCCACAAAC 
D2_508_D1 RP GTTTGTGGAGTCCTTCTCCTTCCACTCCACTCAGGG 
D1_536_D2 FP CAGATGACACAGCCGGATGGGACACAAGAATCACAC 
D1_536_D2 RP GTGTGATTCTTGTGTCCCATCCGGCTGTGTCATCTG 
D2 1-551 D1 552-585 D2 
586-900 
D2_552_D1 FP CAGGATGGGACACAAGAATCACAGAGGATGATCTTCAGAATG 
D2_552_D1 RP CATTCTGAAGATCATCCTCTGTGATTCTTGTGTCCCATCCTG 
D1_585_D2 FP CTTCAAGCTAACCTACCAAAATAAAGTGGTGCGTGTACAAAGA
C 
D1_585_D2 RP GTCTTTGTACACGCACCACTTTATTTTGGTAGGTTAGCTTGAAG 




D2_575_D1 RP GTTTTGGTACGTTAATTTGAAAATGGCTTCAGCAAG 
 
D2 1-625 D1 626-657 D2 
658-900 
D2_626_D1 FP CAGACAGATGGAGGGAGAAGGAATCTTTTCACCCAGTG 
D2_626_D1 RP CACTGGGTGAAAAGATTCCTTCTCCCTCCATCTGTCTG 
D1_657_D2 FP CGTCGAAAGGCTAAAAAGAATGGCCATCAGTGGAGATGATTG 
D1_657_D2 RP CAATCATCTCCACTGATGGCCATTCTTTTTAGCCTTTCGACG 
D2 1-625 D1 626-708 D2 
709-900 
D2_626_D1 FP CAGACAGATGGAGGGAGAAGGAATCTTTTCACCCAGTG 





D2 1-625 D1 626-900 D2_626_D1 FP CAGACAGATGGAGGGAGAAGGAATCTTTTCACCCAGTG 
D2_626_D1 RP CACTGGGTGAAAAGATTCCTTCTCCCTCCATCTGTCTG 
D2 1-657 D1 658-900 D2_658_D1 FP GCGTGAGAGGTTATCAAGAATGGCAATCAGTGGAGATGACTGC
G 
D2_658_D1 RP CGCAGTCATCTCCACTGATTGCCATTCTTGATAACCTCTCACGC 








2.6.2.2 DENV1-4 GFP-NS5 C-terminal-swapped constructs 
DENV1 and 2 GFP-NS5 C-terminal-swapped genes were generated by PCR or 
overlap extension PCR with the primer pairs listed in Table 2-12 and Table 2-17. 
DENV1-4 GFP-NS5 constructs (mentioned above) were used as templates for PCR. 
The PCR products were digested and cloned in pEGFP-C1 vector as described in 
section 2.4.3.1. 
Table 2-17: Primers used to clone NS5 full-length proteins that were C-terminal-swapped 
between DENV1-4 into pEGFP-C1vector (together with those primers listed in Table 2-12). The 
residue numbers in construct name indicate the region on DENV1 and 2 NS5 that was being swapped. 
FP indicates forward primer; RP indicates reverse primer.  
Construct name Primer name Sequence  
D2 1-888 D1 889-900 D2_899_D1 RP CACCAGAGTGCCCCTTCGGGATCACTCTCGTTCTTAAATCTTTTC
ATGGATGGCATGTAG 
D2 1-888 D3 889-900 D2_899_D3 RP ACCAAATGGCTCCCTCCAACTCCTCTTCCTTCCTAAATCTTTTCA
TGGATGGCATGTAG 
D2 1-888 D4 889-900 D2_899_D4 RP TTACAGAACTCCTTCACTTTCGGAAGGAGCGCTAAATCTTTTCA
TGGATGGCATGTAG 
D1 1-882 D2 883-900 (also 










D2 1-882 D1 883-900 












2.6.2.3 DENV1 and 2 GFP-NS5 C-terminal truncated constructs 
DENV1 and 2 GFP-NS5 C-terminal truncated genes were generated by PCR with the 
primer pairs listed in table 2-12 and 2-18. DENV1 and 2 GFP-NS5 constructs 
(mentioned above) were used as templates for PCR. The PCR products were digested 




Table 2-18: Primers used to clone DENV1 and 2 NS5 proteins that were C-terminal truncated 
into pEGFP-C1 vector (together with those primers listed in Table 2-12). The residue numbers in 
construct name indicate the region on DENV1 and 2 NS5 that were being cloned. FP indicates forward 
primer; RP indicates reverse primer; CCCGGG indicates XmaI site. 
Construct name Primer name Sequence  
D1 1-882 D1_882_RP CTAGATCCGGTGGATCCCGGGTCAGTAATCTAGATAATTCTCATTCC
CAATTAG 
D2 1-882  D2_882_RP CTAGATCCGGTGGATCCCGGGCTAGTAGTCTGTGTATTCCTCATTGCC 
D2 1-888 D2_888_RP  CTAGATCCGGTGGATCCCGGGCTATCTTTTCATGGATGGCATGTAGT
C 




2.6.2.4 Generation of 2×GFP construct  
GFP gene was amplified by PCR from pEGFP-C1 plasmid with the following primer 
pair (forward: 5’-GTACAAGTCCGGAATGGTGAGCAAGGGCGAGGAGC-3’ 
and reverse: 5’- CGCCGCCTCGAGCCTTGTACAGCTCGTCCATGCCGAG-3’). 
The underlined sequences correspond to BspEI and XhoI, respectively. The PCR 
product was digested with BspEI and XhoI and cloned into pre-cut pEGFP-C1 vector. 
 
2.6.2.5 DENV1-4 2×GFP-NS5 constructs 
DENV1-4 NS5 gene fragments that corresponded to the indicated NS5 gene segment 
(denote by the residue numbers in construct name) were amplified from the respective 
DENV1-4 GFP-NS5 constructs with the primer pairs listed in Table 2-19. The PCR 
products were digested and cloned in 2×GFP vector as described above. SV40NLS 
gene fragment (sequence) was also cloned into 2×GFP vector to serve as a positive 




Table 2-19: Primers used to clone DENV1-4 NS5 gene fragments into 2×GFP vector. The residue 
numbers in construct name indicate the region on DENV1-4 NS5 that were being cloned. FP indicates 
forward primer; RP indicates reverse primer. CTCGAG in FP indicates XhoI site; CCCGGG in RP 
indicates XmaI site in RP; GCGGCGGC indicates extra nucleotide added for in-frame cloning and 
with the addition of three glycine residues.  
Construct 
name 
Primer name Sequence  
D2320-405 D2NS5_320_FP TCAGATCTCGAGGCGGCGGC CATGGTGAACGGAGTGGTTAG 
D2NS5_405_RP GTGGATCCCGGGCTAGCTTCTCACCTTTCTTGTGAATTC 
D2320-367 D2NS5_320_FP TCAGATCTCGAGGCGGCGGCCATGGTGAACGGAGTGGTTAG 
D2NS5_367_RP GTGGATCCCGGGCTATTTCGGTTCTTGGGTTCTCG 
D2368-405 D2NS5_368_FP TCAGATCTCGAGGCGGCGGCGAAGGCACGAAAAAGCTAATG 
D2NS5_405_RP GTGGATCCCGGGCTAGCTTCTCACCTTTCTTGTGAATTC 
D2368-389 D2NS5_368_FP TCAGATCTCGAGGCGGCGGCCGAAGGCACGAAAAAGCTAATG 
D2NS5_389_RP GTGGATCCCGGGCTACTTTTTCTTTCCTAGTTCTTTCC 
D2387-405 D2NS5_387_FP TCAGATCTCGAGGCGGCGGCCAAGAAAAAGACACCTAGGATGTGC 
D2NS5_405_RP GTGGATCCCGGGCTAGCTTCTCACCTTTCTTGTGAATTC 
D2883-900 D2NS5_883_FP TCAGATCTCGAGGCGGCGGCCATGCCATCCATGAAAAGATTTAG 
D2NS5_900_RP GTGGATCCCGGGCTACCACAAGACTCCTGCCTC 
D1883-900 D1NS5_883_FP TCAGATCTCGAGGCGGCGGCCATGACATCAATGAAGAGATTCAAGAACG 
D1NS5_900_RP CTAGATCCGGTGGATCCCGGGTCACCAGAGTGCCCCTTCGGG 
D3883-900 D3NS5_883_FP TCAGATCTCGAGGCGGCGGCCATGAAGAGATTCAGGAAGGAAGAGG 
D3NS5_900_RP CTAGATCCGGTGGATCCCGGGTTACCAAATGGCTCCCTCCAAC 
D4883-900 D4NS5_883_FP TCAGATCTCGAGGCGGCGGCCATGCCAGTCATGAAAAGATACAGC 
D4NS5_900_RP CTAGATCCGGTGGATCCCGGGTTACAGAACTCCTTCACTTTCGG 
SV40NLS SV40_NLS_FP TCAGATCTCGAGGCGGCGGCCCCAAAAAAGAAGAGAAAGG 
SV40_NLS_RP GTGGATCCCGGGCTATACCTTTCTCTTCTTTTTTGGGCC 
 
All plasmids produced in the study were verified by sequencing (First Base, 
Singapore) before use. 
 
2.6.3 Site-directed mutagenesis  
2.6.3.1 DENV2 GFP-NS5 with α/β and C-terminal NLS mutation constructs 
Mammalian GFP plasmid encoding DENV2 NS5 (mentioned above) was subjected to 
SDM with the primer pairs listed in Table 2-21 to generate alanine mutation at residue 
371-372, 387-389, 887-888 and 890-891. SDM was performed according to the 




Table 2-21: Primers used for SDM of DENV2 pEGFP-C1 GFP-NS5 plasmid. FP indicates forward 
primer; RP indicates reverse primer.  
Construct 
name 
Site of mutation  Sequence  






D2 α/β NLS 
A1+2 
Residues 371-372 and 


















Residues 887-888 and 





All mutations were verified by sequencing (First Base, Singapore) before use. 
 
2.6.3.2 DENV2 cDNA with C-terminal NLS mutation in NS5 gene 
Subclone pWSK29 fragment 3 (see section 2.2.4.1) was subjected to SDM with the 
primer pairs listed in Table 2-21 to generate alanine mutation at residue 887-888 and 
890-891. SDM was performed according to the manufacturer’s instructions. Mutation 
in fragment 3 clone was confirmed by sequencing and was excised from the vector by 
XbaI and SacI and cloned into subclone pWSK29 D2 fragment 1+2 that were 




Chapter 3: Results 
3.1 Fine mapping the interaction region between NS3 and NS5 and 
investigating its impact on virus replication 
3.1.1 NS3 and NS5 interact in vivo and in vitro  
NS3 and NS5 were previously reported to interact in DENV2 infected cells via co-IP 
(Kapoor et al., 1995). To demonstrate that NS3 and NS5 can also interact in DENV1 
infected cells, we used our in-house cross-reactive human anti-NS3 (3F7 and 3F8) 
(Moreland et al., 2012) and NS5 (5R3) (Zhao et al., 2014) IgG antibodies for co-IP 
experiment. We first infected Huh-7 cells with either DENV1 or 2 at MOI = 10 and 
lysed the cells at 24 hours post-infection to obtain the supernatant for co-IP with 
antibodies mentioned above. The elutants from co-IP were subjected to western blot 
analysis with anti-NS3 (3F8) (Moreland et al., 2012) and anti-NS5 (5M1) (Zhao et 
al., 2014) antibodies to check for presence of NS3 and NS5 proteins.  
 
When IP was performed with anti-NS5 5R3, both DENV1 and 2 NS3 and NS5 were 
detected by anti-NS3 and anti-NS5 in western blot (Figure 3-1). This demonstrated 
that anti-NS5 5R3 could immunoprecipitate NS3-NS5 complex from both DENV1 
and 2 infected cells and this is consistent with previous publication that NS3-NS5 
complex could be isolated from infected cells via anti-NS5 (Kapoor et al., 1995). 
However, when IP was carried out with anti-NS3 3F7 and 3F8, only DENV1 and 2 
NS3 were detected by western blot. This showed that anti-NS3 3F7 and 3F8 could 
only immunoprecipitate NS3 from both DENV1 and 2 infected cells, suggesting that 
the interaction between NS3 and NS5 may block the accessibility of NS3 epitope to 
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anti-NS3 (previously mapped to residues 526-531 of NS3) (Moreland et al., 2010) 




Figure 3-1: Co-IPs with lysates from DENV1 and 2 infected cells show that NS3 and NS5 interact 
in vivo. Cell lysates from DENV1 and 2 Huh-7 infected cells were subjected to immunoprecipitation 
with anti-NS3 (3F7 and 3F8) and anti-NS5 (5R3) IgGs. 10% of the total lysate were subjected to 
western blot analysis by anti-NS3 3F8 IgG at 0.2 nM and anti-NS5 5M1 IgG at 25 nM to indicate the 
amount of input NS3 or NS5 from infected cell lysate. 40% of the elutant from beads with the 
respective Abs were also subjected to western blot analysis by the same antibodies.  
 
 
Since NS3 and NS5 can interact in vivo, we next asked the question if NS3 and NS5 
can interact in vitro. To address that, we established an ELISA-based binding assay 
with NS3 and NS5 recombinant proteins to measure NS3-NS5 interaction in vitro. 
(Figure 3-2A). In-house anti-NS2B 3F10 IgG was used as detection reagent in this 
ELISA because anti-NS3 3F8 IgG could block NS3 binding to NS5, as shown in 
Figure 3-1. Furthermore, the binding of 3F10 to NS2B was less likely to block NS3-
NS5 interaction as NS2B is located at the opposite end of the elongated NS2B49-
66NS3FL (residues 49-66 of NS2B fused to NS3 full-length protein, residues 1-618 via 
glycine flexible linker) protein from the C-terminal region that contains NS5 binding 
site. In the assay, we coated DENV3 NS5 RdRP (residues 273-900) protein onto 
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ELISA plate, incubated with increasing concentration of NS2B49-66NS3FL and bound 
NS2B49-66NS3FL was detected by a fixed concentration of 3F10 IgG (1 nM). To test 
the specificity of 3F10-NS3-NS5 ELISA, NS2B49-95NS31-185 (residues 49-95 of NS2B 
fused to NS3 protease domain, residues 1-185 via glycine flexible linker) that only 
contained NS3 protease domain, which was fused to NS2B, was included as a 
negative control. As expected, only NS2B49-66NS3FL that contained full-length NS3 
protein, but not the protease domain, bound to coated NS5 RdRP in a dose-dependent 
manner (Figure 3-2B) (Moreland et al., 2012). Collectively, these results demonstrate 
that NS3-NS5 interaction can occur in vivo and in vitro.  
 
 
Figure 3-2: Interaction ELISA with recombinant NS3 and NS5 proteins shows that NS3 and NS5 
can interact in vitro. (A) Illustration of NS3-NS5 interaction ELISA. (B) Typical binding curve of 
NS2B49-66NS3FL protein (NS3 full-length protein, closed circles) to coated NS5 RdRP protein by 
interaction ELISA. NS2B49-95NS31-185 (protease domain, open squares) was included as a negative 






3.1.2 NS3566-618 interacts with NS5 RdRP 
Even though residues 303-618 of DENV2 NS3 helicase domain was previously 
shown by Y2H study to interact with residues 320-368 (bNLS) of DENV2 NS5 RdRP 
domain (Brooks et al., 2002; Johansson et al., 2001b), the amino acid residues on 
NS3 helicase that are involved in binding to NS5 RdRP have not been identified. 
However based on 3D structure, it was predicted that subdomain III of NS3 helicase, 
residues 482-618, contained the NS5 binding site (Wu et al., 2005; Xu et al., 2005a). 
Therefore, in order to prove that the NS5 binding site resides within the NS3 helicase 
domain, we decided to express a panel of truncated proteins of helicase protein for 
testing in the NS3-NS5 interaction ELISA that we had developed (Figure 3-2A). NS3 
helicase protein has three subdomains, namely I, II and III that are within residues 
172-326, 327-481 and 482-618 (residue numbers are based on DENV2 sequence, 
Figure 3-3A), repsectively, and based on that, we cloned six NS3 gene fragments that 
spanned different subdomains into either His or GST tagged vector for protein 
expression. Among these proteins, only NS3172-618, GST NS3482-618 and GST NS3566-
618 (labels as red in Figure 3-3A) were expressed and purified to adequate amount for 
testing in ELISA. Due to (i) protein stickiness, (ii) protein instability or (iii) low 
protein yield, NS3172-482, NS3307-619 and GST-NS3172-566 (labels as black in Figure 3-





Following the purfiication and quantification of proteins, we used NS3172-618, GST-
NS3482-618 and GST-NS3566-618 to compete with NS3 full-length protein for binding to 
NS5 RdRP in competitive NS3-NS5 interaction ELISA. Briefly, these proteins were 
serially diluted 2-fold starting with a concentration of 20 μM, and added together with 
80 nM of NS3 full-length protein to ELISA plate that was coated by NS5 RdRP 
proteins. NS3 full-length protein that was bound to NS5 RdRP was detected by anti-
NS2B 3F10. As indicated in Figure 3-3B, all the three NS3 truncated proteins were 
able to compete with NS3 full-length protein to bind to coated NS5 RdRP in a dose 
dependent manner. The apparent Kd for NS3-NS5 interaction for NS3172-618, GST-
NS3482-618 and GST-NS3566-618 were found to be comparable (5.33 ± 0.35 μM, 10.18 ± 
0.91 μM and 10.25 ± 1.14 μM (mean ± S.D, n = 3), respectively), and was also similar 
to the Kd for NS3172-618 that was reported previously (Moreland et al., 2012; Zou et al., 
2011). Next, we also computed the IC50 value for NS3172-618 to be 6.07 ± 2.60 μM. 
The IC50 values for GST-NS3482-618 and GST-NS3566-618 were not computed as we 
were unable to reach 100% inhibition due to limited amount of truncated protein. 
Taken together, these data indicate that the NS5 binding site resides within residues 




 Figure 3-3: Competitive NS3-NS5 interaction ELISA shows that residues 566-618 of NS3 are 
responsible for binding to NS5 RdRP. (A) Schematic representation of the NS3 constructs that were 
being made in this study. The residues numbers are shown above each construct. Construct name in red 
indicates that the protein was expressed and purified for this study. Construct name in black indicates 
that the protein was not expressed and/or purified for this study. (B) During incubation of NS2B49-
66NS3FL protein with coated NS5 RdRP, 2-fold serial dilution of various NS3 proteins (starting from 20 
μM) was added in triplicate during competitive ELISA. GST protein was included as negative control. 
Data are shown as the mean ± SD of triplicates from two independent experiments.  
 
 
3.1.3 NS3 N570 is critical for NS3-NS5 interaction  
To narrow down the NS3 region that interacts with NS5, we went on to screen an 
array of overlapping 15-mer peptides (Mimotopes) (Moreland et al., 2010; Rivino et 
al., 2013) that spanned subdomain III of helicase in the same competitive ELISA 
(Figure 3-4A). We identified two consecutive peptides (NS3566-580 and NS3571-585) that 
moderately (p-value = 0.06 and 0.009, respectively) blocked NS3-NS5 interaction, 
therefore narrowing down the interaction site to residues 566-585. We next tested the 
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synthetic peptide NS3566-585 in competitive ELISA and showed that it could also 
prevent NS3-NS5 interaction in a dose-dependent manner with an IC50 value of 128.8 
± 2.57 μM (Figure 3-4B); the same peptide also inhibited NS3-NS5 interaction when 
tested in an AlphaScreen-based NS3-NS5 binding assay (Takahashi et al., 2012) (data 
not shown). To assess the specificity of peptide NS3566-585 in blocking the interaction, 
we also included another peptide, NS386-100 that had similar charge as NS3566-585 in the 
experiment and we could show that this peptide did not compete. This implies that 
NS3-NS5 interaction involves sequence-specific residues on NS3 protein for 
interaction.  
 
Sequence alignment of NS3566-585 of DENV1-4 and other flaviviruses (Figure 3-4C) 
suggests that N570 (highlighted in grey) is highly conserved within this region and 
may be critical for NS3-NS5 interaction. To test this, we synthesized NS3566-585(N570A) 
peptide and carried out the same competitive ELISA. We found that the replacement 
of asparagine by alanine at position 570 of NS3 resulted in a null-peptide with respect 
to its ability to block NS3-NS5 interaction (Figure 3-4B). Next, we expressed and 
purified both NS2B49-66NS3FL WT and N570A full-length protein to measure their 
ATPase activity (Luo et al., 2010) (Figure 3-4D) to determine if residue N570 is 
important for ATPase activity. The ATPase activity of NS3 N570A protein was 
comparable to NS2B49-66NS3FL WT protein; both proteins also had similar affinity to 
ATP (Km = 185.8 ± 10.86 μM and 176.1 ± 8.73 μM for NS2B49-66NS3FL WT and 
N570A, respectively) and similar turnover numbers (kcat = 3.15 s-1 and 3.11 s-1 for 
NS2B49-66NS3FL WT and N570A, respectively). From these results, we concluded that 
N570 in subdomain III of NS3 helicase appears to be critical for NS3-NS5 interaction, 
without affecting the in vitro ATPase activity.  
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 Figure 3-4: In vitro functional characterization of NS3 residue N570. An array of overlapping 15-
mer peptides that spanned subdomain III of NS3 helicase were tested in competitive ELISA as shown 
in Figure 3-2A. 20 μM of helicase was included as negative control. Data are shown as the mean ± SD 
of duplicates from one experiment. (B) 2-fold serial dilution of 20-mer NS3566-585 or NS3566-585(N570A) 
peptide (starting from 480 μM) was tested in the competitive ELISA. NS386-100, which has similar net 
charge as NS3566-585 and NS3571-585 were included as negative controls. Data are shown as the mean ± 
SD of triplicates from two independent experiments. (C) Sequence alignment of NS3 residues 566-585 
of DENV2 with other DENV serotypes and representative members of the Flavivirus genus. NS3 
residue N570 that is critical for NS3-NS5 interaction is highlighted in grey and bold. The alignment 
was performed using ClustalW (Thompson et al., 1994). The virus sequences and their GenBank 
accession numbers are as follows: DENV2 (AF038403), DENV1 (U88535), DENV3 (M93130), 
DENV4 (AF326573), Yellow Fever virus (YFV; X15062), Japanese Encephalitis virus (JEV; M55506), 
Murray Valley Encephalitis virus (MVEV; AF161266) and West Nile virus (WNV; M12294). The 
numbering of residues is based on DENV2 protein sequence. (D) ATPase assay was carried out with 
2.5 nM of NS2B49-66NS3FL WT and N570A proteins, in the presence of increasing concentrations of 
ATP. The amount of inorganic phosphate released during reaction was detected with Malachite green 
reagent and the initial rates were calculated (mol of phosphate released per second). The data points 






3.1.4 NS5320-341 interacts with NS3 helicase 
While we were trying to identify the region on NS3 helicase that contributes to NS3-
NS5 interaction, we also tried to narrow down the region on NS5 RdRP that is 
involved in the interaction. The NS3 binding site on NS5 was shown by Y2H to reside 
within residues 320-368 (Brooks et al., 2002; Johansson et al., 2001b) and upon 
sequence inspection of this region within Flavivirus NS5, we identified a 20 amino 
acid sequence (residues 342-361) that is highly conserved among the Flaviviruses 
(Figure 3-5A). With this observation in mind, we decided to determine if residues 
320-341 or residues 342-368 of NS5 contains the NS3 binding site by two binding 
assays, namely peptide-phage ELISA and surface plasmon resonance (SPR).  
 
For peptide-phage ELISA, we first cloned DENV3 NS5 gene fragments the encoded 
NS5320-368, NS5320-341 or NS5342-368 into the genome of M13 phage to make phage that 
could express NS5 peptide on virus surface. Following that, phages were grown and 
concentrated to obtain high titre stock (≥ 1011 particles/ml). In parallel, we coated the 
ELISA plated with DENV3 [1] NS3 full-length protein (NS2B49-66NS3FL), [2] 
helicase (NS3172-618), [3] helicase subdomain III (NS3482-618), [4] protease (NS2B49-
95NS31-185; as negative control) and [5] BSA (as negative control) (Figure 3-5B). 
Next, we diluted the phage and added 5×109 phage particles to each coated well. 
Bound phages were detected by anti-M13 antibody. From the ELISA result, NS3 
proteins that contained residues 566-585, namely NS3 full-length protein, helicase 
and helicase subdomain III, were shown to bind to NS5320-368 and NS5320-341 peptide-
phages but not NS5342-368 peptide phage (Figure 3-5C); none of the phages bound to 
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NS3 protease and BSA. This result supported the ELISA data in Figure 3-3B that the 
NS5 binding site is indeed found in NS3 helicase subdomain III. 
 
For SPR, we first immobilized either DENV4 NS3 full-length (NS2B49-66NS3FL) or 
helicase (NS3172-618) (Figure 3-5B) on SPR chip and passed through serially diluted 
(2-fold) NS5320-368, NS5320-341 or NS5342-368 peptides to measure real-time binding of 
NS5 peptides to mobilized NS3 proteins; this enables us to compute KD value for the 
interaction. NS5320-368 and NS5320-341 (Figure 3-5D), but not NS5320-341 (data not 
shown), were detected to bind to NS3. After analysis of binding data, we determined 
the KD for NS5320-368 and NS5320-341 10-50 μM and 100-400 μM, respectively. This 
result was in agreement with the ELISA data that supported the presence of NS3 
binding site to be within residues 320-341 of NS5, but not residues 342-368. Taken 
together, we can conclude that the interaction between NS3 helicase and NS5 RdRP is 





Figure 3-5: Sequence alignment of Flavivirus NS5 residues 320-368, SPR and NS5 peptide-phage 
ELISA. (A) Sequence alignment of NS5 residues 320-368 (bNLS) of DENV2 with other DENV 
serotypes and representative members of the Flavivirus genus. The highly conserved 20-amino acid 
region within bNLS is bold. NS5320-341 that was fused to NS3172-618 is underlined and K330 that is 
important in NS3-NS5 interaction is bold and is highlighted in grey (Zou et al., 2011). The alignment 
was performed using ClustalW (Thompson et al., 1994). The virus sequences and their GenBank 
accession numbers are as described in Figure 3-4C. (B) Schematic representation of the NS3 constructs 
that were being used in this study. The residues numbers are shown above each construct. (C) NS3-
NS5 interaction data by peptide-phage ELISA. NS5 peptide sequence (NS5320-368, 320-341 and 342-368) was 
cloned directly into phage genome, which expressed as fusion peptide to protein III and was displayed 
on phage surface. NS3 (NS2B49-66NS3FL, NS3172-618, NS3482-618 or NS2B47NS31-185) or BSA (negative 
control) protein was coated onto ELISA plate and NS5 peptide phage (NS5320-368, NS5320-341 and 
NS5342-368; 5×109/well) was added to coated wells. No peptide/WT phage was included as negative 
control. Data are shown as the mean ± SD of triplicates from one representative experiment out of two 
independent studies. (D) NS3-NS5 interaction data by SPR assay. DENV4 NS3 protein (NS2B49-
66NS3FL or NS3172-618) was mobilized on chip and NS5 biotinylated peptide (NS5320-368, NS5320-341 and 
NS5342-368) was passed through to measure real-time interaction. The resultant affinity for interaction 
was calculated using the ratio of kd/ka from the SPR assay and was reflected as KD (equilibrium 
dissociation constants). Data are shown as the mean ± SD of duplicate from one independent 
experiment. The experiment in D was done in collaboration with Drs Luo Dahai, Julien Lescar and 




3.1.5 NS5320-341 binds to NS3 helicase in solution 
To gain some structural insights on the binding between NS3 and NS5, we made a 
construct that fused DENV4 NS3 helicase to residues 320-341 of DENV4 NS5 
(within bNLS) via a flexible glycine linker (G4SG4, NS3172-618-NS5320-341; Figure 3-6A) 
for crystallization study. The construct was designed based on the experience with the 
dengue NS3 protease where the covalent attachment of NS2B cofactor region to NS3 
protease domain permitted extensive biochemical and biophysical studies (Erbel et al., 
2006; Li et al., 2005; Luo et al., 2008a). Also, we have prior knowledge that NS3 
helicase crystallises easily. We managed to crystallize the fusion protein that was 
made from this construct. However, X-ray diffraction data of the crystal only showed 
electron density from NS3 helicase but not NS5320-341. Therefore, we employed small 
angle X-ray scattering (SAXS) as an alternative approach to X-ray crystallography, in 
hope of obtaining a low resolution, 3D molecular envelope of this protein in solution 
(Svergun et al., 2013). SAXS study was done with highly purified NS3172-618 and 
NS3172-618-NS5320-341 proteins at three different concentrations, namely 1.2 mg/ml, 2.1 
mg/ml and 4 mg/ml for data collection. The data were processed by subtracting the 
scattering intensities of the buffer from that of the protein to yield the final composite 
scattering curve (Figure 3-6B and C). Inspection of the Guinier plots at low angles 
revealed that the protein samples were monodispersed and not aggregated, and the 
dataset was of good quality (inset of Figure 3-6B and C). NS3172-618 has a radius of 
gyration (Rg, deﬁned as the root mean square average of the distance of the electrons 
from the center of the particle) of 25.16 ± 0.6 Å and a maximum dimension (Dmax) of 
72.95 Å, while the NS3172-618-NS5320-341 has a Rg of 25.42 ± 0.6 Å and a Dmax of 75.64 
Å. The distance distribution function curves for both proteins are “bell-shape”, 
indicates that the protein is globular (Figure 3-6D). Comparison of the forward 
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scattering of both proteins with the values obtained from a reference solution of 
lysozyme (14.4 kDa) produced a molecular weight of 44.4 kDa for NS3172-618 and 




Figure 3-6: SAXS of NS3172-618-NS5320-341 indicates NS3-NS5 interaction. (A) Schematic 
representation of recombinant NS3172-618 and NS3172-618-NS5320-341 proteins that were expressed in E. 
coli and used in SAXS study. SAXS scattering pattern (○) and its corresponding experimental fit (—) 
of (B) NS3172-618 and (C) NS3172-618-NS5320-341 at protein concentrations of 1.2 mg/ml (red), 2.1 mg/ml 
(olive) and 4 mg/ml (blue). The curves are displayed in logarithmic unit for clarity. The inserts in (B) 
and (C) show the respective Guinier plots. (D) Distance distribution functions of NS3172-618 (―) and 
NS3172-618-NS5320-341 (- -). (E) Superimposition of crystallographic structure of NS3172-618 (PDB ID: 
2JLS (Luo et al., 2008b)) with the determined solution shape of NS3172-618 (green). Ribbon 
representation of subdomain I, II and III of NS3172-618 are coloured in yellow, orange and red, 
respectively. (F) Superimposition of NS3172-618 and (green) and NS3172-618-NS5320-341 (cyan) solution 
shapes. The Rg of the NS3172-618 and NS3172-618-NS5320-341 were 25.2 Å and 25.4 Å, respectively. The 
arrows indicate two protrusions: the first protrusion is at the bottom of the NS3172-618-NS5320-341 solution 
shape and the second protrusion may be caused by a conformational alteration due to NS3172-618-NS5320-
341 interaction. (G) The EOM Rg-distribution of the selected ensemble (red line) contains a narrow peak 
at 24.6 Å, which is slightly smaller than the center Rg of random pool (grey filled area), 24.8 Å, 
suggesting NS3172-618-NS5320-341 is rigid and compact in solution, and peptide NS5320-341 is bound to 
NS3172-618. This experiment was done in collaboration with Wuan Geok Saw and Dr Gerhard Grüber 
from NTU.  
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The low resolution solution structure of NS3172-618 and NS3172-618-NS5320-341 were 
restored ab initio using program GASBOR (Svergun et al., 2001). The normalized 
spatial discrepancy (NSD) of ten independent reconstructions of NS3172-618 and 
NS3172-618-NS5320-341 are 0.95 ± 0.02 Å and 0.99 ± 0.03 Å, respectively. The 
reconstructions with the least NSD from both proteins were selected, and the obtained 
solution shapes for both proteins produced a good fit to the experimental data in the 
entire scattering range. The corresponding fits for NS3172-618 and NS3172-618-NS5320-341 
had discrepancies of χ = 1.15 and 1.04, respectively. Both NS3172-618 and NS3172-618-
NS5320-341 were globular shapes, with the dimensions of about 59.9 × 54.4 × 34 Å and 
65.6 × 57.7 × 36.8 Å, respectively. When the solution form of NS3176-618 (green) was 
superimposed with the crystal structure of NS3176-618 (PDB ID: 2JLS), it 
accommodated very well into the solution form of the protein (Figure 3-6E), implying 
that the solution data is of high quality and the crystal structure is likely to exist in 
solution. When the solution forms of NS3172-618 (green) and NS3172-618-NS5320-341 
(cyan) were superimposed (Figure 3-6F), two protrusions were observed and were 
denoted by arrows in Figure 3-6F. Protrusion 1 is at the bottom of NS3172-618-NS5320-
341 solution shape and this leads to a more elongated conformation in NS3172-618-
NS5320-341 than NS3172-618, which is also reflected by the increased Dmax in NS3172-618-
NS5320-341 (75.64 Å) when compared to NS3172-618 (72.95 Å) (Figure 3-6D). The 
protrusion is in close proximity to residue N570 (showed as blue stick representation 
in the inset of Figure 3-6F) and to the peptide NS3566-585 that was used in ELISA 
(showed as black cartoon representation in the inset of Figure 3-6F). Protrusion 2 of 
NS3172-618-NS5320-341 may occur due to a conformational alteration that was induced 
by NS3172-618 and NS5320-341 interaction. Taken together, these results appear to be 
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consistent with the ELISA data and suggest a physical interaction between NS3172-618 
and NS5320-341 in solution. 
 
To eliminate the possibility that NS5320-341 may be flexible in solution, the scattering 
dataset of NS3172-618-NS5320-341 were further analyzed by EOM (Bernado et al., 2007; 
Petoukhov et al., 2012) to assess the flexibility and compactness of NS3172-618-NS5320-
341 in solution (Figure 3-6G). Based on the width and position of the selected 
ensemble peak relative to random pool in Rg-distribution, the flexibility and 
compactness of the protein in solution can be determined. With respect to NS3172-618-
NS5320-341, the Rg-distribution of the ensemble contained a narrow peak, indicating 
that NS3172-618-NS5320-341 is rigid in solution. This peak is centered at 24.6 Å, which is 
slightly smaller than the center Rg of a random pool, 24.8 Å, suggesting that NS3172-
618-NS5320-341 is compact in solution. The EOM data demonstrate that peptide NS5320-





3.1.6 NS3:N570A mutant has reduced infectious virus production and 
viral protein synthesis 
To study the impact of NS3:N570A mutation on NS3-NS5 interaction during the virus 
life cycle, we first characterized DENV2 cDNA infectious clone (Figure 3-7A, a kind 
gift from Assoc Prof Eng Eong Ooi (Duke-NUS Graduate Medical School)) in term 
of its ability to produce viral protein and infectious virus. Following the transfection 
of in vitro transcribed DENV2 RNA into BHK-21 cells, IFA of BHK-21 cells showed 
increasing number of E-positive cells from day 1 to 3 post-transfection, with ~50-60% 
of cells being E-positive on day 3 (Figure 3-7B). Plaque assay with supernatant 
showed an increase in infectious virus particle production from day 1 to 3, peaking at 
1×105 pfu/ml on day 3 (Figure 3-7C). The size of plaque on BHK-21 cells that was 
produced by the supernatant of BHK-21 transfected cells was comparable to those 
produced by the supernatant of C6/36 transfected cells (left and right inset of Figure 
3-7C, respectively). These results indicate that the RNA transcribed from DENV2 
cDNA clone is infectious and that infectious virus particle can be produced in both 






 Figure 3-7: Characterization of DENV2 cDNA infectious clone. (A) Schematic representation of 
full-length DENV2 cDNA clone. The DENV2 genome (represented approximately to scale) contains a 
single open reading frame that encodes three structural proteins (C, prM and E) and seven NS proteins 
(NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). The cDNA clone was subdivided into three 
fragments based on unique restriction sites that are present within the genome to facilitate the assembly 
of full-length clone. The complete DENV2 clone has T7 promoter at 5’ end for in vitro transcription 
and SacI site at 3’ end for linearization of plasmid. (B and C) BHK-21 cells were electroporated with 
10 μg of in vitro transcribed DENV2 RNA and samples were harvested daily, for 3 days. (B) Infected 
cells were analysed by IFA with mouse anti-E 4G2 antibody on 48 and 72 hours post-transfection for 
presence of E protein and percentage infection was determined. (C) Culture supernatants were used for 
plaque assay on BHK-21 cells to determine viral titer. The size of plaque on BHK-21 cells that was 
derived from the supernatant of either BHK-21 (left inset) or C6/36 (right inset) cells, which was 
transfected with DENV2 WT RNA was shown. This experiment was performed in collaboration with 





After determining the growth kinetics of DENV2 WT virus that was derived from 
cDNA clone, DENV2 NS3:N570A cDNA mutant clone was constructed by SDM and 
its phenotype in viral protein synthesis and infectious virus production was examined 
over the course of 5-day post transfection. We also constructed DENV2 NS5:K330A 
mutant clone (Zou et al., 2011), a known NS3-NS5 interaction defective mutant that 
failed to replicate by reverse genetics studies for bench-marking our studies. Similar 
to NS5:K330A mutant, no infectious virus particle was recovered from NS3:N570A 
mutant even when neat supernatant was used for titering (Figure 3-8B). In agreement 
with the absence of infectious virus, extracellular viral RNA level for both mutants 
were at the limit of detection of viral RNA by real-time RT-PCR and did not change 
over the course of 5-day, suggesting that both mutants are inviable (Figure 3-8A). The 
viral RNA detection for WT increased over 72 hours when it reached maximal 
detection that stabilized until 120 hours. Next, to determine if polyprotein synthesis 
from the transfected RNA is occurring and that the lack of infectious virus may be 
due to absence of packaging and/or release of infectious virion, we checked the level 
of NS3 protein of transfected cells by both western blot and IFA. Surprisingly, for the 
cells that were transfected with NS3:N570A mutant transcript, we could detect NS3 
protein with anti-NS3 3F8 IgG (Moreland et al., 2012) in 24 and 48 hours samples 
(Figure 3-8C, red arrows) but not in 72 hour sample. The highest percentage of NS3-
positive cells (5-10%) was observed at 48 hours post-transfection, which reduced to ≤ 
5% of NS3-positive cells at 72 hours post-transfection (Figure 3-8D), and finally to an 
undetectable level at 96 and 120 hours post-transfection (data not shown). On the 
contrary, for NS5:K330A mutant, NS3 protein was almost undetectable by both 
western blot and IFA (≤ 1% of NS3-positive cells) at all time points post-transfection 
(Figure 3-8C and D). Taken together, the results imply that reduced NS3-NS5 
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Figure 3-8: Growth kinetics of BHK-21 cells that were transfected with DENV2 WT, NS5:K330A 
or NS3:N570A RNAs were monitored over the course of 5-day. (A-C) BHK-21 cells were 
electroporated with 10 μg of WT and mutant (NS3:N570A and NS5:K330A as control) in vitro RNA 
transcripts and samples were harvested daily, for 5 days. Supernatants were used to (A) determine 
absolute copy numbers of extracellular viral RNA by real-time RT-PCR and to (B) check for plaque 
production on BHK-21 cells. Absolute copy numbers of viral RNA in log scale per ml of supernatant 
used for real-time RT-PCR were plotted; data are shown as the mean ± SD of duplicate from two 
independent experiments. The grey line indicates the detection limit of assay. (C) Western blot and (D) 
IFA against NS3 protein were performed with anti-NS3 3F8 IgG (Moreland et al., 2012), and one 
representative experiment out of two independent studies was shown. This experiment was performed 





3.1.7 NS3:N570A mutant has a defect in RNA replication 
The reduction in viral protein synthesis for NS3:N570A mutant and lack of detectable 
infectious plaques suggests that attenuated RNA replication could occur at an early 
time point for this mutant. Hence, we examined the RNA replication kinetics by real-
time RT-PCR and IFA for detection of dsRNA. The results showed that intracellular 
viral RNA can be detected for NS3:N570A and WT but intriguingly, not for 
NS5:K330A transfected cells (Figure 3-9A and B). The viral RNA copy number for 
WT increased from ~106 copies/μg at 6 hours post-transfection to 109 copies/μg at 120 
hours, as detected by real-time RT-PCR. Although less than WT, a 10-fold increase in 
intracellular viral RNA copy number was observed from 24 to 48 hours post-
transfection (p-value = 0.008) for NS3:N570A mutant and thereafter, the level 
declined till 120 hours. The viral RNA copy number for NS5:K330A mutant 
decreased from 6 to 48 hours post-transfection and remained relatively stable from 48 
to 120 hours, implying that there was no active viral RNA replication and only the 
input RNA that was transfected by electroporation was being detected. Interestingly, 
the detection of peak intracellular RNA level for NS3:N570A mutant on at 48 hours 
correlated with the highest level of NS3 protein detected by western blotting (Figure 
3-8C). Collectively, this result clearly shows that NS3:N570A mutant is defective in 




 Figure 3-9: RNA replication kinetics of BHK-21 cells that were transfected with DENV2 WT, 
NS5:K330A or NS3:N570A RNAs were monitored over the course of 5-day. (A-B) Same 
experiment setup was performed as mentioned in Figure 3-8. (A) RNA was extracted from infected 
cells and absolute copy numbers of intracellular viral RNA were determined by real-time RT-PCR. (B) 
Infected cells were analysed by IFA for presence of dsRNA with mouse anti-dsRNA antibody on 48 
and 72 hours post-transfection and percentage infection was determined. Data from one independent 
experiment are shown and it is a separate experiment from Fig 3-7B and 3-8D. The grey line in (A) 
indicates the amount of residual negative-strand from transfected RNA. This experiment was 





3.1.8 Validation of strand-specific quantitative RT-PCR assay  
To examine the dynamics of RNA synthesis of WT and both mutants further, we 
developed real-time RT-PCR assay that can accurately measure the level of 
intracellular negative- and positive-strand viral RNA with strand-specific tagged 
primers (Lim et al., 2013a) (Lanford et al., 1994). We adopted this approach because 
the phenomenon of self-priming by reverse transcriptase (RT) prevents accurate 
strand-specific detection as RT can initiate cDNA synthesis from the 3’ end of RNA 
template in the absence of any primer (also known as endogenous priming) (Lanford 
et al., 1995) and such cDNA product can contribute to significant amount of PCR 
product during RT-PCR assay (Tuiskunen et al., 2010). However, the fusion of tag 
sequence to template complementary primer has been reported to prevent the 
amplification of self-primed cDNA during RT-PCR (Lanford et al., 1994). In our 
study, the tag sequence (sequence not found in DENV genome, coloured in orange in 
Figure 3-10) that was described by (Plaskon et al., 2009) was fused to the sequence 
that binds to DENV E gene (coloured in red in Figure 3-10) (Johnson et al., 2005) to 
create a primer that can bind to either negative- or positive-strand during the cDNA 
synthesis step to generate cDNA strand of reverse polarity by exogenous priming 
(Figure 3-10) (Note: cDNA was also generated in the same reaction mix by 
endogenous priming). We chose to use primer pair directed against the E gene for 
fusion to tag sequence because we are familiar with this primer pair (Low et al., 2014) 
and we wanted to avoid detecting sfRNA that is located at 3’UTR region (Pijlman et 
al., 2008). Following cDNA synthesis, the reaction mix was used for strand-specific 
quantitative RT-PCR assay, where the tag and E specific primers were used to 
distinguish exogenous primed cDNAs that were transcribed from either negative- or 
positive-strand template from self-primed (endogenous primed) cDNAs (Tuiskunen et 
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al., 2010); the absolute viral RNA copy numbers were then determined by comparing 




Figure 3-10: Schematic representation of strand-specific quantitative RT-PCR assay. Only the 
positive-strand detection is depicted here; the reverse also applies to negative-strand detection. During 
cDNA synthesis, dengue-specific sense primer that is fused to sense tag sequence (sequence not found 
in DENV genome) is used by RT to synthesize cDNA strand from template strand by exogenous 
priming. However, cDNA strand can also be synthesized by RT from template strand, in the absence of 
dengue-specific primer by endogenous priming. During RT-PCR, in the first cycle, both exogenous and 
endogenous primed cDNA products are used by Taq polymerase as template for amplification by 
dengue-specific anti-sense primer. However, in the second cycle, only the complementary strand from 
exogenous primed cDNA product can bind to antisense tag sequence primer for amplification whereas 
the complementary strand from endogenous primed cDNA product cannot bind to antisense tag 
sequence primer because it lacks the sense tag sequence. Therefore, exogenous primed cDNA product 





We first evaluated the specificity of assay using tag and E primers with synthetic 
negative- and positive-strand cDNA transcripts. Both negative- and positive-strand 
specific primers were used to detect negative-strand (Figure 3-11A) and positive-
strand (Figure 3-11B) cDNA standards that were serially diluted 10-fold, starting 
from 108 to 103 copies per reaction. As shown in Figure 3-11A and B, both negative- 
and positive-strand specific primers are highly specific because at 108 copies of 
negative-strand standard, negative-strand specific primer gave a Ct value of 6.96 
whereas positive-strand specific primer gave a Ct value of 34.36 (difference of 27.4) 
and no Ct values were obtained for lower dilution. In agreement with that, at 108 
copies of positive-strand standard, negative-strand specific primer gave a Ct value of 
32.76 whereas positive-strand specific primer gave a Ct value of 8.33 (difference of 
24.43) and no Ct values were obtained for lower dilution. This indicates that the 
primers are highly specific to its complementary template.  
 
Next, we determined the sensitivity and reproducibility of the assay by mixing 
negative- and positive-strand cDNA standard with the opposite strand at various ratios 
or with the addition of BHK-21 cDNA to detect specific-strand with respective 
primers. Negative-strand standards that were serially diluted 10-fold (starting from 
107 to 102 copies) were mixed with 107 copies of positive-strand standard (Figure 3-
11C) or 40 ng of BHK-21 cDNA (Figure 3-11E). As shown in Figure 3-11C and E, 
the negative-strand detection assay was highly reproducible within the range of 103-
107 dilution even when it was mixed with 107 copies of positive-strand standard or 40 
ng of BHK-21 cDNA; therefore, we determined the minimum detection level for 
negative-strand to be 103 copies. The reverse experiment was also performed, where 
positive-strand standards that were serially diluted 10-fold (starting from 107 to 102 
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copies) were mixed with 107 copies of negative-strand standard (Figure 3-11D) or 40 
ng of BHK-21 cDNA (Figure 3-11F). As shown in Figure 3-11D and F, the positive-
strand detection assay was also highly reproducible within the range of 102-107 
dilution even when it was mixed with 107 copies of negative-strand standard or 40 ng 
of BHK-21 cDNA; the minimum detection level for positive-strand was determined to 
be 102 copies and it was one log lower than the minimum detection limit for negative-
strand. Taken together, the results suggest that the presence of opposite-sense cDNA 
transcript or cellular cDNA does not inhibit the accurate quantification of negative- 





 Figure 3-11: Validation of strand-specific quantitative RT-PCR assay. The strand-specific RT was 
carried out with a standard curve of 108 copies of negative- and positive-strand standards that were 
serially diluted 10-fold up to 102 copies. The log of the RNA copies is plotted against the cycle 
threshold (Ct). Data points are plotted for those that have Ct value ≤ 35. (A and B) The specificity of 
assay for detection of negative- and positive-strand RNA transcript using tag and E specific primers. 
Negative- and positive-strand specific primers were used to detect negative- and positive-strand RNA 
in (A) negative-strand standard samples (starting from 108 copies) and (B) positive-strand standard 
samples (starting from 108 copies). (C-F) Quantification of negative- and positive-strand RNA 
transcripts with the opposite strand at various ratios or with the addition of 40 ng of BHK-21 RNA. 
Negative-strand standards that were serially diluted 10-fold (starting from 107 copies) were mixed with 
(C) 107 copies of positive-strand standard or (E) 40 ng of BHK-21 RNA for detection of detection of 
negative-strand RNA transcript by negative-strand specific primers. Positive-strand standards that were 
serially diluted 10-fold (starting from 107 copies) were mixed with (D) 107 copies of negative-strand 
standard or (F) 40 ng of BHK-21 RNA for detection of detection of positive-strand RNA transcript by 





To demonstrate the possibility of using this assay in both viral RNA transfected and 
infected systems, BHK-21 cells were either transfected with 10 μg of in vitro 
transcribed DENV2 WT RNAs or infected with DENV2 at MOI =1, and cells were 
harvested at indicated time points for RNA extraction, for a total of 24 hours. The 
extracted RNAs from all time points were subjected to the assay, as described above 
and absolute viral RNA copy numbers were determined with the use of standard curve. 
Intriguingly, we found that in transfected system, during 2 to 4 and 6 to 8 hours 
periods, the level of positive-strand decreased drastically, whereas its level remained 
relatively stable from 4 to 6 hours period (Fig 3-12A). Similar observation was also 
seen in infected system, where the positive-strand level also remained relatively stable 
from 4 to 6 hours period (Fig 3-12B). This suggests that during this period, positive-
sense viral RNA from both systems may form a complex with ribosome and hence, 
prevent it from degradation, which may coincide with translation of DENV 
polyprotein. This is supported by the observation in both systems that during 8 to 10 
hours period, a slight increase in negative-strand level was detected and its level 
continued to increase till 24 hours; this implies that following translation that occurs 
during 4 to 6 hours period, the polyprotein underwent processing to release individual 
viral proteins for replication, which can then act on positive-sense RNA template to 
synthesize negative-strand RNA during 8 to 10 hours period and continue all the way 
to the last timepoint (24 hours). Further work is required in this aspect to determine 
the correlation between dynamics of RNA synthesis and polyprotein translation. 
Nevertheless, we have demonstrated that the assay is a useful and reliable tool for 
evaluating the kinetics of positive- and negative-strand RNA synthesis in both 






Figure 3-12: Viral RNA replication kinetics of BHK-21 cells that were either transfected with 
DENV2 WT RNAs or infected with DENV2 were monitored over the course of 24-hour. BHK-21 
cells were either (A) electroporated with 10 μg of WT in vitro RNA transcripts or (B) infected with 
DENV2 at MOI=1 and samples were harvested at indicated time points, up to 24 hours. RNA was 
extracted from infected cells and was used to quantify the amount of negative and positive-strand 
synthesis by real-time RT-PCR. Absolute copy numbers of both strands in log scale per μg of RNA 
used for real-time RT-PCR were plotted; data are shown as the mean ± SD of duplicate from one 
independent experiment. The grey line in (A) indicates the amount of residual negative-strand from 
transfected RNA. The grey line in (B) indicates the amount of negative-strand that was present in virus 
stock. This data in B was kindly provided by Kitti Chan from Duke-NUS Graduate Medical School. 
 
 
3.1.9 NS3:N570A mutant shows accumulation of negative-strand RNA 
Following the evaluation of strand-specific quantitative RT-PCR assay, we employed 
this assay to study the dynamics of RNA synthesis for WT, and NS5:K330A and 
NS3:N570A mutant viruses. As expected, for WT RNA transfected cells, the level of 
both negative- and positive-strand RNAs increased over time until 72 hours and 
declined at slightly different rates after that until 120 hours (Figure 3-13). The 
quantification was consistent with previous data that an excess of positive- over 
negative-strand RNA can be detected in WT virus infected cells (Tomassini et al., 
2003). The RNA quantification for NS3:N570A mutant revealed a different trend to 
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WT and NS5:K330A mutant. Overall, the levels of negative- and positive-strand 
RNA for NS3:N570A were lower than WT. However, the rate of negative-strand 
RNA synthesis (rate = 2.06×104 ± 9.77×102 negative-strand/hour) for NS3:N570A 
appeared to increase faster than positive-strand RNA synthesis (rate = -2.17×105 ± 
5.82×104 positive-strand/hour) during 6 to 24 hours period, and at somewhat similar 
rate for both strands (rate = 3.55×105 ± 3.74×103 negative-strand/hour and 7.48×105 ± 
1.28×105 positive-strand/hour) during 24 to 48 hours period, suggesting that the 
negative-strand RNA may be accumulating as double-stranded replicative form by 
base-pairing with the transfected positive-sense RNA. Interestingly, beyond 48 hours, 
the rates at which both strands accumulated for NS3:N570A mutant over time were 
almost identical. For NS5:K330A mutant, the level of detected negative- and positive-
strand RNA corresponds to the amount of transfected negative- and positive-strand 
RNA that degraded over time (Note: T7 transcribed positive-sense RNA used for 
transfection contained ~0.1-0.3% negative-sense RNA that could be detected by the 
primers that bind to E gene and is the basis for the grey cutoff line for the residual 
negative-strand from transfected RNA in Figure 3-13). The NS3:N570A mutant 
probably results in either reduced or completely abolished NS3-NS5 interaction and 
hence, is unable to use the double-stranded replicative form as template to support 
further RNA synthesis (Chu & Westaway, 1985). This is consistent with the detection 
of highest percentage of dsRNA-positive cells at 48 hours (5-10%) by intracellular 
RNA staining that does not accumulate as seen in WT at the later time points (Fig 3-
9B). Interestingly, our detailed analysis suggests that NS5:K330A mutant cannot 
synthesize negative-strand RNA although the mutation has been shown to have no 
effect on the in vitro enzymatic activities of NS5 protein (Zou et al., 2011). These 
results suggest that the impairment of viral protein synthesis and infectious virus 
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production in NS3:N570A mutant may be due to the inability of the mutant NS3 to 
engage with NS5 and use the dsRNA template to produce more positive-strand 




Figure 3-13: Dynamics of viral RNA replication of BHK-21 cells that were transfected with 
DENV2 WT, NS5:K330A or NS3:N570A RNAs were monitored over the course of 5-day. Same 
experiment setup was performed as mentioned in Figure 3-9. Extracted RNA was used to quantify the 
amount of negative and positive-strand synthesis by real-time RT-PCR. Absolute copy numbers of both 
strands in log scale per μg of RNA used for real-time RT-PCR were plotted; data are shown as the 
mean ± SD of duplicate from one independent experiment. The grey line in indicates the amount of 
residual negative-strand from transfected RNA. This experiment was performed in collaboration with 






3.1.10 Peptides spanning NS3-NS5 interaction site reduce RNA replication  
Since mutation in NS3-NS5 interaction site can impair viral replication, we next 
asked the question if synthetic peptides that span NS3-NS5 interaction site can also 
reduce RNA replication in viral inhibition assay. At 6 hours post-infection, Huh-7 
cells were treated with either NS3566-585 peptide, which formed non-convalent 
complex with penetrating peptide, penetratin (1:3 molar ratio, 7.5 μM of NS3 peptide) 
or NS5320-341 peptide that was covalently linked to penetratin (7.5 μM of NS5 peptide) 
(Brugidou et al., 1995; Derossi et al., 1996; Keller et al., 2013). At 24 hours post-
infection, infected cells were harvested for RNA extraction and were subjected to 
real-time RT-PCR for viral RNA quantification. As indicated in Figure 3-14A and B, 
both peptides could reduce viral replication by ~33% (p-value for NS3566-585 = 0.0195 
and p-value for NS5320-341 = 0.0043, Figure 3-14) when compared penetratin control. 
This implies that blocking interaction between NS3 and NS5 could be a potential 







Figure 3-14: Viral inhibition assay was performed with NS3 or NS5 peptide that spanned NS3-
NS5 interaction site. (A) For NS3 peptides, they formed non-convalent complex with penetratin 
peptide, which also enables NS3 peptide to be transported into the cells (1:3 molar ratio) (Keller et al., 
2013). (B) For NS5 peptides, they were synthesized as penetratin fusion peptide as penetratin has been 
shown to have cell-penetrating property (Brugidou et al., 1995) and this enables NS5 peptide to be 
transported into the cells. (A and B) 6 hours post-infection, the cells were treated with 7.5 μM of each 
peptide. Infected cells were harvested at 24 hours post-infection for cellular viral RNA quantification 
by real-time RT-PCR analysis. Fold-change was normalized to 24 hours control (penetratin alone) was 
plotted and data are shown as the mean ± SD of duplicate from one independent experiment. The x-axis 
labels are as follows: penetratin, penetratin and NS3566-585 complex (NS3566-585+penetratin), and 
penetratin and NS386-100 complex (NS386-100+penetratin) for (A) and penetratin, penetratin fused to 
NS5320-341 (peneNS5320-341) and penetratin fused to scrambled NS5320-341 (peneNS5s320-341) for (B). This 





3.2 Investigating the subcellular localization pattern of NS5 for 
DENV1-4 serotypes and its impact on virus replication  
3.2.1 DENV1-4 NS5 of infected and transfected cells show differential 
subcellular localization  
In order to detect DENV1-4 NS5 in infected cells, we first generated antibody against 
NS5 by biopanning of naïve human Fab-phage display library against NS5 MTase and 
RdRP proteins, while alternating between serotype 2 and 3 between each round of 
panning (Tay et al., 2014a). After four rounds of panning and characterization, two 
Fabs, 5M1 and 5R3 were identified to bind to DENV1-4 MTase and RdRP proteins, 
respectively (Zhao et al., 2014) and they were converted to IgG format as described 
previously to improve avidity (Moreland et al., 2012). The specificity and avidity of 
IgG were tested in ELISA following conversion. As shown in Figure 3-15A and B, 
both IgGs have increase avidity as compared to their Fab counterparts to bind NS5 
MTase and RdRP and the specificity of the IgGs are retained. Based on the ELISA 
results, 10 nM of 5M1 IgG and 30 nM of 5R3 IgG were used for IFA. Next, to ensure 
that 5R3 IgG can still recognise conformational epitope upon conversion (Zhao et al., 
2014), dot blot with both native and boiled NS5 full-length protein was done and as 
expected, 5R3 IgG still retains its ability to distinguish native folded NS5 from 






Figure 3-15: Conversion of cross-reactive anti-NS5 from Fab format to IgG format increases the 
avidity of anti-NS5. (A-C) Anti-NS5 IgGs were characterized by ELISA and dot blot. (A-B) ELISA 
with anti-NS5 of either Fab or IgG format (5M1 or 5R3, 2-fold serial dilution, starting from 200 nM) 
was performed against (A) DENV2 and 3 NS5 MTase and (B) DENV2 and 3 NS5 RdRP to determine 
antibody avidity and specificity. Data represent the mean ± SD (n=2) from a single experiment. (C) Dot 
blot was performed with either boiled or native DENV3 NS5 (2-fold serial dilution, starting from 2.5 
μg) to determine the nature of epitope (linear or conformational) that 5R3 IgG recognises.  
 
 
After the characterization of anti-NS5 IgGs, 5R3 was employed to detect NS5 of 
DENV1-4 Huh-7 infected cells (MOI=10) that were fixed at 24 hours post-infection 
by IFA and CLSM (Figure 3-16A). Nuclear to cytoplasmic fluorescence ratio (Fn/c) 
were determined from image analysis (Collins, 2007) of digitized CLSM images 
(such as those in (Figure 3-16B), conﬁrmed that DENV3 NS5 was predominantly 
nuclear like DENV2 NS5 (Fn/c = 11 and 12, respectively), whereas DENV1 NS5 was 
predominately cytoplasmic and it also exhibited localization in perinuclear region and 
possibly, in cytoskeleton region too (Fn/c = 0.8) (similar phenomenon was able seen in 
another DENV1 strain Hawaii (Figure A-1), as well as with another anti-NS5 IgG 
131 
 
5M1 (Figure A-2). For DENV4 NS5, it was found in both cytoplasm and nucleus, 
with slightly more NS5 in nucleus (Fn/c = 1.7). Similar results were also observed in 
DENV1-4 BHK-21 infected cells (data not shown). Therefore, although NS5 is 
clearly present in the nucleus of DENV1-4 infected cells, the amount of nuclear NS5 






Figure 3-16: NS5 from DENV1-4 NS5 infected cells display nuclear localization, but to differing 
extents. Huh-7 cells were mock-infected or infected with DENV1-4 (known as EDEN isolates in this 
sutdy; GenBank accession numbers are: DENV1 (EU081230), DENV2 (EU081177), DENV3 
(EU081190) and DENV4 (GQ398256)) at an MOI of 10 and fixed at 24h post-infection. (A) Anti-NS5 
(5R3 IgG, 30 nM; green) and anti-E (4G2 IgG, 1:1000; red) antibodies were used for immunostaining. 
Images were captured by CLSM using a Zeiss LSM 710 upright confocal microscope by 63× oil 
immersion lens. (B) Image analysis was performed on digitized images that were based on anti-NS5 
staining (green) to determine nuclear to cytoplasmic fluorescence ratio (Fn/c) with background 
fluorescence subtracted, for NS5 of each serotype using ImageJ software. Data represent the mean ± 
SEM (n > 25 cells) from a single experiment, representative of two independent experiments. (B) is 
adapted from (Tay et al., 2013). Image analysis was kindly performed by Dr Johanna Fraser from 




The nuclear targeting ability of DENV1-4 NS5 was further examined by fusing NS5 
gene fragments to that of GFP and expressed GFP-NS5 fusion protein in Vero cells. 
The cells were fixed at 24 hours post-transfection, and cells were stained by both anti-
GFP and anti-NS5 5R3. CLSM of transfected cells gave results that were similar to 
those NS5 from infected cells; all GFP-NS5 proteins showed nuclear localization, 
with DENV2 and 3 NS5 showing greater accumulation than DENV1 and 4 (Figure 3-
17). Staining with anti-NS5 5R3 co-localize with the staining with anti-GFP indicates 
that GFP-NS5 proteins were properly folded and they resembled the native form of 
NS5 from infected cells because 5R3 recognizes conformational NS5 epitope. 
Collectively, these results demonstrate that the NS5 of DENV1-4 localize differently 






Figure 3-17: NS5 from DENV1-4 transfected cells show similar subcellular localization pattern as 
compared to NS5 from DENV1-4 infected cells. Vero cells were transfected with either GFP or GFP-
NS5 from DENV1-4 (sequences as in Figure 3-16) and fixed at 24h post-transfection. Anti-GFP 
(ab6556 IgG, 1:1000; green) and anti-NS5 (5R3 IgG, 30 nM; red) antibodies were used for 





3.2.2 DENV1 NS5 has a functional α/βNLS  
With the observation that DENV1 NS5 was predominately cytoplasmic, we focused 
on DENV1 and 2 NS5 as examples of protein that did not or did localize to the 
nucleus in subsequent experiments in order to explore any functional significance for 
our observation. A time course experiment where infected cells were fixed at various 
time points post-infection revealed more NS5 in the nucleus of DENV1 infected cells 
at later time points (ie. 36 hours onwards, Figure 3-18), which suggests that DENV1 
NS5 may have a functional α/βNLS to allow its nuclear translocation, just like 
DENV2 NS5. This is further supported by AlphaScreen binding assay that detected 
binding between DENV1 and 2 NS5 with importin-α/β1 with similar apparent Kd 
(DENV1=0.2 nM and DENV2=0.4 nM), and also the treatment of DENV1 NS5 
transfected cells with CRM1 specific inhibitor LMB that led to the accumulation of 
nuclear NS5 (data shown in (Tay et al., 2013), both experiments did by Dr Johanna 
Fraser from Monash University). However, the α/βNLS of DENV1 NS5 did not allow 
it to nuclear-localise to the same extent as DENV2 NS5, which implies that it has a 
weaker NLS. In line with the hypothesis that DENV1 α/βNLS is probably weaker, the 
rational for focusing on DENV1 and 2 NS5 was also driven by the consistent 
observation in our laboratory that DENV1 produced more infectious virus particles 
than DENV2, (Figure 3-19A and B), despite similar MOI and infection rate as 
determined by anti-E 4G2 staining (data shown in (Tay et al., 2013); similar 





Figure 3-18: DENV1 NS5 shows increased nuclear localization over time in infected cells, but to a 
lower extent than DENV2 NS5 in infected cells. Huh-7 cells were mock-infected or infected with 
DENV1 or 2 (sequences as in Figure 3-16) at an MOI of 10 and fixed at various times post-infection. 
Images were captured by CLSM using a Zeiss LSM 710 upright confocal microscope by 63× oil 





Figure 3-19: DENV1 produced more infectious virus particles than DENV2 despite similar MOI. 
Huh-7 cells were mock-infected or infected with DENV1 and 2 (refer to Figure 3-16 for 
GenBank accession numbers) at an MOI of 0.1, 1 and 10 and supernatants were collected at 24 hours, 
48 hours and 72 hours post-infection. Viral titer was determined by plaque assay on BHK-21 cells and 






Comparison of NES and α/βNLS sequence between DENV1 and 2 NS5 only revealed 
difference in the first basic cluster of α/βNLS; for DENV1, it is 371AQ, whereas for 
DENV2, it is 371KK. Therefore, we hypothesized that by mutating DENV2 
371KKAQ, we should be able to disrupt DENV2 NS5 nuclear localization because 
371KKAA mutation was already shown by (Pryor et al., 2007) to affect DENV2 
NS5 localization in infected cells. Despite the change, DENV2 NS5 remains nuclear-
localized (data not shown).  
 
In order to characterize the α/βNLS of DENV1 NS5 more efficiently, we decided to 
exchange the corresponding gene segment that encodes α/βNLS sequence (residues 
320-405) of DENV1 NS5 into DENV2 NS5 and vice versa. The experiment was done 
in a context of a full-length NS5 protein, in a transfected system to ensure that each 
chimeric GFP-NS5 protein is properly folded and the NLS sequence can function in 
the context of native NS5. Furthermore, the use of transfected system enables quicker 
molecular manipulation of gene fragment as compared to reverse genetics system and 
it can also produce similar results as infected system (as shown in Figure 3-16A and 
3-17). During the study, anti-NS5 5R3 was employed to detect chimeric NS5 to 
ensure that the protein is properly folded (Note: a summary of anti-NS5 5R3 staining 





Through overlap extension PCR (Figure 2-1), the corresponding gene segments that 
encode α/βNLS sequence were successfully exchanged between the two serotypes of 
NS5. When DENV2 α/βNLS was replaced by DENV1 α/βNLS, the latter could target 
full-length DENV2 NS5 protein to the nucleus. On the contrary, when DENV1 
α/βNLS was replaced by DENV2 α/βNLS, DENV2 α/βNLS could not target full-
length DENV1 NS5 protein to the nucleus (Figure 3-20). These results suggest that 
DENV1 α/βNLS is functional; it can target protein greater than 45 kDa to the nucleus. 
However, despite a functional α/βNLS, there seems to be a greater signal (we named 
it CRS) outside the exchanged gene segment, which is either in residues 1-319 or 406-




Figure 3-20: α/βNLS of DENV1 NS5 can target DENV2 NS5 to the nucleus. α/βNLS-swapping 
experiment between DENV1 and 2 GFP-NS5 was performed to determine if DENV1 α/βNLS is 
functional. Exchanges of gene segments (residues 320-405) that encode α/βNLS sequence between 
DENV1 and 2 GFP-NS5 were generated by overlap extension PCR. The plasmids were transfected into 
Vero cells and fixed 24 hours post-transfection. The cells were stained and images were captured as 
described in Figure 3-17. Red letters in construct name indicates gene segment from DENV1 NS5; 
black letters in construct name indicates gene segment from DENV2 NS5 (first column). Anti-GFP 
(ab6556 IgG, 1:1000; green) and anti-NS5 (5R3 IgG, 30 nM; red) antibodies were used for 
immunostaining. Anti-NS5 5R3 IgG recognises conformational epitope and was used to assess the 
folding of NS5 protein (second column). Schematic representation of the NS5 gene segments that were 
exchanged between DENV1 and 2 is showed in third column. NES indicates nuclear export signal and 






3.2.3 Small molecule inhibitor ivermectin can block interaction of DENV1 
and 2 NS5 with importin-α/β1 in vitro and inhibit DENV1-4 viral 
replication 
It was reported previously that ivermectin, a broad-spectrum anti-helminthic drug, can 
specifically block interaction between DENV2 NS5 and importin-α1/β1but not of 
importin-β1 alone in mid μM range (half-maximal inhibitory concentration (IC50) = 
17 μM, (Omura, 2008; Wagstaff et al., 2012)). Since we have shown that α/βNLS of 
DENV1 NS5 is functional and it can bind to importin-α/β1 in AlphaScreen binding 
assay, we next determined if ivermectin can also block the interaction between 
DENV1 NS5 and importin-α/β1. AlphaScreen binding assay was carried out as 
described in (Tay et al., 2013), in the presence of increasing concentrations of 
ivermectin and the IC50 for DENV1 and 2 NS5 to importin-α/β1 were 2.3 and 1.5 μM, 
respectively (experiment carried out by Dr Johanna Fraser from Monash University). 
This suggests that ivermectin specifically blocks NS5-importin-α/β1 interaction and 
this inhibition is supported by findings that ivermectin has no impact NS3-NS5 
interaction and NS5 RdRP activity (data shown in (Tay et al., 2013)).  
 
To explore the implications of in vitro finding of ivermectin with respect to its 
antiviral potential in infected cell system, we tested its ability to protect against 
infection by DENV1-4 in Huh-7 and BHK-21 cells in cell-based infection assays that 
were established previously in our laboratory (Rathore et al., 2011b; Tan et al., 2014; 
Wang et al., 2009b; Watanabe et al., 2012). BHK-21 cells were either mock-infected 
or infected with DENV1-4 at an MOI of 0.3 in the absence or presence of increasing 
concentrations of ivermectin, followed by ﬁxation and quantitation of IFA-positive 
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cells (based on anti-E 4G2 staining) at 48 h post-infection. The half-maximal effective 
concentration (EC50) values were comparable for DENV1-4 (1.6-2.3 μM; see Table 3-
1). In order to corroborate the observation that the inhibition is not cell-line dependent, 
we tested ivermectin’s antiviral action in Huh-7 for DENV1 and 2 using established 
plaque assay and obtained similar EC50 values (Table 3-1).  
 
With the observation that DENV1-4 NS5 nuclear-localize to different extents, it was 
not surprising to us that ivermectin could inhibit DENV1-4 with similar EC50 values 
because it was consistent with the idea that ivermectin specifically targets the host 
protein importin-α1 (Wagstaff et al., 2011) and it does not inhibit NS5 RdRP activity 
and NS3-NS5 interaction (Tay et al., 2013). However, it is also possible during 
DENV infection, ivermectin may exhibit its antiviral effect by blocking nuclear 
import of unidentified host protein(s) that is(are) important for viral replication. It 
should also be noted that ivermectin has also been reported to have inhibitory effect 
against helicase activity of NS3 and similar EC50 values were obtained (Mastrangelo 
et al., 2012), meaning that it is not entirely possible to attribute the antiviral effect of 
ivermectin be solely due its action on NS5 nuclear import. Taken together, we have 
clearly shown that ivermectin has antiviral activity against all four serotypes of DENV 




Table 3-1. Summary of antiviral activities of ivermectin and other agents towards 
DENV1-4. Table is adapted from (Tay et al., 2013).  
Serotypes Agent EC50 (μM) BHK-21* Huh-7^ 
DENV1 
Ivermectin@ 2.32 ± 1.06 2.97 ± 0.07 
Celgosivir# 0.26 ± 0.00 N.D.+ 
NITD008# 1.37 ± 0.41 2.53 ± 0.08 
DENV2 
Ivermectin 2.08 ± 0.94 1.74 ± 0.15 
Celgosivir 0.32 ± 0.05 N.D.+ 
NITD008 1.32 ± 0.56 0.22 ± 0.05 
DENV3 
Ivermectin 1.66 ± 0.66 N.D.+ 
Celgosivir 0.09 ± 0.02 N.D.+ 
NITD008 0.50 ± 0.19 N.D.+ 
DENV4 
Ivermectin 1.90 ± 0.89 N.D.+ 
Celgosivir 0.08 ± 0.01 N.D.+ 
NITD008 0.65 ± 0.28 N.D.+ 
 
*Data are for the mean ± SD (2 independent experiments performed in triplicate) as 
determined by CFI assay on mock or DENV1-4 infected BHK-21 cells treated with 0-45 
μM of the indicated agents. 
^Data are for the mean ± SD (single experiment performed in duplicate), as determined by 
plaque assay on BHK-21 cells using media supernatant at 48h post-infection of mock-
infected or DENV1 or 2 infected Huh-7 cells treated with 0.16-5 μM of the indicated 
agents.  
@CC50 for BHK-21 and Huh-7 for ivermectin are 9.8 and 7.3 μM, respectively (48h 
treatment). 
#Established inhibitors of DENV celgosivir (Rathore et al., 2011a) and NITD008 (Yin et 
al., 2009) were included in the assays as controls; CC50 values of > 100 μM.  




3.3 Identifying potential nuclear or cytoplasmic binding partners that 
are unique to DENV1 and 2 GFP-NS5 by co-immunoprecipitation 
coupled to mass spectrometry 
3.3.1 Validation of DENV1 and 2 GFP-NS5 co-immunoprecipitation 
elutants prior to mass-spectrometry by silver staining and western 
blot 
In order to better understand the nuclear role of DENV2 NS5, we set out to identify 
human host proteins that can bind to DENV1 and 2 GFP-NS5. The rationale for 
including DENV1 GFP-NS5 in this study was due to our finding that in both infected 
and transfected cells, DENV1 NS5 localizes to the cytoplasm, whereas DENV2 NS5 
localizes to the nucleus. Based on this finding, we hypothesized that the physical 
compartmentation of these two proteins enabled them to interact with host proteins 
that are either unique to nucleus or cytoplasm, which in turn may help us to identify 
binding partners that are unique to either protein. For this study, we adopted the co-IP 
coupled with mass spectrometry approach for identifying protein-protein interactions 
between NS5 and host proteins because co-IP enables more interaction partners to be 
identified from purified NS5-host protein complexes as compared to Y2H that detects 
binary interaction. The co-IP experiments were carried out with lysates from GFP-
NS5 (DENV1 and 2), GFP-NS3 (DENV1 and 2), GFP and mock-transfected cells. 
We included DENV1 and 2 GFP-NS3 in this study because we considered them to be 
a better control than GFP in term of size (GFP, ~25 kDa; GFP-NS3, ~100 kDa and 
GFP-NS5, ~125 kDa) and it may aid the identification of host proteins that are 
common to both NS3 and NS5.  
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We first transfected all the GFP plasmids into HEK293T cells (two 10-cm plates per 
construct). Prior to lysis at 24 hours post-transfection, the cells were checked under 
the fluorescence microscope to determine NS5 localization and transfection 
efficiency. The subcellular localization of DENV1 and 2 GFP-NS5 were similar to 
those in Vero cells (Figure 3-17 and 21). The transfection efficiency for GFP, GFP-
NS3 and GFP-NS5 plasmids were ~80-90%, 50-60% and 40-50% respectively.  
 
 
Figure 3-21: Subcellular localization patterns of DENV1 and 2 GFP-NS3 and GFP-NS5 in 
HEK293T cells. Plasmids encoding GFP-NS5 and GFP-NS3 of DENV1 and 2 were transfected into 
HEK293T cells. Fluorescent images of live transfected cells were taken at 24 hours post-transfection 
by Olympus fluorescence microscope to determine NS5 localization and transfection efficiency. 







Following the lysis of these cells, the supernatants were subjected to IP overnight with 
GFP-Trap_A resin at 4°C. On the following day, the beads were washed three times 
and bound proteins were eluted from the beads first by vigorous vortexing for 5 
minutes at RT, in the presence of 50 μl of 0.2% RapiGest SR surfactant reagent 
(termed as non-boiled elution here), followed by a second elution by boiling at 95°C 
for 5 minutes with 50 μl of 0.2% RapiGest SR surfactant reagent (termed as boiled 
elution here). The concentration of both types of elutants were determined by 
Nanodrop (amount of elutants listed in Table 3-2) and fixed amount of elutants were 
loaded onto two 8% SDS-PAGE gel for assessment by silver staining and western 
blot prior to sending them to the Duke University Protemics Facility (NC, USA) for 
LC-MS/MS protein identification (Figure 3-22).  
 
Table 3-2: Total amount of elutants that were eluted from GFP-Trap_A resin and the amounts 
that were used for SDS-PAGE and LM-MS/MS. The amounts of elutants were determined by 
Nanodrop (*crude protein quantitation for SDS-PAGE gel loading) and BCA assay (#accurate protein 








































Total amount of elutant 
(μg) in 50 μl* 12.85 27.1 16.45 66.55 43.6 5.15 
Amount used for SDS-
PAGE/gel (μg)* 1.29 2.71 1.65 4.03 4.03 0.52 
% of total elutant used 









 Total amount of elutant 
(μg) in 50 μl* 18.35 18.85 13.1 44.9 41.5 14.1 
Amount used for SDS-
PAGE/gel (μg)* 1.84 1.89 1.31 2.79 2.79 1.41 
% of total elutant used 
for SDS-PAGE/gel* 10 10 10 6.22 6.72 10 
Total amount of proteins eluted by both 































Total amount of elutant 
(μg) in 40 μl# 1.2 2 0.8 8.8 6.8 1.2 
Amount injected for MS 
(μg) # 0.14 0.91 0.36 1 0.77 0.14 
% of total elutant 
injected for MS# 11.36 45.44 45.44 11.36 11.36 11.36 
The silver-stained gel from non-boiled elutants showed that the elution profiles of 
GFP-NS3 and GFP-NS5 were different, indicating that we were likely to identify 
unique binders to each protein from MS (Figure 3-22A). Closer inspection of silver-
stained gels did not readily reveal any protein band that was unique to either DENV1 
or 2 NS5, similarly for DENV1 or 2 NS3. Comparison of non-boiled elutants silver-
stained gel (Figure 3-22A) against boiled elutants silver-stained gel boiled elutants 
silver-stained gel (Figure 3-22C) clearly demonstrated that there were less host 
proteins and more GFP-NS3 and GFP-NS5 proteins in boiled elutants, indicating that 
we had eluted most of the host proteins during the first elution. We could also 
determine the level of GFP protein expression from silver-stained gels; the order of 
GFP proteins in term of their expression levels (from the highest to the lowest) was as 






Figure 3-22: STAT2, MATR3, DDX5 and DDX3X are found in protein complex that are being 
pulled down with DENV1 and 2 GFP-NS5. Plasmids encoding GFP-NS5 and GFP-NS3 of DENV1 
and 2 were transfected into HEK293T cells and were lysed at 24 hours post-transfection for co-IP. Co-
IP was carried out overnight at 4°C with GFP-Trap_A resin. Bound proteins were eluted twice; first 
elution was by vortexing at RT for 5 minutes in 50 μl of 0.2% RapiGest SR surfactant reagent (termed 
as non-boiled elution here) and second elution was by boiling at 95°C for 5 minutes in 50 μl of 0.2% 
RapiGest SR surfactant reagent (termed as boiled elution here). Fixed amount of both types of elutants 
(indicate in Table 3-2) were loaded onto two 8% SDS-page (A-D). One set was subjected to (A and C) 
silver staining and the other one set was subjected to (B and D) western blotting with antibodies against 
STAT2, MATR3, DDX5, DDX3X and GFP. Lysates from GFP- and mock-transfected cells served as 
controls to exclude proteins that bound to either GFP or resins. No detection of GFP in GFP sample 






Next, in order to verify that co-IP can pull down previously identified/characterized 
host proteins we did western blot for both types of elutants with antibodies against 
STAT2, MATR3, DDX5 and DDX3X (see Table 3-4 for the references of these 
proteins). As shown in Figure 3-22C for non-boiled elutant, STAT2 and MATR3 that 
were previously reported to interact with DENV2 NS5 via Y2H assays (Khadka et al., 
2011; Le Breton et al., 2011) could also co-elute with DENV1 GFP-NS5. 
Interestingly, DDX5 that was previously reported to interact with both JEV NS3 and 
NS5 via pulldown assay (Li et al., 2013) could also co-elute with DENV1 GFP-NS3, 
and DENV1 and 2 GFP-NS5. DDX3X was previously reported to bind to both JEV 
NS3 and NS5 via pulldown assay but in our study, we could only detect co-elution of 
DDX3X with DENV1 and 2 GFP-NS5, but not DENV1 and 2 NS3 (Li et al., 2014a). 
No binding of STAT2 to NS3 implies that the binding of STAT2 to NS5 is unique to 
NS5. For boiled elutants (Figure 3-22D), we observed less STAT2 and DDX5 being 
detected and almost no detection of MATR3 and DDX3X, which further supported 
the presence of most of the relevant host proteins in samples by non-boiled elution. 
Collectively, the western blot data indicates data reliability of the co-IP experiment 





3.3.2 Mapping DENV GFP-NS3- and GFP-NS5-human protein 
interaction network 
Prior to MS analysis, the non-boiled elutants were quantified by BCA assay (Table 3-
2). Based on BCA protein quantification, 11.36% of total elutant for DENV1 and 2 
GFP-NS5, GFP and mock, and 44.54% of total elutant for DENV1 and 3 GFP-NS5 
(maximum of 1 μg for each protein) were used for MS analysis.  
 
Analysis of MS data by Scaffold Proteome software (version 4.3.4) (Searle, 2010) led 
to the identification of 405 human host proteins (refer to appendices Table A-1 for the 
whole list); each of these host proteins was represented by at least two unique peptide 
sequences and they were negative for GFP- and mock-transfected elutants. Through 
manual processing of protein dataset, 185 host proteins were identified to co-elute 
with DENV1/2 GFP-NS3, whereas 298 and 273 host proteins were identified to co-
elute with DENV1 and 2 GFP-NS5, respectively (Note: DENV1 and 2 GFP-NS3 are 
considered as a single dataset because both proteins are cytoplasmic and DENV2 
GFP-NS3 on its own has a small dataset (10 out 185 proteins). DENV1 and 2 GFP-
NS5 are considered as two separate datasets because DENV1 NS5 is in cytoplasm 




Figure 3-23: Venn diagram illustrating the overlap between the data sets of DENV1 and 2 GFP-
NS3 and DENV1 and 2 GFP-NS5. DENV1 and 2 GFP-NS3 are considered as a single dataset because 
both proteins are cytoplasmic. DENV1 and 2 GFP-NS5 are considered as two separate datasets because 





3.3.3 Validation of interactions through comparison to published dataset 
of viral proteomics screens  
As of now, there have been several large-scale proteomics screens that have been 
done for DENV to look at human host proteins that physically interact with viral 
RNA, NS3 and NS5 proteins, either via RNA affinity chromatography (Ward et al., 
2011), Y2H (Chua et al., 2004; Khadka et al., 2011; Le Breton et al., 2011; Mairiang 
et al., 2013) or co-IP coupled to quantitative MS (Carpp et al., 2014); comparison of 
our dataset to published dataset of host proteins that were identified by various 
proteomics screens enable us to identify meaningful hits for further study, as well as 
validating the reliability of our dataset through demonstrating the presence of 
expected/previously published host proteins in our dataset.  
 
We first compared our dataset to existing set of human host proteins that was 
previously reported by Y2H, co-IP and pulldown studies to be interacting with 
flavivirus proteins through manual literature curation and this led to identification of 
29 proteins that were listed in Table 3-3 and among these host proteins, HS90B was 
common to this study and all the other studies. In both this study and Y2H studies the 
matching hits are as follows: 8 proteins co-eluted with GFP-NS3 - GOGB1, HS90B, 
IKBA, NRBP, PTBP1, ILF3, PABP1 and RS20, 8 proteins co-eluted with GFP-NS5 - 
STAT2, MATR3, DDX3X, RB6I2, HNRPF, CGNL1, RIPL2 and SIAH2 and one 
protein bound to both GFP-NS3 and GFP-NS5 - DDX5 (Khadka et al., 2011; Le 
Breton et al., 2011; Mairiang et al., 2013). Interestingly, we also identified LA protein 
that was previous identified to be interacting with DENV4 5’ and 3’ UTR, NS3 and 
NS5 to be also co-eluting with both GFP-NS3 and GFP-NS5 in this study (Garcia-
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Montalvo et al., 2004b). Our finding further supports the presence of LA protein in 
RC, even though its role in viral replication remains to be fully understood. LA 
protein is ubiquitous in eukaryotic cells and it binds to all nascent RNA transcripts to 
protect the 3' ends of these RNAs from exonucleases. The stabilization of RNA by La 
is needed for maturation of pre-tRNA, assembly of small RNAs into functional RNA-
protein complexes, and nuclear retention of certain small RNAs (Wolin & Cedervall, 
2002). It is likely that LA protein may be involved in either stabilization of RNA 
genome or translation of RNA genome since it can interact with both UTRs and major 
replicative enzymes (Alvarez et al., 2005b; Paranjape & Harris, 2010; Wolin & 
Cedervall, 2002).  
 
During the course of our study, Carpp and colleagues published their work on 
identifying viral-host protein interaction between human host proteins and NS3 or 
NS5. They also used supernatant from HEK293T that were either transfected by 
DENV2 GFP-NS3 or GFP-NS5 plasmid for co-IP, which was similar to our approach. 
However, following transfection, they infected the cells with DENV2 virus to identify 
viral-host interaction in the context of viral infection by quantitative MS and this 
enabled them to identify high confidence interactors of NS3 and NS5. They found 53 
host proteins to be associated with NS5, 52 of which were novel and 41 host proteins 
to be associated with NS3, all of which were novel. Among them, 13 were common to 
GFP-NS3 and GFP-NS5 (Carpp et al., 2014). Through comparison of our dataset to 
theirs, we have 4 common proteins that co-eluted with GFP-NS5 proteins - HS90A, 
TIM50, AIFM1 and DPM1, 9 common proteins that co-eluted with GFP-NS3 proteins 
- HS90B, HSP71, HSP7C, HSPB1, CH60, RCN2, RS27A, TBA1C and TBB6, and 
one common protein that bound to both GFP-NS3 and GFP-NS5 - S61A1 (also 
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known as transport protein Sec61 subunit alpha isoform A, will be discussed further 
in section 4.3). Interestingly, among the host proteins that were common to GFP-NS3 
in this study and Carpp’s study, some of the proteins were enriched in protein folding 
and unfolded protein response, which suggests that the unfolded protein response 
pathway plays an important role in viral replication (Fink et al., 2007; Paradkar et al., 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Lastly, when we compared our western blot data and MS data, we could demonstrate 
that STAT2, MATR3, DDX5 and DDX3X that were detected to bind to both DENV1 
and 2 GFP-NS5 by western blot were also identified by MS with unique peptide count 
of more than 5 for each protein (Table 3-4). It is also surprising to note that STAT2 
that was not detected by western blot to co-elute with GFP-NS3 was also not detected 
by MS, and this further confirmed that binding of STAT2 to NS5 is indeed unique to 
NS5. Taken together, through extensive (and not yet exhaustive) intra- and inter-
comparisons of datasets, we were convinced that the dataset is of good quality for 
further studies.  
 
Table 3-4: MS unique peptide count of proteins that co-eluted with DENV1 and 2 GFP-NS3 and 
GFP-NS5.  







STAT2 0 8 9 0 0 0 
MATR3 0 18 10 19 0 0 
DDX5 0 18 22 15 0 0 
DDX3X 0 21 21 12 0 0 






3.3.4 Enriched features of GFP-NS3 and GFP-NS5 interaction networks  
Due to lack of time to select and identify in detail unique host targets from our co-IP 
study, further bioinformatics characterization was carried out by generating GFP-NS3 
and GFP-NS5 interaction networks with GeneMANIA (Warde-Farley et al., 2010) to 
identify significantly enriched/over-represented Gene Ontology (GO) annotations 
(Table A-2 to A8). As expected, GFP-NS3 and GFP-NS5 interaction networks were 
enriched by features that were associated with [1] already known functions of NS3 
and NS5 and [2] possible new/unknown functions of NS3 and NS5.  
 
3.3.4.1 Enriched features of interactors that are common to both GFP-NS3 and 
GFP-NS5 
Among 405 human host proteins, 110 proteins were identified to be interacting with 
both GFP-NS3 and GFP-NS5 proteins (Figure 3-23). Submission of these 110 
proteins for GO analysis revealed enriched features that were associated with already 
known functions of NS3 and NS5, namely RNA binding, viral transcription and viral 
life cycle (Table A5). Therefore, it is likely that among these host proteins, some may 
be the key proteins that are needed for RNA replication. In order to provide evidence 
for this idea, we did manual literature curation and we managed to identify 13 out of 
110 proteins that were previously reported to be interacting with flavivirus RNA 
(Table 3-5). Among the 10 proteins, 5 proteins, namely G3BP1, G3BP2, UBP10, 
CAPR1 and CNBP that were previously reported to bind to DENV2 5’ and 3’ UTRs 
(Ward et al., 2011) were identified to co-elute with both GFP-NS3 and GFP-NS5 in 
our study. On top of that, PTBP1 that was identified to bind to DENV2 NS4A, and 5’ 
and 3’UTR of DENV2 RNA for efficient virus particle production also co-eluted with 
157 
 
both GFP-NS3 and GFP-NS5 (Anwar et al., 2009). Similarly, LA that was reported to 
NS3 and NS5, and also 5’ and 3’UTR of DENV4 RNA also co-eluted with GFP-NS3 
and GFP-NS5 is this study (Garcia-Montalvo et al., 2004b). Taken together, these 
findings indicate that NS3 and NS5 interact with RNA-binding proteins or proteins 
that are involved in RNA-related processes in viral life cycle and hence, suggesting 
the potential involvement of these host proteins in RC, which is consistent with early 
studies in flavivirus replication that hypothesized the influence of host proteins in RC 
(Lindenbach & Rice, 2003; Westaway et al., 2003).  
 
Apart from the proteins that are associated with known functions of NS3 and NS5, we 
also identified some additional proteins that have not been reported to bind to NS3 or 
NS5 (Table A5) and thus, suggesting that these proteins may have important role in 
virus life cycle. Specifically, we observed proteins that are related RNA processing 
machinery, host translation pathway, and cytoplasm stress granule, which collectively 
suggests that NS3 and NS5 may recruit host RNA processing and translation 
machineries for viral RNA and protein synthesis (Pastorino et al., 2009). The 
implication of these enriched functional features among the identified host proteins in 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3.4.2 Enriched features of interactors that are unique to DENV1 and 2 GFP-
NS5  
As the purpose of the study at the outset was to identify any differences in the 
interaction of DENV1 and 2 GFP-NS5 with host factors to account for their 
differences in subcellular localization during the infection cycle, the host proteins that 
co-eluted with DENV1 and 2 GFP-NS5 were analysed separately by interaction 
networks (Table A3 and 4). Not surprisingly, the nucleocytoplasmic transport was one 
of the features that was significantly enriched (q-value ≤ 104), which is consistent 
with our finding that DENV1 and 2 NS5 have the ability to recruit the host nuclear 
transport machinery for them to traffic into the nucleus; in contrast, this feature was 
not found in GFP-NS3 interaction network because NS3 is not known to be 
transported to the nucleus and only associated with replication that occurs in the 
cytoplasm, however, it is worth noting that we observed DENV1 GFP-NS3 binding to 
importin-α1 whereas in Carpp et al’s study, they observed DENV2 GFP-NS3 binding 
to importin-4 (gene name: IPO4, 119 kDa); the implication of this finding is unknown 
and remains to be determined.  
 
From the dataset, we can see DENV1 and 2 GFP-NS5 binding to both importin-α1 
and importin-α5 proteins (correspond to KPNA2 and KNPA1 genes, respectively, 
Table 3-6) which supports the AlphaScreen data in section 3.2.2 that both DENV1 
and 2 NS5 can bind to importin-α1 despite the differences in nuclear localization. On 
the contrary, importin-α3 only bound to DENV1 GFP-NS5 whereas importin-α7 only 
bound to DENV2 GFP-NS5; it is unclear to us at the moment why DENV1 and 2 NS5 
bind preferentially to certain importin-α isoform but it is possible that within the 
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context of a cell, different import cargoes may compete for a particular importin-α 
isoform that favor its entry into the nucleus (Kohler et al., 1999) because of the 
specificity of NLS-importin-α interaction that is dependent on both the NLS and 
protein context (Gabriel et al., 2011) and the differences in the binding strength of 
each importin-α isoform to different NLSs and the strength of auto-inhibitory activity 
on its NLS-binding pocket that is mediated by its importin-β1 binding domain 
(Pumroy & Cingolani, 2014; Pumroy et al., 2015). It is worth mentioning that in 
recent years, importin-α3 and importin-α7 are found to be important in mediating the 
host tropism of avian and mammalian influenza A viruses (Gabriel et al., 2011). The 
authors found out that for efficient influenza virus replication that occurs in the 
nucleus, avian influenza virus requires importin-α3 for its polymerase subunit (PB2) 
and nucleoprotein (NP) to traffic into the nucleus whereas mammalian influenza virus 
requires importin-α7. However, during avian-mammalian adaptation, the avian virus 
can switch to using importin-α7 to promote interspecies transmission and also, 
enhance pathogenicity (Gabriel et al., 2011). Interestingly, mutation in PB2 was 
identified and may be implicated in promoting the switch to importin-α7 usage 
(Gabriel et al., 2011). In the context of DENV, the virus is known to replicate in both 
mosquito and human, and it has also been demonstrated that the localization patterns 
for DENV1-4 NS5 are similar in both mosquito and human cells (Hannemann et al., 
2013) and hence, it will be interesting to study if particular importin-α isoform 
dependency is also observed in DENV NS5 protein in both mosquito and human and 
is there an interplay between viral, mosquito and human factors in this manner in 




Table 3-6: List of importin-α isoforms that bind to DENV1 and 2 GFP-NS3 and GFP-NS5. The 
peptide count reflects the number of unique peptides that is associated with the identified protein.  











importin-α1 KNPA2 58 kDa 0 4 0 6 6 0 
importin-α5 KPNA1 60 kDa 0 0 0 4 4 0 
importin-α7 KNPA6 60 kDa 0 0 0 0 2 0 
importin-α3 KNPA4 58 kDa 0 0 0 6 0 0 
 
 
When we further dissected the dataset, we identified 71 proteins to be unique to 
DENV1 GFP-NS5 and 41 proteins to be unique to DENV2 GFP-NS5. Submission of 
these host proteins for GO analysis did not readily reveal any protein that was 
specifically associated with either the nucleus or cytoplasm and hence, we submitted 
the host proteins to GeneMANIA (Warde-Farley et al., 2010) to construct interaction 
networks for DENV1 and 2 GFP-NS5 separately for identification of new potential 
roles for NS5 (Figure 3-24). To our surprise, no common GO feature was observed 
between the two interaction networks; the interaction network that was unique to 
DENV1 GFP-NS5 was enriched by biological processes that were related to RNA 
processing and splicing, which possibly occur in the nucleus (Figure 3-24A), whereas 
the one that was unique to DENV2 GFP-NS5 was enriched by component and 
biological process that were related to COPI vesicle coat and Golgi transport, which 
take place in the cytoplasm (denoted by red dot in Figure 3-24B). This seems to 
suggest that DENV1 and 2 NS5 may have slight differences in their roles in DENV 
life cycle, even though they share a huge group of proteins that are common to both in 
this study (218 host proteins, Figure 3-23) and this idea is indirectly supported by a 
recent study by Carpp and coworkers (Carpp et al., 2014). They have demonstrated 
features like retrograde vesicle-mediated transport, Golgi to ER, COPI vesicle coat, 
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COPI-coated vesicle membrane, COPI-coated vesicle and etc. (denoted by red dot in 
Figure 3-24C) being enriched in their DENV2 GFP-NS5 interaction network and 
these features were also observed in our DENV2 GFP-NS5 interaction network but 
not in DENV1 GFP-NS5 interaction network. Furthermore, Carpp’s DENV2 GFP-
NS5 interaction network was established in the context of DENV2 infected cells, 
which further strengthened the possibility that the viral-host protein-protein 
interactions that we captured in our study were likely to be present in DENV infected 
cells. Taken together, we have demonstrated the reliability of the dataset and also 
provided additional evidence for previously identified interactions. The findings from 
this study will be used to identify new host factors and pathways/processes that are 






Figure 3-24: GO functional enrichment analysis of human host proteins that were identified to 
co-elute with either DENV1 or 2 GFP-NS5 by us and (Carpp et al., 2014). GO terms that are 
associated with (A) DENV1 GFP-NS5 (71 proteins, in this study), (B) DENV2 GFP-NS5 (41 proteins, 
in this study) and (C) DENV2 GFP-NS5 (53 proteins, (Carpp et al., 2014)) interaction networks are 
listed in graphs. GO terms that are common between groups are denoted by red dots. The Benjamini-
Hochberg procedure was used to calculate the q-value (x-axis) of each enriched GO feature. For each 
enriched GO feature that is associated with the generated interaction network, the number of proteins in 
the interaction network listed in that group, as well as the number of total proteins in the Homo sapiens 
proteome associated with the same GO feature.  
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3.4 Characterizing a newly discovered C-terminal NLS of DENV2 
NS5 and studying its importance in virus replication 
3.4.1 DENV1 NS5 residues 709-900 contributes to its cytoplasmic 
retention 
In section 3.2.2, we identified the CRS of DENV1 NS5 to reside either within 
residues 1-319 or 406-900 and therefore, in this study, we intended to further narrow 
down the region on DENV1 NS5 to identify the CRS sequence by adopting the same 
gene shuffling approach that we used in section 3.3.2. To do this, we exchanged gene 
fragment between DENV1 and 2 NS5 via overlap extension PCR based on the basis 
of functional domains that each gene fragment encodes; NS5 has two functional 
domains: MTase (residues 1-272) and RdRP (residues 273-900), and a previously 
classified NLS region (residues 320-405). Therefore, we exchanged gene segments 
that correspond to residues 1-272, 1-319 and 1-405 between DENV1 and 2 NS5 to 
generate GFP-NS5 plasmids that encode full-length NS5 protein for transfection 
(schematic representation of constructs in Figure 3-25).  
 
The newly constructed plasmids were used to transfect Vero cells, and cells were 
fixed at 24 hours post-transfection for staining by anti-GFP (green) and anti-NS5 
(5R3, red in Figure 3-25). The GFP-NS5 fusion constructs D11-272D2273-900 and D11-
319D2320-900 were localized to the nucleus and this rules out the possibility that the 
DENV1 NS5 CRS is within the MTase domain. Similarly, GFP-NS5 fusion construct 
D11-405D2406-900 was also localized to the nucleus and this implies that DENV1 NS5 
CRS is not within the linker region (residues 320-405) and it is in agreement with 
Figure 3-20 that DENV1 α/βNLS is functional. On the contrary, the GFP-NS5 fusion 
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construct D21-272D1273-900 was localized to the cytoplasm, suggesting that DENV1 
NS5 CRS resides within the RdRP domain. Likewise, the GFP-NS5 fusion constructs 
D21-319D1320-900 and D21-405D1406-900 were also localized to the cytoplasm and this 
provided further support that DENV1 NS5 CRS is within the C-terminal end of RdRP 




Figure 3-25: DENV1 NS5 residues 406-900 contributes to its cytoplasmic retention. Domain-
swapping experiment between DENV1 and 2 GFP-NS5 was performed to identify region on DENV1 
NS5 that is responsible for cytoplasmic retention. Exchanges of gene segments that encode functional 
domains (residues 1-272 is MTase domain, residues 273-900 is RdRP domain, and residues 320-405, 
which is previously known as the linker region, has been identified to an integral part of RdRP domain) 
between DENV1 and 2 NS5 were generated by overlap extension PCR. The plasmids were transfected 
into Vero cells and fixed 24 hours post-transfection. The cells were stained and images were captured 






To further narrow down the region within residues 406-900 of DENV1 NS5 to 
identify the CRS, we replaced the corresponding gene fragment of DENV2 NS5 with 
DENV1 sequence via overlap extension PCR based on the structural motifs (ie. α-
helices and β-strands) of the protein segment that is encoded by NS5. With DENV3 
NS5 RdRP (PDB: 2J7U (Yap et al., 2007) and JEV NS5 full-length 4K6M (Lu & 
Gong, 2013) crystal structures as templates, we defined the following regions of 
DENV2 NS5, namely residues 363-394, 395-497, 509-537, 543-576, 627-658, 627-
900 and 709-900, for replacement (schematic representation of constructs in Figure 3-
26). Transfection of these GFP-NS5 plasmids into Vero cells showed that D21-
362D1363-394D2395-900, D21-394D1395-497D2498-900, D21-508D1509-537D2538-900, D21-542D1543-
576D2577-900 and D21-626D1627-658D2659-900 were in nucleus and this implies that DENV1 
NS5 CRS is not within the exchanged regions. On the other hand, the GFP-NS5 
fusion constructs D21-626D1627-900 and D21-708D1709-900 were in the cytoplasm and this 
collectively suggested that DENV1 NS5 CRS probably resides within the last 190 





Figure 3-26: DENV1 NS5 residues 709-900 contributes to cytoplasmic retention. Motif-swapping 
experiment between DENV1 and 2 GFP-NS5 was performed to identify region on DENV1 NS5 that is 
responsible for cytoplasmic retention. Gene segments within residues 406-900 that encode protein 
segment of particular structural motif (ie. α-helices and β-strands) of DENV2 NS5 were replaced by 
corresponding DENV1 NS5 sequence by overlap extension PCR. The plasmids were transfected into 
Vero cells and fixed 24 hours post-transfection. The cells were stained and images were captured as 
described in Figure 3-16. Figure legends were as described in Figure 3-20. 
 
 
3.4.2 DENV2 NS5 may have a monopartite NLS that resides at C-
terminal end 
Inspection of the last 190 amino acid residues of DENV1 and 2 NS5, revealed a 
striking sequence difference in the last 10 residues; in fact, this region is also very 
different for DENV3 and 4 NS5. Closer examination of this region of DENV2 and 3 
NS5 revealed that the sequence is rich in glutamic acid (892EEEE for DENV2 and 
892EEESE for DENV3). Therefore, we hypothesized that this region of the different 
serotypes of NS5 may interact with different unknown host proteins that eventually, 
fine tune the subcellular localization of the respective NS5’s in both infected and 
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transfected cells. We replaced residues 890-900 of DENV2 NS5 with residues 890-
900 of DENV1, 3 and 4 respectively via conventional PCR and transfected the 
plasmids into Vero cells (Figure 3-27). To our surprise, DENV2 NS5 with residues 
890-900 of DENV1 and 3 was mostly nuclear-localized whereas DENV2 NS5 with 
residues 890-900 of DENV4 was predominantly in the cytoplasm. Upon analysis of 
this region in greater details, it turned out that replacing this region with DENV4 
sequence might disrupt a potential NLS sequence that is in DENV2 NS5 and 
somehow, replacing this region with DENV1 sequence retained the minimum NLS 
sequence for DENV2 NS5 nuclear localization. Interestingly, replacing the region 
with DENV3 sequence retains DENV2 NS5 nuclear-localizing ability (see Figure 3-
28A for sequence alignment).  
 
 
Figure 3-27: Residues 890-900 of DENV4 NS5, but not DENV1 NS5 affects nuclear localizing 
ability of DENV2 NS5. C-terminal-swapping experiment between DENV1-4 GFP-NS5 was performed 
to identify region on DENV1 NS5 that is responsible for cytoplasmic retention. Residues 890-900 of 
DENV2 NS5 were replaced with residues 890-900 of DENV1 (red), 3 (blue) and 4 (orange) 
respectively via conventional PCR. The plasmids were transfected into Vero cells and fixed 24 hours 






3.4.3 DENV2 NS5 residues 883-900 can target an unrelated protein into 
the nucleus 
To determine if the C-terminal end of DENV2 NS5 indeed contains a monopartite 
NLS sequence, we first did a sequence alignment of DENV1-4 NS5 residues 883-900 
and compared it with the general consensus sequences of classical NLS (Figure 3-
28A). This region of DENV1, 2 and 3 NS5 contains sequence of basic residues that 
resembles classical monopartite NLS. On the contrary, this region of DENV4 NS5 
does not contain sequence that resembles classical monopartite NLS.  
 
We next submitted NS5 protein sequences of DENV1-4 to online tool: cNLS Mapper 
(http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) that can be used to 
predict classical NLSs that are specific to importin-α/β pathway through a position-
specific scoring matrix that was developed based on experimental data (Kosugi et al., 
2009a; Kosugi et al., 2009b). Interestingly, cNLS Mapper supported the finding that a 
monopartite NLS is likely to be present at the C-terminal end of both DENV2 and 3 
NS5; it also supported the finding that a monopartite NLS is unlikely to be present at 
the C-terminal end of DENV1 and 4 NS5 (Table 3-7). 
Table 3-7: NLS search results from cNLS Mapper. The predicted monopartite and bipartite NLSs 
sequences, as well as their scores are listed in the table; the higher the score, the higher the NLS 
activity. The scoring is as follows: 1-2, localized to the cytoplasm; 3-5, localized to both nucleus and 
cytoplasm; 7-8, partially localized to the nucleus; 8-10, exclusively localized to nucleus (Kosugi et al., 
2009a; Kosugi et al., 2009b). “-” indicates not found’ “N.A.” indicates not applicable. The basic 





Score Predicted bipartite NLS Score 
DENV1 385SRNKKPRICTREEF 6 - N.A. 
DENV2 882YMPSMKRFRREEE 7.5 - N.A. 
DENV3 
385GRNKRPRLCTREEF 8.5 382RTLGRNKRPRLCTREEFTKKVRTN 7.7 
882YMPSMKRFRKEEE 6.5 - N.A. 




To demonstrate experimentally that residues 883-900 of DENV2 NS5 indeed contains 
a monopartite NLS that can target an unrelated protein into the nucleus, we fused this 
region, as well as the corresponding region of DENV1 and 4 NS5, to the C-terminal 
of a tandem GFP gene construct (2×GFP), to encode a protein >45 kDa that could be 
transported into the nucleus actively by importin-α/β pathway, and not by passive 
diffusion (Figure 3-28A). We also fused SV40 NLS sequence to 2×GFP construct to 
act as positive control for monopartite NLS. These plasmids were transfected in Vero 
cells and cells were fixed and stained 24 hours post-transfection for CLSM. Results 
for nuclear to cytoplasmic fluorescence ratio (Fn/c) (Figure 3-28C) were determined 
from image analysis of digitized CLSM images (such as those in Figure 3-28B) by 
ImageJ software (Collins, 2007) demonstrated that DENV2 NS5 residues 883-900 
(Fn/c = 5.06 ± 0.22, refer to Table 3-8 for pooled data) was capable of driving an 
unrelated protein into the nucleus, just like the monopartite SV40 NLS (Fn/c = 6.97 ± 
0.37), whereas the corresponding region of DENV4 NS5 did not (Fn/c = 0.63 ± 0.02), 
just like the negative control 2×GFP (Fn/c = 0.81 ± 0.03). Interestingly, this 
corresponding region of DENV1 NS5 caused 2×GFP to be distributed equally in both 
nucleus and cytoplasm (Fn/c = 1.03 ± 0.06), indicating that DENV1 NS5 residues 883-
900 may have the ability to target an unrelated protein to the nucleus, albeit slower or 




 Figure 3-28: Fusion of residues 883-900 of DENV2 NS5 to 2×GFP targets 2×GFP to the nucleus. 
(A) Sequence alignment of residues 883-900 of DENV1-4 NS5 with SV40 NLS, which is a 
monopartite NLS. The virus sequences and their GenBank accession numbers are as described in 
Figure 3-4C. (B) Vero cells were transfected with either 2×GFP or 2×GFP-fusion plasmids encoding 
residues 883-900 of DENV1, 2 and 4 NS5, and fixed at 24h post-transfection. 2×GFP-fusion plasmid 
encoding SV40 NLS was included as a positive control for monopartite NLS. Anti-GFP (ab6556 IgG, 
1:1000; green) antibody was used for immunostaining. Images were captured by CLSM using a Zeiss 
LSM 710 upright confocal microscope by 40× oil immersion lens. (C) Images, such as those shown in 
A were analysed to determine nuclear to cytoplasmic fluorescence ratio (Fn/c) as previously described 
(Kumar et al., 2013; Pryor et al., 2007; Rawlinson et al., 2009; Tay et al., 2013). Data are shown as 





We next asked if previously reported DENV2 NS5 α/βNLS that resides within 
residues 368-405 is able to target an unrelated protein to the nucleus, just like residues 
883-900. Residues 368-405 of DENV2 NS5, as well as residues 320-405 that included 
previously reported NES and α/βNLS, was fused to 2×GFP construct (Figure 3-29A). 
In our hands both the 2×GFP-fusion constructs carrying the previously characterized 
internal NLS (Fn/c = 0.88 ± 0.05 and 0.77 ± 0.02, respectively) could not be targeted 
to the nucleus, just like the negative control 2×GFP (Fn/c = 0.81 ± 0.03, Figure 3-29B 
and C). 2×GFP-fusion constructs that spanned other regions that were within residues 
320-405, namely residues 320-367, 368-389 and 387-405, also behaved similarly (Fn/c 
ratio not determined). Taken together, our result suggests that residues 883-900 of 




Figure 3-29: Fusion of residues 368-405 of DENV2 NS5 to 2×GFP does not target 2×GFP to the 
nucleus. (A) Schematic representation of transfected 2×GFP-fusion constructs. The displayed sequence 
is from residue 320-405 of DENV2 NS5. Regions are highlighted in grey, cyan and magenta denote 
NES, α/βNLS and CK2 site. The amino acids that are conserved among flavivirus NS5 are bold. The 
basic amino acid that constitutes the NLS is bold and underlined. The grey dotted line indicates the 
boundary of each construct. “*” indicates the position of basic amino acid. (B) Vero cells were 
transfected with either 2×GFP or 2×GFP-fusion plasmids encoding residues 320-405, 320-367, 368-
405, 368-389, 387 and 405 and 883-900 of DENV2 NS5, and fixed at 24h post-transfection. 2×GFP-
fusion plasmid encoding SV40 NLS was included as a positive control for monopartite NLS. The cells 
were stained and images were captured as described in Figure 3-28B. Images were analysed to 
calculate mean Fn/c ± SEM (error bars), n = 30 cells from a single assay, representative of two 
independent experiments, as described in Figure 3-28C. “*” indicates that the Fn/c ratio for these 




3.4.4 DENV2 NS5 residues 883-900 can target DENV1 NS5 into the 
nucleus 
Since residues 883-900 of DENV2 NS5 can target 2×GFP into nucleus, we 
hypothesized that replacing this corresponding region on DENV1 NS5 can target 
DENV1 NS5 into nucleus (Figure 3-30A). As predicted, DENV1 NS5 with 
DENV2883-900 could localize to the nucleus (Fn/c = 4.57 ± 0.25) (Figure 3-30B and C) 
more efficiently than DENV1 NS5 WT (Fn/c = 0.86 ± 0.02). On the other hand, 
replacing residues 883-900 of DENV2 NS5 with corresponding DENV1 sequence 
caused more NS5 protein to be in cytoplasm (Fn/c = 1.01 ± 0.02) as compared to 
DENV2 NS5 WT (Fn/c = 13.28 ± 1.08). Taken together, these results suggest that 
residues 883-900 of DENV2 NS5 indeed contains a functional monopartite NLS.  
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 Figure 3-30: Replacement of residues 883-900 of DENV1 NS5 by corresponding sequence of 
DENV2 NS5 targets DENV1 NS5 to the nucleus. (A) Schematic representation of transfected GFP 
constructs. “*” indicates the position of basic amino acid. (B) Vero cells were transfected with the 
constructs showed in A and fixed at 24h post-transfection. Anti-GFP (ab6556 IgG, 1:1000; green) and 
anti-NS5 (5R3 IgG, 30 nM; red) antibodies were used for immunostaining and images were captured as 
described in Figure 3-16A. (C) Images taken from anti-GFP stained cells were analysed to calculate 
mean Fn/c ± SEM (error bars), n = 30 cells from a single assay, representative of two independent 





3.4.5 DENV2 NS5 residues 887-888 and 890-891 are needed for nuclear 
localization of DENV2 NS5  
To further test if monopartite NLS is indeed present in residues 883-900 of DENV2 
NS5, we made DENV2 NS5 GFP constructs that expressed NS5 residues 1-882 
protein, which terminated before the putative monopartite NLS sequence, as well as 
NS5 residues 1-891 protein, which stopped right after the basic cluster of the putative 
monopartite NLS sequence (refer to Figure 3-31A). Both proteins gave expected 
results; DENV2 NS51-882 protein was predominantly localized to the cytoplasm (Fn/c = 
0.73 ± 0.04), whereas DENV2 NS51-891 protein was mostly nuclear-localized (Fn/c = 
5.85 ± 0.33), albeit much less efficiently than DENV2 NS5 full-length protein (Fn/c = 
13.28 ± 1.08) (Figure 3-31B and C). On the other hand, DENV1 NS51-882 protein still 
remained mainly in the cytoplasm (Fn/c = 0.92 ± 0.03), just like DENV1 NS5 full-
length protein (Fn/c = 0.86 ± 0.02).  
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 Figure 3-31: Truncation of residues 883-900 from DENV2 NS5 reduces its nuclear localization. 
(A) Schematic representation of transfected constructs. “*” indicates the position of basic amino acid. 
(B) Vero cells were transfected with the constructs showed in A and fixed at 24h post-transfection. The 
cells were stained and images were captured as described in Figure 3-16A. (C) Images taken from anti-
GFP stained cells were analysed to calculate mean Fn/c ± SEM (error bars), n = 30 cells from a single 




Next, we disrupted the NLS sequence by mutating the basic residues that constitute 
the monopartite NLS sequence (hereafter defines as C-terminal NLS, short form; C-
term NLS) to alanine to generate DENV2 C-term A1 (887KRAA), A2 (890RRAA) 
and A1+A2 (887KRAA+890RRAA) DENV2 NS5 GFP constructs (refer to Figure 
3-32A). We also included previously published α/βNLS mutants, namely DENV2 
α/βNLS A2 (387KKKAAA) and A1+A2 (371KKAA+387KKKAAA) DENV2 
NS5 GFP constructs for comparison. As expected, by disrupting the NLS sequence 
through alanine mutation reduced the ability of DENV2 NS5 to nuclear-localize; 
alanine mutation to either basic cluster of C-terminal NLS gave comparable Fn/c ratios 
(The Fn/c ratios for C-term A1, C-term A2 and C-term A1+A2 mutants were 0.50 ± 
0.01, 0.22 ± 0.01 and 0.56 ± 0.03, respectively) (Figure 3-32B and C). Through Fn/c 
ratio comparison, C-terminal NLS mutants seemed to have more cytoplasmic NS5 
than α/βNLS A1+A2 mutant (Fn/c = 0.77 ± 0.02). Taken together, these results 
supported the idea that the C-terminal end of DENV2 NS5 resides a functional 
























































































































































































































































































































3.4.6 C-terminal NLS mutant virus affects viral replication and disrupts 
DENV2 NS5 nuclear localization 
To corroborate these results in the context of virus infection, NS5 C-terminal alanine 
mutations were introduced into DENV2 cDNA clone. We also included another 
DENV2 cDNA clone that had its NS5 RdRP sequence (residues 273-900) being 
replaced by corresponding DENV1 sequence for comparison (defined as DENV2/1) 
because its chimeric NS5 protein also has less nuclear targeting ability (Figure 3-25). 
In vitro RNA transcripts that were produced from these clones were used to transfect 
BHK-21 cells and samples were harvested over the course of a 5-day experiment. The 
harvested supernatants were used to determine viral titres and extracellular viral RNA 
copy numbers, whereas the infected cells were used to determine intracellular viral 
RNA copy numbers and for IFA.  
 
No infectious virus was recovered from the supernatant of DENV2 C-terminal A1 and 
A1+A2 mutant viruses, and DENV2/1 chimeric virus, whereas the number of 
infectious virus that was produced by DENV2 C-terminal A2 mutant virus was 100× 
lower than WT virus for day 2 and 3 post-trasfection, and smaller plaque was seen 
(Figure 3-33A and B). To confirm that no infectious virus was indeed present in 
supernatant, we employed real-time RT-PCR to measure absolute copy numbers of 
extracellular viral RNA. Interestingly, though no visible plaque was seen for 
DENV2/1 chimeric virus, we could detect similar level of extracellular viral RNA for 
both DENV2 C-terminal A2 mutant virus and DENV2/1 chimeric virus (Figure 3-
33C). On the contrary, in agreement with plaque assay data, the extracellular viral 
RNA level for both DENV2 C-terminal A1 and A1+A2 mutant viruses remained 
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consistent throughout the 5-day experiment, indicating no infectious virus particles 
were being produced for these mutant viruses. Next, we also measured the absolute 
copy numbers of intracellular viral RNA and showed that DENV2 C-terminal A2 
mutant virus and DENV2/1 chimeric virus replicated at similar rate and their viral 
RNA copy numbers were at least 10× lower than DENV2 WT for days 1-4 post-
transfection (Figure 3-33D). On the other hand, viral RNA copy numbers for DENV2 
C-terminal A1 and A1+A2 mutant viruses remained fairly consistent throughout the 
5-day experiment, implying that no active RNA replication was taking place and both 
mutations were lethal to virus. 
 
To confirm that the lower replication rates of DENV2 C-terminal A2 mutant virus and 
DENV2/1 chimeric virus were linked to reduced nuclear targeting of NS5, we 
examined the localization pattern of dsRNA and NS5 protein of transfected cells by 
IFA. We observed co-localization of NS5 (red) and cytoplasmic dsRNA (green) on 
day 3 post-transfection for DENV2 C-terminal A2 mutant virus and DENV2/1 
chimeric virus but not for DENV2 WT virus (Figure 3-33E). This data further 
supported the finding that 890RR of DENV2 NS5 is important for NS5 nuclear 
localization (Figure 3-32) and there may be a correlation between lower virus 
replication rate and reduced nuclear targeting ability of NS5. We did not detect any 
NS5 and dsRNA staining for DENV2 C-terminal A1 and A1+A2 mutant viruses, 
which was in agreement with real-time RT-PCR data and this further supported the 




In conclusion, we have shown a possible correlation between reduced DENV2 NS5 
nuclear localization and lower virus replication. It also appears that 887KR has a more 
severe effect on virus replication than 890RR. However, this effect may not be fully 
attributed to just nuclear localization defect because basic amino acids (either KR or 
RR) at residues 887-888 are highly conserved among flaviviruses and the extent of 
NS5 nuclear localization is not a conserved feature among flaviviruses (Figure 3-34); 
the implication of this finding will be further discussed in section 4-4. Nevertheless, 
based on these findings, further studies have been initiated to gain a more 
comprehensive understanding on the C-terminal region DENV2 NS5, as well as other 
serotypes of NS5, on its binding to importin-α via biochemical and structural 






Figure 3-33: DENV2 NS5 C-term NLS A2 mutant virus and DENV2/1 chimeric virus have 
reduced nuclear accumulation of NS5 protein and viral replication. (A-E) BHK-21 cells were 
electroporated with 10 μg of genomic-length RNA of WT and mutants; supernatants and infected cells 
were harvested daily, for 5 days. Supernatants were used to (A-B) check for plaque production on 
BHK-21 cells and to (C) determine absolute copy numbers of extracellular viral RNA by real-time RT-
PCR. Absolute copy numbers of viral RNA in log scale per ml of supernatant used for real-time RT-
PCR was plotted; data are shown as the mean ± SD from one experiment. (D) RNA was extracted from 
infected cells and absolute copy numbers of intracellular viral RNA was determined by real-time RT-
PCR. Absolute copy numbers of viral RNA per μg of RNA used for real-time RT-PCR was plotted; 
data are shown as the mean ± SD from one experiment. (E) Infected cells were analysed for presence of 
NS5 (red) and dsRNA (green) by IFA on day 3 post-transfection. Data from one experiment are shown.  
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 Figure 3-34: Sequence alignment of NS5 residues 860-900 of DENV2 with other DENV serotypes 
and representative members of the Flavivirus genus. In this study, residues 883-900 is defined as C-
terminal NLS and the basic residues that important are important for binding to importin-α are bold. 
Residues 890-900 that are exchanged between serotypes in Figure 3-27 are highlighted in grey. The 
alignment was performed using ClustalW (Thompson et al., 1994). The numbering is based on DENV2 




Table 3-8: Summary of Fn/c ratio, western blot and IFA data of WT and chimeric NS5 of 
DENV1-4. The Fn/c ratios were computed from images that had NS5 being stained by in transfected 
vero cells by anti-GFP; anti-NS5 (5R3) was included to check the folding of WT and chimeric NS5 
proteins. GFP-NS5 and 2×GPF constructs were also transfected into HEK293T cells to check the 
expression of these proteins by western blot with anti-NS5. Under construct name, D1 = DENV1 and 
D2 = DENV2. The number of “*” denotes the intensity of western blot band; “*****” indicates the 
highest intensity, “*” indicates the lowest intensity. “Y” denotes yes, “N” denotes no. N.D. indicates 
not determined. Fn/c = nuclear to cytoplasmic fluorescence ratio, Fn/c < 1, predominantly cytoplasmic, 
Fn/c > 1, predominantly nucleus.  
Construct name 
Vero HEK293T 




D1 Y Y 0.86 ± 0.02 *** 
D2 Y Y 13.28 ± 1.08 ** 
D1 1-319 D2 320-405 D1 406-900 Y Y N.D. * 
D2 1-319 D1 320-405 D2 406-900  Y N N.D. ***  
D1 1-272 D2 273-900 Y Y N.D. ** 
D1 1-319 D2 320-900 Y Y N.D. ***** 
D1 1-405 D2 406-900 Y Y N.D. *** 
D2 1-272 D1 273-900 Y Y N.D. ***** 
D2 1-319 D1 320-900 Y Y N.D. * 
D2 1-405 D1 406-900 Y N N.D. * 
D2 1-362 D1 363-394 D2 395-900  Y Y N.D. N.D. 
D2 1-394 D1 395-497 D2 498-900  Y Y N.D. N.D. 
D2 1-508 D1 509-537 D2 538-900  Y Y N.D. N.D. 
D2 1-542 D1 543-576 D2 577-900  Y Y N.D. N.D. 
D2 1-626 D1 627-658 D2 659-900  Y N N.D. * 
D2 1-626 D1 627-900 Y N N.D. N.D. 
D2 1-708 D1 709-900 Y Y N.D. ** 
D2 1-888 D1 889-900 Y Y N.D. N.D. 
D2 1-888 D3 889-900 Y Y N.D. ** 
D2 1-888 D4 889-900 Y Y N.D. **** 
D1 with D2 883-900 Y Y 4.57 ± 0.25 ** 
D2 with D1 883-900 Y Y 1.01 ± 0.02 ** 
D1 1-882 Y Y 0.92 ± 0.03 N.D. 
D2 1-882 Y Y 0.73 ± 0.04 N.D. 
D2 1-891 Y Y 5.85 ± 0.33 N.D. 
D2 α/βNLS A2 Y Y 4.25 ± 0.31 ** 
D2 α/βNLS A1+A2 Y N 0.77 ± 0.02 * 
D2 C-term A1 Y Y 0.50 ± 0.01 ** 
D2 C-term A2 Y Y 0.22 ± 0.01 * 
D2 C-term A1+A2 Y Y 0.56 ± 0.03 *** 
2×GFP fusion constructs 
D1 883-900 Y N.A. 1.03 ± 0.06 **** 
D2 883-900 Y N.A. 5.06 ± 0.22 **** 
D4 883-900 Y N.A. 0.63 ± 0.02 **** 
D2 320-405 Y N.A. 0.77 ± 0.02 *** 
D2 320-267 Y N.A. N.D. **** 
D2 368-405 Y N.A. 0.88 ± 0.05 **** 
D2 368-389 Y N.A. N.D. **** 




Chapter 4: Discussion 
4.1 Preface  
This work aimed to understand in detail the viral factors that modulate the replication 
cycle of DENV and test the hypothesis that such knowledge can lead to validation of 
potential targets for antiviral therapy. In infected cells, protein-protein interactions 
among viral proteins and between viral and host proteins are key players in mediating 
virus replication and disease pathogenesis. Considerable amount of effort has been put 
into characterizing the largest and most highly conserved NS5 protein in term of its 
enzymatic roles and potential as a directly acting antiviral target. However, molecular 
studies on the impact of its interaction with other viral proteins, as well as with host 
proteins on virus replication and diseases pathogenesis is still lacking and also often 
restricted to the study of DENV2 NS5.  
 
DENV2 NS5 exists in two different forms in infected cells: cytoplasmic NS5 and 
nuclear NS5. Cytoplasmic NS5 interacts with NS3 in the perinuclear region to 
participate in viral RNA replication (Cui et al., 1998; Kapoor et al., 1995; Welsch et 
al., 2009; Yon et al., 2005; Yu et al., 2013) whereas nuclear NS5 interacts with 
importin-α/β1 in the cytoplasm to translocate into nucleus, where it may mediate 
infectious virus production and IL-8 secretion (Brooks et al., 2002; Forwood et al., 
1999; Johansson et al., 2001a; Kumar et al., 2013; Pryor et al., 2007). Previous 
studies have identified NS3-NS5 and NS5-importin-α/β1 interaction sites to reside 
within previously identified interdomain linker region, residues 320-405 of NS5 
(Figure 1-16) through Y2H studies (Brooks et al., 2002; Forwood et al., 1999; 
Johansson et al., 2001a). Mutations in NS5 330KA and 
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371KKAA+387KKKAAA disrupt NS3-NS5 and NS5-importin-α interactions, 
respectively and mutagenesis studies with DENV2 infectious cDNA clone showed 




4.2 NS3-NS5 interaction is required for coordinated positive- and 
negative-strand RNA synthesis 
With the availability of structural information for domains or full-length proteins of 
DENV NS3 & NS5 (Erbel et al., 2006; Luo et al., 2010; Luo et al., 2008a; Xu et al., 
2005b; Yap et al., 2007), the information on the interaction sites can be used to 
facilitate structure-guided drug design. In this study, we have fine mapped the 
interaction region on NS3 that is involved in NS3-NS5 interaction to residues 566-585 
by competitive NS3-NS5 interaction ELISA, peptide-phage ELISA and SPR (in 
collaboration with Profs Luo Dahai and Julien Lescar (NTU)). Although obtaining 
crystal structures of the complex has been challenging and not yet available, this study 
obtained a solution structure by SAXS in collaboration with Prof Gerhard Gruber and 
Miss Saw Wuan Geok (NTU) that supports physical interaction between NS3172-618 
and NS5320-341 is a significant contribution towards the reconstruction of the RC. 
 
Electrostatic potential surface analysis of NS3566-585 and NS5320-341 shows a 
negatively-charge contiguous surface on NS3 and a positively-charged contiguous 
surface on NS5 that are charge-complementary to each other and this further supports 
the data that the two regions can indeed interact with one another via charge 
interaction (Figure 4-1A). This study demonstrates that NS3 residue N570 is 
important for NS3-NS5 interaction and its mutation to alanine disrupted in vitro NS3-
NS5 interaction (Figure 3-4B). When the same mutation was introduced into DENV2 
cDNA infectious clone, it abolished infectious virus production (Figure 3-8A and B), 
similar to NS5:K330A mutant, which is a known NS3-NS5 interaction defective 
mutant (Zou et al., 2011). However, unlike NS5:K330A mutant, NS3:N570A mutant 
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was able to synthesize low but unsustainable amount of viral RNA and proteins 
(Figure 3-8C and D and Figure 3-9). Comparison of the pattern of negative- and 
positive-strand RNA synthesis between WT, NS3:N570A and NS5:K330A confirmed 
that the NS5:K330A mutant is completely inactive since transfected positive-strand 
RNA degraded over time and the negative-strand RNA detected corresponded to 
background (Figure 3-13). The WT RNA transfected cells showed synchronized 
synthesis of negative- and positive-strand RNA, which is in agreement with previous 
studies that have shown an excess of positive- to negative-strand RNA in DENV 
infected cells (Tomassini et al., 2003). However, it is possible that the long term 
coordinated synthesis of negative- and positive-strand RNA requires a functional RC 
with optimum protein interaction affinities between NS3 and NS5 (Figure 4-1B). This 
is supported by NS3:N570A mutant that showed fairly robust negative-strand 
synthesis using the transfected RNA as a template, and is probably analogous to the 
situation at the early stages of viral replication in an infected cell. The weakened or 
abolished interaction between NS3 and NS5 in NS3:N570A mutant does not support 
the replication of new positive-strand RNA from 6 to 24 hour when compared to WT 
virus, which fits rather well with the carefully conducted real-time RT-PCR 
quantifications. Surprisingly, the NS5:K330A mutant that has been shown to be 
enzymatically active in vitro and demonstrated to have no interaction with NS3 did 
not show a similar increase in negative-strand RNA as compared to NS3:N570A 
mutant. There may be two possible reasons for - the inactivity of NS5:K330A mutant 
in making negative-strand RNA. First, it may be due to impaired intramolecular 
signalling between the two NS5 domains that probably coordinates the two functional 
activities of NS5 (Li et al., 2014b; Lu & Gong, 2013; Wu et al., 2015) required for in 
vivo polymerase activity, or second, that its weak/abolished interaction with NS3 may 
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affect the unwinding of secondary structures in the transfected positive-sense RNA 
that is needed for negative-strand synthesis. Taken together, the results from this 
study imply that different NS3-NS5 interaction defective mutants can impair viral 
protein synthesis, infectious virus production and viral RNA replication to varying 
degree, which is likely to be dependent on the importance of the amino acids that are 
involved in NS3-NS5 interaction (ie. it is possible that other residues within the 
conserved region that we mapped are also important), and also possibly, 
intramolecular interactions in NS5. It is interesting to note that the coordinated 
synthesis of negative- and positive-strand RNA at the early stages of replication can 
be further explored by studying NS3-NS5 interaction mutants displaying varying 
strength/degree of binding and also, the contribution of intramolecular cross-talk 
between domains of NS5 in strand-specific RNA synthesis in the RC. Importantly, we 
also note that although NS3 residue N570 is conserved amongst the four DENV 
serotypes and several members of flavivirus genus, it is not conserved in YFV NS3 
which has a histidine in place of asparagine at this position in NS3 and, tyrosine 
instead of lysine at position 330 of NS5 (refer to Figure 3-4C and Figure 3-5A for 
sequence alignment). This suggests that protein interaction sites of different 
flaviviruses could co-evolve with the different host proteins. 
 
The fine tuning of NS3-NS5 interaction site in this study, together with the available 
3D structural data can be used in conjunction with ab initio modelling and in silico 
drug discovery efforts to discover novel inhibitors against DENV. As a starting point 
the validation that peptide sequences in the interaction region can function as 
inhibitors in cellular infection studies (Figure 3-14) also opens the way to examine 
stapled-peptides approach (Verdine & Hilinski, 2012) to inhibit protein-protein 
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interaction. Another attractive proposition from this study is that mutant such as 
NS3:N570 may serve as potential RNA-mediated vaccine since our study shows that 
low level translation of viral proteins can be achieved with residues that are selected 
on the basis of structure and function. However, for developing RNA-based vaccines 
new technologies need to be developed in the area of stabilization and delivery.  
 
 
Figure 4-1: Schematic representation of NS3-NS5-RNA interaction. (A) Surface electrostatic 
potential presentation of NS5273-900 (RdRP) and NS3172-618 (Helicase). The protein backbones of NS5320-
341 and NS3566-585 are shown in ribbon presentation. The side-chains of NS5 K330 and NS3 N570 are 
displayed. (B) Simplified schematic model of NS3-NS5 interaction complex with RNA. The orange 
and red solid ovals represent residues 566-585 of NS3 and residues 320-341 of NS5, respectively. 
Dotted line (green) is used to denote that the uncertain path that exiting template RNA from NS3 takes 
to enter NS5 for complementary daughter strand synthesis. Dark blue line denotes the unwound 
parental strand; green line denotes the parental strand that serves as template; grey line denotes the 
newly synthesized daughter strand.  
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4.3 GFP-NS3 and GFP-NS5 interaction networks reveal novel host 
factors that interact with NS3 and NS5 for DENV replication and 
pathogenesis 
Even though DENV2 NS5 nuclear localization has been known for twenty years 
(Kapoor et al., 1995), its precise role in nucleus remains elusive. Furthermore, both 
our finding (Tay et al., 2013) and that of the Dr Davidson’s group (Hannemann et al., 
2013) that variations in DENV1-4 NS5 subcellular localization can be observed, 
throws some doubt if nuclear NS5 has any critical functions. However, the most 
powerful case in favor of its important role in nucleus comes from the drug discovery 
approach used in the laboratory of Prof David Jans, where the AlphaScreen 
technology has been used to identify compounds that inhibit the interaction between 
DENV NS5 and mouse importin-α/β1 (Fraser et al., 2014; Tay et al., 2013; Wagstaff 
et al., 2011; Wagstaff et al., 2012). One possible hypothesis is that an important host 
protein that is required for viral RNA replication in the RC may be recruited through 
the nuclear-cytoplasmic shuttling of NS5. For this purpose, a detailed proteomics, 
genomics and interactomics based approach that characterize host protein interaction 
network is important and this will be greatly facilitated by the wealth of knowledge 
accumulated in recent years from genome-wide siRNA screens (Krishnan et al., 2008; 
Le Sommer et al., 2012; Sessions et al., 2009), microarray (Becerra et al., 2009; 
Conceicao et al., 2010; Fink et al., 2007; Loke et al., 2010; Nasirudeen & Liu, 2009; 
Sessions et al., 2013; Villas-Boas et al., 2009), proteomics (Chiu et al., 2014; Pando-
Robles et al., 2014) and interactomics (Carpp et al., 2014; Khadka et al., 2011; Le 
Breton et al., 2011; Mairiang et al., 2013) studies (see (Acosta et al., 2014) and 
(Krishnan & Garcia-Blanco, 2014) for a complete review). The task to integrate this 
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fragmented information will be challenging but it will be rewarding in identifying 
critical host factors and new/novel therapeutic targets (Huang & Fraenkel, 2009).  
 
In this study, the co-IP coupled to MS approach was used to address the potential 
roles of nuclear NS5 on dengue pathogenesis. A total of 405 human proteins were 
identified, of which 185, 298 and 273 co-eluted with DENV1/2 GFP-NS3, DENV1 
GFP-NS5 and DENV2 GFP-NS5, respectively. Out of 405 human proteins, around 
10% of the hits have already been reported (most of them are not characterized in 
term of their importance in virus replication and pathogenesis) by various studies 
(Y2H, pulldown assay, co-IP coupled to quantitative MS and RNA affinity 
chromatography) to be interacting with NS3, NS5 or viral RNA (Table 3-3 and 3-5). 
Comparison of our dataset to four dataset of published viral-host protein interaction 
screens that involved the same viral proteins, NS3 and NS5 (three Y2H datasets 
(Khadka et al., 2011; Le Breton et al., 2011; Mairiang et al., 2013) and one co-IP 
dataset (Carpp et al., 2014)) yielded a small overlap in datasets (Figure 4-2, circle in 
blue). Similarly, comparison among these 5 datasets also generated a small overlap in 
datasets. Taken together, this implies that dataset from each screen is unlikely to be 
exhaustive and complementary proteomic approaches that capture direct and indirect 
interactions are required to generate a comprehensive virus-host interaction network 




Figure 4-2: Comparisons of dataset overlap between published Y2H screens, co-IP study and our 
co-IP work. Each dataset is labelled according to the first name of the author. The datasets that we 
generated in our study are labelled according to the GFP-proteins (in red) that they co-eluted with. The 
description in bracket describes the method (either Y2H or co-IP) that was used in each study. The 
region that overlaps is circled in blue.  
 
 
As mentioned in results, both Carpp et al and this work used GFP-tagged NS3 and 
NS5 proteins for co-IP. However, they did co-IP in the context of DENV2 infected 
cells to identify bona fide high confidence viral-host protein interactions. Out of 41 
and 53 host proteins that Carpp and colleagues have reported to be interacting with 
GFP-NS3 and GFP-NS5, respectively, we observed an overlap of 5 and 10 with our 
GFP-NS3 and GFP-NS5 interaction networks. One protein, Sec61α1 (protein 
transport protein Sec61 subunit alpha isoform 1) is common to both GFP-NS3 and 
GFP-NS5 of Carpp et al and our screen. Sec61α1 is a component of the heterotrimeric 
Sec61 complex (composed of three subunits: α, β and γ) that forms a transmembrane 
channel in the ER membrane to mediate the translocation of newly synthesized 
unfolded proteins into ER, and it is a component of ER-associated protein degradation 
pathway (ERAD), which targets misfolded protein from ER to proteasome for 
ubiquitin-mediated degradation (Meusser et al., 2005). Surprisingly, Sec61α1, β and γ 
have been collectively shown to be proviral host factors for DENV2, WNV and YFV 
in human and mosquito genome-wide siRNA screens (Krishnan et al., 2008; Le 
195 
 
Sommer et al., 2012; Sessions et al., 2009). In the work by Krishnan and colleagues, 
the knockdown of Sec61α1 and γ in human HeLa cells led to the reduction of WNV 
and DENV2 positive cells by ~50 and ~85%, respectively. Through further functional 
studies in WNV infected cells, the authors have shown a ~10% reduction in infectious 
virus production when ERAD components were knockdown and ruled out the 
involvement of ERAD in virus internalization, endosomal transport, or RNA 
translation in mediating the reduction (Krishnan et al., 2008). In another study the 
knockdown of Sec61β in Drosophila Mel-2 cells led to the reduction of DENV2 
positive cells by ~75%; an ~90% reduction in infectious virus production by Huh-7 
DENV2 infected cells was observed with Sec61β knockdown (Sessions et al., 2009). 
Taken together, these findings highlight the possible importance of Sec61 complex in 
DENV life cycle, and NS3 and NS5 may be involved in biological processes that are 
associated with the function of Sec61 complex in ERAD pathway. 
 
Although our primary goal to identify nuclear host factors for NS5 with our 
experiment setup has not readily revealed any hits, we have however, managed to 
identify new potential roles for NS3 and NS5 in DENV replication and pathogenesis 
for further study by performing GO enrichment analysis on the co-eluted host 
proteins. Specifically, cellular processes related to RNA processing, translation 
machinery and cytoplasm stress granule components appear to be significantly 





RNA processing machinery and host translation pathway - GO terms for 110 proteins 
that co-eluted with both GPF-NS3 and GFP-NS5 were associated with RNA 
processing and splicing, viral transcription, viral gene expression, translation, 
ribosome, eukaryotic translation initiation factor 3 complex and protein targeting to 
ER and membrane. Collectively, this suggests the potential involvement of both NS3 
and NS5 in biological processes or molecular functions that are related to RNA 
processing machinery and host translation pathway (Table A-5) which fits with the 
known functions of NS3 and NS5 in DENV replication cycle because DENV is a 
positive-sense RNA virus that replicates in cytoplasm and therefore it has to 
recruit/exploit components of host RNA processing or translation machinery for its 
synthesis of viral genome and proteins (Li et al., 1999a; Pastorino et al., 2009). In 
fact, Pando-Robles and colleagues have recently published a novel set of human 
proteins that is involved in protein biogenesis during DENV2 infection (Pando-Robles 
et al., 2014), which supports the importance of targeting the host translation 
machinery by DENV during infection. Coincidentally, among this novel set of human 
proteins, hnRNPC (heterogeneous nuclear ribonucleoproteins C1/C2), EIF2α 
(eukaryotic initiation factor 2 subunit 1 alpha), PABPC1 (polyadenylate-binding 
protein 1) and YB-1 (nuclease-sensitive element-binding protein 1) were found to co-
elute with both GFP-NS3 and GFP-NS5 in our study. Previous studies have already 
reported that hnRNPC interacted with DENV2 NS1 and vimentin (Kanlaya et al., 
2010; Noisakran et al., 2008b), whereas PABPC1 (Polacek et al., 2009) and YB-1 
(Paranjape & Harris, 2007) were found to bind DENV2 3’UTR (also see result Table 
3-5). Interestingly, YB-1 was also identified to interact with HCV NS3/4A to 
influence the equilibrium between viral RNA replication and infectious virus 
production at different stages of HCV life cycle (Chatel-Chaix et al., 2011), whereas 
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in DENV2, it binds 3’UTR to repress synthesis of viral RNA and protein (Paranjape 
& Harris, 2007). Therefore, it appears that NS3 and NS5, together with their RNA-
binding ability, may bind viral RNA and proteins of RNA processing machinery/host 
translation pathway to regulate the switch between translation and replication.  
 
Cytoplasm stress granule - Stress granules are cytoplasmic RNA granules that serve 
as site for mRNA degradation; they are typically formed during cellular stress (eg. 
viral infection, heat shock, oxidative stress and ischemia) to accompany global 
translational shutdown as part of an integrated stress response (Anderson & Kedersha, 
2008; Kedersha et al., 2013). In recent years, stress granule formation during viral 
infection has been proposed to play an important role in host antiviral defence 
because of increasing reports on inhibition of stress granule formation by several 
viruses (reviewed by (Beckham & Parker, 2008) and (Bidet & Garcia-Blanco, 2014)). 
For example, among flaviviruses, viral components like WNV NS3 and JEV capsid 
proteins can interact with stress granule proteins like TIA1/TIAR (T cell intracellular 
antigen-1/TIA-1-related protein) (Emara & Brinton, 2007) and Caprin-1 (Katoh et al., 
2013), respectively, to inhibit stress granule formation. Similar phenomenon was 
observed in other positive-sense RNA viruses, like poliovirus, where its viral 
proteinase 3C cleaved G3BP1 (Ras GTPase-activating protein-binding protein 1) to 
trigger the disassembly of stress granules (White et al., 2007). In both instances, the 
inhibition of stress granule formation favors virus propagation in general, either by 
recruiting stress granule proteins to replication site to aid genome synthesis in 
perinuclear region (Emara & Brinton, 2007) or possibly restore host translation 
machinery for viral protein translation (White et al., 2007). Of the 110 proteins that 
co-eluted with GFP-NS3 and GFP-NS5, we found 16 common proteins to be among 
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the up- and down-regulated protein lists (Table A-10) of Pando-Robles et al’s study 
that looked at changes in the proteome of DENV2 infected Huh-7 cells at 24 hours 
post-infection by LC-MS/MS. Coincidentally, GO analysis of down-regulated 
proteins (12 out of 16) revealed the cellular component - cytoplasm stress granule to 
be significantly enriched (q-value=9.41×10-6, Table A-11). This implies that DENV 
may interfere with stress granule formation through down-regulation of stress granule 
proteins and both NS3 and NS5 both play a role in mediating that.  
 
The proteomic approach to identifying novel factors is still work-in-progress but the 
increased interest in this area and the comparison with published works suggest that 
hits from this study can be further characterized experimentally to identify significant 
host protein partners that are important for DENV replication and pathogenesis. 
Integrating our dataset with published datasets from siRNA screens (see above), viral-
host protein interaction screens, whole genome proteomics and gene expression 
studies can be used to build a comprehensive and highly confident virus-host 




4.4 The search for cytoplasmic retention factor reveals surprising 
complexity of nucleocytoplasmic transport of DENV NS5  
Although the nuclear-localizing ability of DENV2 NS5 in infected and transfected 
cells has been the subject of study by several groups, the ability of NS5 of other 
serotypes to do the same had not been explored previously (Brooks et al., 2002; 
Kumar et al., 2013; Pryor et al., 2007; Rawlinson et al., 2009). Based on the 
similarities in NS5 α/βNLS sequence that is contained within residues 320-405 
(Figure 1-11), it has been long hypothesized that DENV1, 3 and 4 NS5 should 
nuclear-localize to similar extent as DENV2 NS5. Therefore, we tested this 
hypothesis, by first generating a cross-reactive anti-NS5 antibody for this study. 
Using the Fab-phage display technology, we generated two anti-NS5 IgG antibodies, 
5M1 and 5R3 that can bind to NS5 of all serotypes (Figure 3-15). 5M1 epitope was 
mapped to residues 6-20 of NS5 MTase domain, whereas 5R3 epitope was mapped to 
a conformational epitope on NS5 RdRP domain, within residues 786-800 (residues 
786-800 is found within NS5 priming loop). Using 5R3 antibody, we were able to 
show for the first time that DENV1-4 NS5 displayed differential localization patterns 
in both infected and transfected cells, with DENV2 and 3 NS5 being predominately 





DENV1 NS5 α/βNLS is functional - Because of the higher sequence identity between 
DENV1 and 2 NS5 (79%) than between DENV4 and 2 NS5 (75%) we focused on 
DENV1 and 2 NS5, as examples of NS5 protein that remained predominantly 
cytoplasmic or nuclear for further study. By exchanging gene fragments (DNA 
shuffling) between the two serotypes, we demonstrated DENV1 α/βNLS to be 
functional when it was inserted into the corresponding DENV2 NS5 sequence even 
though in the context of its own sequence it is more cytoplasmic. Two scenarios are 
possible: one is that the DENV1 NS5 may require some additional post-translational 
modification (phosphorylation or dephosphorylation) to retain the protein in the 
cytoplasm (Jans & Hubner, 1996) or alternatively, a host factor that binds to a specific 
CRS on DENV 1 NS5 may mediate the observed subcellular localization (Moseley et 
al., 2009).  
 
Functional NLS sequences in NS5 - Based on functional and structural motifs, 
extensive swapping of gene fragments and functional analysis was carried out in this 
work to ultimately make a serendipitous discovery that a sequence that resembles a 
monopartite NLS is located at the C-terminal end of DENV2 NS5, within residues 
883-900 (C-terminal NLS). We have supported this finding by demonstrating that (i) 
first, by fusing C-terminal NLS sequence of DENV2 NS5 to a tandem GFP gene 
construct (2×GFP), targets the predominantly cytoplasmic 2×GFP (Fn/c = 0.81 ± 
0.03), into the nucleus (Fn/c = 5.06 ± 0.22), similar to the classical monopartite SV40 
NLS (Fn/c = 6.97 ± 0.37); (ii) second, by replacing the C-terminal NLS sequence of 
DENV1 NS5 with corresponding region of DENV2 NS5, we showed that 
predominantly cytoplasmic DENV1 NS5 (Fn/c = 0.86 ± 0.02) could be trafficked into 
the nucleus (Fn/c = 4.57 ± 0.25); (iii) third, by truncating the C-terminal end from 
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DENV2 NS5, its nuclear targeting ability was also greatly reduced (from Fn/c = 13.28 
± 1.08 for DENV2 full-length NS5 to Fn/c = 0.73 ± 0.04 for DENV2 NS5 residues 1-
882) despite an intact importin-α/β1 NLS within the previously identified interdomain 
linker region, residues 320-405 of NS5 and (iv) forth, by disrupting the C-terminal 
NLS sequence in DENV2 NS5 protein through alanine mutation resulted in a 
predominantly cytoplasmic NS5 protein (Fn/c = 0.50 ± 0.01, 0.22 ± 0.01 and 0.56 ± 
0.03 for 887KRAA, 890RRAA and 887KRAA+890RRAA, respectively). Taken 
together, these results suggest that the rapid nuclear localization observed for DENV2 
NS5 in the context of infection appears to be largely due to C-terminal NLS within 
residues 883-900 of DENV2 NS5. This is in agreement with the observation that 
classical NLS is usually found at either at N- or C-terminal end of nuclear cargo 
proteins so that they are accessible to nuclear transport factors (Marfori et al., 2012). 
Intriguingly, there is a lack of structural information of this region of NS5, especially 
residues 890-900 in various flavivirus NS5 crystal structures (Lim et al., 2013b; Lu & 
Gong, 2013; Malet et al., 2007; Yap et al., 2007; Zhao et al., 2015). This suggests that 
the C-terminal sequence of NS5 is highly flexible and disordered, which also fits with 
the finding that truncation of the last 5 amino acids of DENV3 NS5 formed high 
quality crystals that resulted in the resolution of the first full-length structure of 
DENV3 NS5 (Zhao et al., 2015), Furthermore, the disordered C-terminal region 
containing an NLS is also consistent with other studies that have found that peptide 
sequences that contain the NLS are usually disordered/unfolded until importin-α is 





The discovery of the C-terminal NLS cannot entirely exclude the existence of an 
internal α/βNLS because of the availability of extensive supportive published data 
with both recombinant proteins and infectious clones (Kumar et al., 2013; Pryor et al., 
2007; Rawlinson et al., 2009). Mutations in NS5 α/βNLS in the context of DENV2 
infectious cDNA clone, namely 387KKKAAA (“A2”) and 
371KKAA+387KKKAAA (“A1+A2”) were previously shown to reduce both 
infectious virus production and NS5 nuclear accumulation (Kumar et al., 2013; Pryor 
et al., 2007). Furthermore, it was argued recently that there is no strict correlation 
between efficient viral RNA replication and DENV2 NS5 nuclear localization 
because mutation of negatively charged residues (397EEAA) that are outside the 
minimal α/βNLS sequence could also affect NS5 nuclear localization drastically in 
mutant virus (Fn/c =~13 for WT and Fn/c =~1.5 for 397EEAA) and yet, it could 
replicate like WT with an intact in vivo NS5 activity (Kumar et al., 2013). 
Nevertheless, in this study when C-terminal NLS mutations were introduced into 
DENV2 infectious cDNA clone, namely 887KRAA (“C-term NLS A1”), 
890RRAA (“C-term NLS A2”), and 887KRAA+890RRAA (“C-term NLS 
A1+A2”), lower viral RNA replication and reduced NS5 nuclear localization was 
observed for C-term NLS A2 mutant virus, whereas C-term NLS A1 and A1+A2 
mutations were lethal (Figure 3-33). Taken together, it is unclear at this stage if 
α/βNLS and C-terminal NLS play a synergistic or mutually exclusive role in 





A thorough evaluation of α/βNLS and C-terminal NLS data and their implications is 
in progress (Jans, Forewood and Vasudevan, personal communication). It is the report 
that hyperphosphorylated DENV2 NS5 accumulated in the nucleus of infected cells 
by (Kapoor et al., 1995) resulted in the identification of the putative bipartite α/βNLS 
between residues 369-405 (Forwood et al., 1999). However, the initial identification 
was based on the sequence resemblance of this region to bipartite NLS sequence of 
nucleoplasm (Vancurova et al., 1995), and the fusion of DENV 2 NS5 residues 369-
405 to normally cytoplasmic β-galactosidase could be targeted to the nucleus in both 
in vivo and in vitro confocal microscopy-based assay. Subsequently, yeast two-hybrid 
technique coupled with site-directed mutagenesis provided further support for the 
finding and also additionally found out that NS3 residues 313-608 interacted with 
NS5 residues 320-368. The NS3 interaction site was predicted to contain a 20 amino 
acid sequence (residues 342-361) that is completely conserved in all flaviviruses 
(Brooks et al., 2002; Johansson et al., 2001a; Khromykh et al., 1999). At that stage, 
since there were no available crystal structures for NS5 MTase or RdRP domains, the 
NLS region was thought to be a potential interdomain linker; the initial idea was 
suggested by (Egloff et al., 2002) when they observed a compact MTase domain 
within residues 7-267 in a DENV NS5 truncated protein (residues 1-296) and the 
remaining unstructured/disordered region (residues 268-296) was thought to be the 





The discovery of the C-terminal NLS in this work was driven by the search for CRS 
within DENV1 NS5. Despite the confounding issues with DENV NS5 nuclear 
localization, the inhibitors that have been identified by in vitro AlphaScreen-based 
NS5-importin-α/β1 binding assay function in vitro and one of them, 4-HPR (N-(4-
hydroxyphenyl) retinamide) is even active in vivo in a mouse model and human 
PBMC infection assay (Fraser et al., 2014). Therefore, taken together, NS5 nuclear 





4.5 The thumb subdomain of NS5 may be a hotspot for viral-viral 
and viral-host protein interactions 
The DENV3 NS5 RdRP structure threw a surprise when it showed that NS5 residues 
320-405 (coloured in yellow in Figure 4-3) are an integral part of the RdRP domain, 
and were distributed with α2-α7 helices (βNLS in α2-α5 and α/βNLS in α6-α7 (circled 
in purple)) (Yap et al., 2007). The α2-α4 helices (residues 323-341) are part of the 
thumb subdomain (coloured in red); α5 and α7 helices (residues 349-355 and 397-
405) are found at the finger tips, between the fingers (coloured in blue) and thumb 
subdomains and α6 helix (residues 367-386) is close to the palm subdomain (coloured 
in green). Given the involvement and/or close proximity of these helices to the three 
subdomains, it may not be surprising if mutations (Iglesias et al., 2011; Kumar et al., 
2013; Pryor et al., 2007) or truncations (Rawlinson et al., 2009; Yap et al., 2007) in 
residues 320-405 destabilize NS5 protein structure. This can conceivably result in a 
pleiotropic effect on NS5 activity, nuclear localization and RNA replication. On the 
other hand, the newly discovered C-terminal NLS is at the C-terminal end of NS5 
protein (not visible in the structure, resides within the thumb subdomain, circled in 
green) that is far from the RNA template tunnel (indicated by arrow), priming loop 
(circled in grey) and palm subdomain (coloured in green) and hence, mutations or 
truncations at the C-terminal end of NS5 are less likely to impact on protein structure 





With the recently solved crystal structure of full-length DENV3 NS5, the MTase is 
placed above the fingers subdomian, and the MTase and RdRP domains interact at 
two contact areas via residues from the MTase domain (residues 63-69, 95-96 and 
252-256), the linker region (residues 262-273) and the fingers subdomain from the 
RdRP domain to create an interaction interface that is unique to DENV. Intriguingly, 
analysis of the solution structure of NS5 by hydrogen/deuterium exchange mass 
spectrometry demonstrated that the thumb subdomain has a higher deuterium 
exchange dynamics than its fingers and palm subdomains (circled in orange in Figure 
4-3). This suggests that the thumb subdomain is more flexible and may be able to 
adopt different conformations to interact with different viral proteins and host 
proteins. Indeed, this idea is supported by findings from this thesis that both the NS3 
binding site (residues 320-341, within α3 helix, circled in blue) and the newly 
discovered importin-α binding site (residues 883-900, circled in green, missing in 
structure) reside within the thumb subdomain. Moreover, as discussed in section 4.4, 
887KR may have the ability to RNA, and possibly viral RNA and therefore, it is 
tempting to speculate the 87KR residues may help to facilitate the newly unwound 
template strand that is exiting from the helicase to enter RdRP (Figure 4-1, green line) 
via the template tunnel (Figure 4-3) because (1) 87KR are conserved among the 
flaviviruses (Figure 3-34), (2) residues 890-900 is flexible and (3) it is close to NS3-
NS5 interaction site and hence, the inability for viral RNA to enter the template tunnel 
properly may prevent the synthesis of complementary strand, which results in the 
inability for sustained RNA replication to occur in 887KRAA and 
887KRAA+890RRAA mutant viruses (Figure 3-33). Indeed, elegant mutational 
study on basic residues of NS5 have led to the identification of dibasic residue on 
thumb subdomain, namely 840KR (located within helix α26) that were lethal to virus 
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when mutated to alanine, despite an intact polymerase activity, which used viral RNA 
as template (Iglesias et al., 2011) and therefore, this further supports the importance 
involvement of basic residues in RNA binding activity that is not directly related to 
NS5 polymerase activity. Interestingly, several viral proteins have been reported to 
have their functional NLS sequence overlapping with RNA binding domain (Donnelly 
et al., 2007; Elster et al., 1997; Yik et al., 2004). Based on the importance of the87KR 
in this study and its location in thumb subdomain, it is tempting to hypothesize that 
887KR may be involved in binding to both RNA and importin-α/β1 and it is likely that 
the loss of binding to RNA resulted in absence of virus replication. Further work 
examine this aspect is currently ongoing.  
 
Taken together, the thumb subdomain may hold the key to controlling the localization 
of NS5 through interacting with either NS3 and/or viral RNA, and possibly host 
factors to stay in the cytoplasm for viral RNA replication or importin-α/β1 to enter the 




 Figure 4-3: Dynamics of DENV3 NS5 in solution. Ribbon representation of DENV3 NS5 RdRP 
(residues 273 to 900, PDB: 2J7U, (Yap et al., 2007)) and full-length (in inset, residues 6-895, PDB: 
4V0Q (Zhao et al., 2015)) structures. The fingers, palm and thumb subdomains and residues 320-405 
are colored blue, yellow, green and red, respectively. The MTase is shaded in light green. The 
secondary structures (α-helix and β-strand) and protein termini (N and C) are labeled as described in 
(Yap et al., 2007)). The region that is missing in the structure is also defined by the boundary numbers. 
The template entry tunnel is arrowed. The priming looing is circled in grey. The α/βNLS and C-
terminal NLS are circled in purple and green, respectively; C-terminal NLS is missing in the structure 
and the position is to denote its location in the structure, should it be resolved. NS5 K330 that is 
important for NS3-NS5 interaction reside in α3 and it is circled in blue. The regions on NS5 RdRP that 
were shown (Zhao et al., 2015) by Hydrogen/Deuterium Exchange Mass Spectrometry to be of higher 
dynamics as compared to other parts of the protein are circled in orange, which include residues 735-
748, 781-809, 812-850 and 853-895 from thumb subdomain and residues 311-340 from fingers 
subdomain. Inset: The different regions are coloured as per described above, with the following 
exception: the MTase is coloured in grey and an arrow is used to indicate the position of K330. Figure 




4.6 Future directions  
This thesis has collectively studied the two aspects of NS5 - its interaction with it 
viral replication partner NS3, and its interaction with host proteins, namely importin-α 
and human proteins that were identified by our co-IP study. The future work will 
ultimately converge to help us understand the role of NS5 in DENV replication and 
pathogenesis and they include the following: 
- Since we have demonstrated for the first time that NS3-NS5 interaction play an 
important role in coordinating the balanced synthesis of positive- and negative-
strand, further analysis with different NS3-NS5 interaction mutants may be useful 
to elucidate the underlying mechanism of NS3-NS5 interaction in coordinating 
the synthesis of plus- and minus-strand. The studies could provide some insights 
on how this interaction can influence the dynamics of circular and linear forms of 
genomic RNA needed for initiation of negative-strand synthesis (Alvarez et al., 
2005b), since perturbing the transition between circular and linear forms may 
upset the 1:10-100 ratio of negative- versus positive-strand RNA in infected cells 
(Cleaves et al., 1981; Tomassini et al., 2003; Villordo et al., 2010).  
 
- With the dissection of co-IP data in section 3.3, another future work emanating 
from this study will include the validation of some of the host proteins including 





- The role of the C-terminal NLS in dengue pathogenesis will form a very 
productive future study given the recent finding that Sanofi tetravalent vaccine 
was least effective against DENV serotype 2. It is tempting to speculate that the 
rapid localization of NS5 to the nucleus may have contributed to the reduced 
efficacy against this serotype and studies could be carried out to evaluate this 
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Figure A-1: Subcellular localization pattern of DENV1 NS5 in infected cells is not strain-
dependent, and it is a common observation seen in DENV1. Huh-7 cells were mock-infected or 
infected with DENV1 or 2 (sequences as in Figure 3-16) at an MOI of 10 and fixed at 24h, 30h and 36h 
post-infection. DENV1 of Hawaii strain (GenBank accession number: EU848545) was also done for 





Figure A-2: Subcellular localization of DENV1 NS5 in infected cells remains the same, despite the 
use of a different cross-reactive anti-NS5 IgG. Huh-7 cells were mock-infected or infected with 
DENV1 or 2 (sequences as in Figure 3-16) at an MOI of 10 and fixed at 24h and 36h post-infection. 
Anti-NS5 (5M1 IgG, 20 nM; green) and anti-E (4G2 IgG, 1:1000; red, not shown here) antibodies were 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table A-2: GO functional enrichment analysis of 185 human host proteins that co-eluted with 
DENV1/2 GFP-NS3. The Benjamini-Hochberg procedure was used to calculate the q-value (false 
discovery rate adjusted p-value) of each enriched GO feature. For each enriched GO feature that is 
associated with the generated interaction network, the number of proteins in the interaction network 
listed in that group, as well as the number of total proteins in the Homo sapiens proteome associated 
with the same GO feature. The table is arranged in order of increasing q-value.  
 
GO feature q-value Genes in network 
Genes in 
genome 
translational initiation 1.29E-64 53 150 
cytosolic ribosome 9.42E-57 42 90 
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 8.12E-55 44 116 
RNA catabolic process 4.72E-54 52 215 
ribosomal subunit 4.72E-54 44 121 
translational termination 1.86E-53 40 89 
SRP-dependent cotranslational protein targeting to membrane 2.93E-53 42 107 
protein targeting to ER 3.69E-53 42 108 
cotranslational protein targeting to membrane 3.69E-53 42 108 
establishment of protein localization to endoplasmic reticulum 5.37E-53 42 109 
protein localization to endoplasmic reticulum 9.79E-53 43 120 
mRNA catabolic process 1.41E-52 49 190 
viral gene expression 1.27E-50 39 94 
nuclear-transcribed mRNA catabolic process 4.43E-49 46 179 
ribosome 5.51E-49 44 155 
translational elongation 5.51E-49 39 102 
multi-organism metabolic process 1.30E-48 39 104 
cytosolic part 6.63E-48 43 151 
protein targeting to membrane 1.96E-45 42 157 
cellular protein complex disassembly 3.72E-45 40 135 
establishment of protein localization to membrane 3.46E-43 47 253 
protein localization to membrane 1.46E-42 45 227 
protein complex disassembly 2.31E-42 40 156 
viral transcription 4.99E-42 40 159 
viral life cycle 4.99E-42 40 159 
macromolecular complex disassembly 1.45E-41 40 163 
single-organism cellular localization 6.32E-39 45 272 
single-organism localization 6.32E-39 45 272 
structural constituent of ribosome 1.92E-37 32 97 
cytosolic small ribosomal subunit 2.40E-37 24 36 
protein targeting 1.04E-35 44 299 
small ribosomal subunit 4.23E-33 25 55 
cytosolic large ribosomal subunit 7.13E-21 18 51 
large ribosomal subunit 4.85E-20 19 67 
regulation of translation 6.78E-18 23 152 
ribonucleoprotein complex biogenesis 3.03E-16 22 158 
posttranscriptional regulation of gene expression 2.06E-15 27 298 
mRNA processing 9.57E-15 26 288 
ribosome biogenesis 3.33E-14 16 78 
ncRNA metabolic process 3.31E-13 21 194 
RNA splicing 3.31E-13 24 274 
mRNA binding 6.76E-13 15 77 
RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile 1.27E-12 21 208 
mRNA splicing, via spliceosome 1.27E-12 21 208 
spliceosomal complex 1.55E-12 17 118 
RNA splicing, via transesterification reactions 2.16E-12 21 214 
translation initiation factor activity 2.57E-12 11 31 
ribosomal small subunit biogenesis 5.81E-11 9 20 
ribonucleoprotein complex assembly 8.22E-10 14 102 
cytoplasmic stress granule 9.84E-10 9 26 
ribonucleoprotein complex subunit organization 2.00E-09 14 109 
ncRNA processing 2.53E-09 14 111 
rRNA processing 3.22E-09 11 56 
249 
 
translation factor activity, nucleic acid binding 3.88E-09 11 57 
double-stranded RNA binding 7.55E-09 10 45 
rRNA metabolic process 8.19E-09 11 61 
ribosome assembly 2.02E-08 7 15 
ribonucleoprotein granule 9.49E-08 11 76 
RNA 3'-end processing 1.50E-07 12 101 
eukaryotic translation initiation factor 3 complex 1.51E-06 6 15 
catalytic step 2 spliceosome 2.58E-06 10 80 
negative regulation of translation 3.76E-06 9 62 
positive regulation of translation 3.86E-06 8 44 
ribonucleoprotein complex binding 4.59E-06 8 45 
mRNA 3'-end processing 6.19E-06 10 88 
ribosome binding 7.18E-06 6 19 
single-stranded RNA binding 9.79E-06 7 33 
polysome 1.37E-05 6 21 
U12-type spliceosomal complex 3.27E-05 6 24 
poly-purine tract binding 3.39E-05 5 13 
response to unfolded protein 3.42E-05 10 106 
ATP catabolic process 4.13E-05 11 137 
ribonucleoside monophosphate catabolic process 4.60E-05 11 139 
purine nucleoside monophosphate catabolic process 4.60E-05 11 139 
purine ribonucleoside monophosphate catabolic process 4.60E-05 11 139 
nucleoside monophosphate catabolic process 4.88E-05 11 140 
response to topologically incorrect protein 5.78E-05 10 113 
helicase activity 6.56E-05 8 64 
RNA helicase activity 9.66E-05 6 29 
regulation of translational initiation 1.44E-04 7 49 
ATP metabolic process 1.55E-04 11 158 
ATPase activity 1.97E-04 12 197 
RNA-dependent ATPase activity 4.24E-04 5 21 
purine nucleoside monophosphate metabolic process 4.53E-04 11 177 
purine ribonucleoside monophosphate metabolic process 4.53E-04 11 177 
poly(A) binding 4.57E-04 4 10 
maturation of SSU-rRNA 4.57E-04 4 10 
regulation of mRNA processing 4.76E-04 7 59 
ribonucleoside monophosphate metabolic process 5.10E-04 11 180 
nucleoside monophosphate metabolic process 7.30E-04 11 187 
purine NTP-dependent helicase activity 8.21E-04 6 42 
ATP-dependent helicase activity 8.21E-04 6 42 
protein folding 1.02E-03 9 124 
positive regulation of mRNA catabolic process 2.64E-03 4 15 
mitochondrial matrix 2.64E-03 12 257 
ATPase activity, coupled 3.15E-03 9 143 
regulation of mRNA stability 3.83E-03 5 33 
regulation of mRNA catabolic process 4.32E-03 4 17 
mitochondrial nucleoid 4.32E-03 5 34 
regulation of RNA stability 4.32E-03 5 34 
RNA localization 4.45E-03 7 84 
nucleic acid transport 4.67E-03 7 85 
establishment of RNA localization 4.67E-03 7 85 
RNA transport 4.67E-03 7 85 
nucleoid 4.76E-03 5 35 
negative regulation of RNA splicing 5.12E-03 4 18 
ATP-dependent RNA helicase activity 7.91E-03 4 20 
positive regulation of mRNA processing 9.61E-03 4 21 
regulation of RNA splicing 9.80E-03 6 66 
mRNA polyadenylation 1.14E-02 4 22 
'de novo' protein folding 1.25E-02 5 43 
RNA stabilization 1.34E-02 4 23 
mRNA stabilization 1.34E-02 4 23 
RNA polyadenylation 1.58E-02 4 24 
nucleobase-containing compound transport 1.73E-02 7 106 
mitochondrion organization 1.73E-02 10 225 
organelle assembly 1.78E-02 10 226 
250 
 
ATP-dependent DNA helicase activity 1.80E-02 4 25 
RNA export from nucleus 1.99E-02 6 76 
mRNA 3'-UTR binding 2.08E-02 4 26 
translation regulator activity 2.40E-02 4 27 
nuclear export 2.45E-02 7 113 
MHC protein complex binding 2.49E-02 3 11 
MHC class II protein complex binding 2.49E-02 3 11 
nuclear body 3.92E-02 8 162 
negative regulation of mRNA splicing, via spliceosome 5.24E-02 3 14 
telomeric DNA binding 5.24E-02 3 14 
DNA strand elongation involved in DNA replication 5.67E-02 4 34 
RNA phosphodiester bond hydrolysis 6.19E-02 5 62 
replication fork 6.25E-02 4 35 
positive regulation of mRNA 3'-end processing 6.31E-02 3 15 
regulation of mRNA splicing, via spliceosome 6.87E-02 4 36 
intrinsic apoptotic signaling pathway 7.42E-02 8 180 
regulation of mRNA 3'-end processing 7.42E-02 3 16 
negative regulation of mRNA processing 7.42E-02 3 16 
DNA strand elongation 7.42E-02 4 37 
DNA helicase activity 8.10E-02 4 38 
'de novo' posttranslational protein folding 8.10E-02 4 38 
DNA-dependent DNA replication 8.43E-02 6 102 
mRNA export from nucleus 8.75E-02 5 68 





Table A-3: GO functional enrichment analysis of 298 human host proteins that co-eluted with 
DENV1 GFP-NS5. The Benjamini-Hochberg procedure was used to calculate the q-value (false 
discovery rate adjusted p-value) of each enriched GO feature. For each enriched GO feature that is 
associated with the generated interaction network, the number of proteins in the interaction network 
listed in that group, as well as the number of total proteins in the Homo sapiens proteome associated 
with the same GO feature. The table is arranged in order of increasing q-value. 
 
GO feature q-value Genes in network 
Genes in 
genome 
translational initiation 2.35E-45 48 150 
RNA splicing, via transesterification reactions 1.85E-41 51 214 
RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile 4.50E-41 50 208 
mRNA splicing, via spliceosome 4.50E-41 50 208 
RNA splicing 4.50E-41 55 274 
mRNA processing 1.15E-38 54 288 
spliceosomal complex 1.40E-37 39 118 
ribonucleoprotein complex biogenesis 3.01E-36 42 158 
RNA catabolic process 2.84E-30 42 215 
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 4.51E-29 33 116 
catalytic step 2 spliceosome 7.93E-29 29 80 
mRNA catabolic process 1.18E-27 38 190 
cytosolic ribosome 3.70E-27 29 90 
SRP-dependent cotranslational protein targeting to membrane 3.81E-26 30 107 
protein targeting to ER 4.56E-26 30 108 
cotranslational protein targeting to membrane 4.56E-26 30 108 
protein localization to endoplasmic reticulum 5.59E-26 31 120 
establishment of protein localization to endoplasmic reticulum 5.59E-26 30 109 
translational termination 5.63E-26 28 89 
ribosomal subunit 6.67E-26 31 121 
translational elongation 1.42E-25 29 102 
viral gene expression 2.78E-25 28 94 
nuclear-transcribed mRNA catabolic process 3.35E-25 35 179 
multi-organism metabolic process 6.06E-24 28 104 
ribosome 1.09E-23 32 155 
protein targeting to membrane 1.61E-23 32 157 
cytosolic part 7.40E-23 31 151 
ribonucleoprotein complex assembly 7.40E-23 27 102 
ribonucleoprotein complex subunit organization 4.93E-22 27 109 
ribosome biogenesis 6.40E-22 24 78 
cellular protein complex disassembly 6.61E-22 29 135 
protein complex disassembly 3.13E-21 30 156 
establishment of protein localization to membrane 3.95E-21 36 253 
viral transcription 5.15E-21 30 159 
viral life cycle 5.15E-21 30 159 
macromolecular complex disassembly 1.08E-20 30 163 
protein targeting 1.17E-20 38 299 
protein localization to membrane 1.18E-20 34 227 
translation initiation factor activity 1.81E-20 17 31 
structural constituent of ribosome 1.61E-19 24 97 
single-organism cellular localization 4.18E-18 34 272 
single-organism localization 4.18E-18 34 272 
translation factor activity, nucleic acid binding 6.30E-18 19 57 
posttranscriptional regulation of gene expression 5.64E-15 32 298 
eukaryotic translation initiation factor 3 complex 7.55E-15 11 15 
regulation of translation 1.01E-14 24 152 
cytosolic large ribosomal subunit 2.00E-14 16 51 
small nuclear ribonucleoprotein complex 3.37E-14 14 35 
RNA helicase activity 6.81E-14 13 29 
large ribosomal subunit 1.07E-13 17 67 
ncRNA metabolic process 2.74E-13 25 194 
cytosolic small ribosomal subunit 1.98E-12 13 36 
rRNA processing 2.44E-12 15 56 
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ncRNA processing 4.24E-12 19 111 
rRNA metabolic process 9.48E-12 15 61 
helicase activity 2.02E-11 15 64 
mRNA binding 2.16E-11 16 77 
small ribosomal subunit 3.93E-11 14 55 
ribonucleoprotein complex binding 4.84E-11 13 45 
nuclear body 4.49E-10 20 162 
spliceosomal complex assembly 8.93E-10 11 34 
RNA-dependent ATPase activity 4.45E-09 9 21 
ribosome assembly 6.65E-09 8 15 
cytoplasmic stress granule 4.27E-08 9 26 
negative regulation of translation 6.60E-08 12 62 
regulation of translational initiation 6.80E-08 11 49 
ATP-dependent RNA helicase activity 1.14E-07 8 20 
purine NTP-dependent helicase activity 2.33E-07 10 42 
ATP-dependent helicase activity 2.33E-07 10 42 
positive regulation of translation 3.76E-07 10 44 
regulation of mRNA processing 5.27E-07 11 59 
U12-type spliceosomal complex 5.87E-07 8 24 
poly(A) binding 8.08E-07 6 10 
nuclear transport 1.29E-06 21 281 
ATP catabolic process 1.29E-06 15 137 
ribonucleoside monophosphate catabolic process 1.52E-06 15 139 
purine nucleoside monophosphate catabolic process 1.52E-06 15 139 
purine ribonucleoside monophosphate catabolic process 1.52E-06 15 139 
nucleoside monophosphate catabolic process 1.64E-06 15 140 
regulation of RNA splicing 1.64E-06 11 66 
nuclear speck 1.89E-06 11 67 
nucleocytoplasmic transport 5.18E-06 20 278 
poly-purine tract binding 5.58E-06 6 13 
ribonucleoprotein granule 7.17E-06 11 76 
ATP metabolic process 8.02E-06 15 158 
single-stranded RNA binding 8.19E-06 8 33 
regulation of mRNA splicing, via spliceosome 1.69E-05 8 36 
ATPase activity 2.43E-05 16 197 
purine nucleoside monophosphate metabolic process 3.42E-05 15 177 
purine ribonucleoside monophosphate metabolic process 3.42E-05 15 177 
ribonucleoside monophosphate metabolic process 4.22E-05 15 180 
nucleoside monophosphate metabolic process 6.85E-05 15 187 
ATPase activity, coupled 9.91E-05 13 143 
double-stranded RNA binding 9.91E-05 8 45 
ribosomal small subunit biogenesis 1.00E-04 6 20 
spliceosomal snRNP assembly 1.15E-04 7 32 
Cajal body 1.84E-04 6 22 
mRNA 3'-end processing 2.64E-04 10 88 
negative regulation of translational initiation 3.41E-04 5 14 
alternative mRNA splicing, via spliceosome 5.22E-04 6 26 
RNA 3'-end processing 9.09E-04 10 101 
ribosome binding 1.80E-03 5 19 
DNA conformation change 1.99E-03 11 135 
regulation of mRNA stability 2.20E-03 6 33 
methylosome 2.24E-03 4 10 
regulation of RNA stability 2.58E-03 6 34 
organelle assembly 2.97E-03 14 226 
MHC protein complex binding 3.26E-03 4 11 
MHC class II protein complex binding 3.26E-03 4 11 
preribosome 3.26E-03 4 11 
oligodendrocyte development 3.26E-03 4 11 
small nucleolar ribonucleoprotein complex 3.26E-03 4 11 
regulation of alternative mRNA splicing, via spliceosome 3.54E-03 5 22 
RNA stabilization 4.38E-03 5 23 
mRNA stabilization 4.38E-03 5 23 
maturation of 5.8S rRNA 4.66E-03 4 12 
protein folding 4.83E-03 10 124 
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mRNA 3'-UTR binding 8.03E-03 5 26 
translation regulator activity 9.64E-03 5 27 
histone modification 1.04E-02 14 256 
regulation of DNA-templated transcription, elongation 1.14E-02 5 28 
mRNA splice site selection 1.18E-02 4 15 
covalent chromatin modification 1.25E-02 14 261 
nuclear export 1.26E-02 9 113 
nucleolar part 1.83E-02 5 31 
regulation of histone modification 2.88E-02 6 53 
oligodendrocyte differentiation 3.68E-02 4 20 
positive regulation of DNA-templated transcription, elongation 3.68E-02 4 20 
NF-kappaB binding 3.68E-02 4 20 
exosome (RNase complex) 3.68E-02 4 20 
polysome 4.46E-02 4 21 
DNA-templated transcription, elongation 4.83E-02 8 108 
mRNA polyadenylation 5.30E-02 4 22 
RNA localization 5.48E-02 7 84 
U1 snRNP 6.23E-02 3 10 
regulation of transcription elongation from RNA polymerase II 
promoter 6.23E-02 3 10 
regulation of chromatin organization 6.86E-02 6 63 
RNA polyadenylation 7.23E-02 4 24 
regulation of cysteine-type endopeptidase activity involved in apoptotic 
process 8.10E-02 9 147 
ATP-dependent DNA helicase activity 8.38E-02 4 25 
positive regulation of cysteine-type endopeptidase activity involved in 
apoptotic process 9.05E-02 7 92 
termination of RNA polymerase II transcription 9.68E-02 5 45 







Table A-4: GO functional enrichment analysis of 273 human host proteins that co-eluted with 
DENV2 GFP-NS5. The Benjamini-Hochberg procedure was used to calculate the q-value (false 
discovery rate adjusted p-value) of each enriched GO feature. For each enriched GO feature that is 
associated with the generated interaction network, the number of proteins in the interaction network 
listed in that group, as well as the number of total proteins in the Homo sapiens proteome associated 
with the same GO feature. The table is arranged in order of increasing q-value. 
 
GO feature q-value Genes in network 
Genes in 
genome 
translational initiation 1.21E-39 43 150 
RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile 2.77E-28 39 208 
mRNA splicing, via spliceosome 2.77E-28 39 208 
RNA splicing 2.93E-28 43 274 
RNA splicing, via transesterification reactions 5.25E-28 39 214 
mRNA processing 1.68E-27 43 288 
spliceosomal complex 3.07E-24 29 118 
translation initiation factor activity 1.93E-22 18 31 
RNA catabolic process 3.70E-22 34 215 
catalytic step 2 spliceosome 4.14E-22 24 80 
ribonucleoprotein complex biogenesis 8.78E-22 30 158 
translation factor activity, nucleic acid binding 1.02E-19 20 57 
cytosolic ribosome 1.96E-19 23 90 
mRNA catabolic process 1.96E-19 30 190 
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 2.33E-19 25 116 
SRP-dependent cotranslational protein targeting to membrane 5.32E-19 24 107 
protein localization to endoplasmic reticulum 5.32E-19 25 120 
protein targeting to ER 5.74E-19 24 108 
ribosomal subunit 5.74E-19 25 121 
cotranslational protein targeting to membrane 5.74E-19 24 108 
establishment of protein localization to endoplasmic reticulum 6.91E-19 24 109 
viral gene expression 8.35E-18 22 94 
regulation of translation 1.09E-17 26 152 
ribosome 1.75E-17 26 155 
eukaryotic translation initiation factor 3 complex 2.27E-17 12 15 
protein targeting to membrane 2.27E-17 26 157 
translational termination 4.32E-17 21 89 
ribonucleoprotein complex assembly 4.32E-17 22 102 
translational elongation 4.32E-17 22 102 
nuclear-transcribed mRNA catabolic process 4.53E-17 27 179 
posttranscriptional regulation of gene expression 5.44E-17 33 298 
multi-organism metabolic process 6.16E-17 22 104 
cytosolic part 9.82E-17 25 151 
ribonucleoprotein complex subunit organization 1.72E-16 22 109 
establishment of protein localization to membrane 3.56E-16 30 253 
viral life cycle 4.41E-15 24 159 
protein targeting 4.41E-15 31 299 
protein localization to membrane 1.86E-14 27 227 
structural constituent of ribosome 7.85E-14 19 97 
cellular protein complex disassembly 2.60E-13 21 135 
protein complex disassembly 4.25E-13 22 156 
macromolecular complex disassembly 1.07E-12 22 163 
RNA helicase activity 1.27E-12 12 29 
single-organism cellular localization 1.54E-12 27 272 
single-organism localization 1.54E-12 27 272 
viral transcription 6.68E-12 21 159 
ribosome biogenesis 7.79E-12 16 78 
ribonucleoprotein complex binding 1.83E-11 13 45 
cytosolic large ribosomal subunit 1.08E-10 13 51 
helicase activity 1.26E-10 14 64 
large ribosomal subunit 2.43E-10 14 67 
cytoplasmic stress granule 5.49E-10 10 26 
small nuclear ribonucleoprotein complex 5.49E-10 11 35 
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regulation of translational initiation 1.39E-09 12 49 
RNA-dependent ATPase activity 2.20E-09 9 21 
nuclear body 8.48E-09 18 162 
cytosolic small ribosomal subunit 2.15E-08 10 36 
negative regulation of translation 2.56E-08 12 62 
ATP-dependent RNA helicase activity 6.25E-08 8 20 
small ribosomal subunit 1.06E-07 11 55 
purine NTP-dependent helicase activity 1.06E-07 10 42 
ATP-dependent helicase activity 1.06E-07 10 42 
positive regulation of translation 1.72E-07 10 44 
double-stranded RNA binding 2.14E-07 10 45 
ribosome assembly 2.16E-07 7 15 
ribonucleoprotein granule 2.70E-07 12 76 
spliceosomal complex assembly 2.73E-07 9 34 
mRNA binding 3.06E-07 12 77 
ribosome binding 1.51E-06 7 19 
regulation of mRNA processing 3.23E-06 10 59 
ATP catabolic process 3.42E-06 14 137 
ribonucleoside monophosphate catabolic process 3.95E-06 14 139 
purine nucleoside monophosphate catabolic process 3.95E-06 14 139 
purine ribonucleoside monophosphate catabolic process 3.95E-06 14 139 
nucleoside monophosphate catabolic process 4.28E-06 14 140 
ATPase activity, coupled 5.55E-06 14 143 
ncRNA metabolic process 6.27E-06 16 194 
ATPase activity 7.69E-06 16 197 
U12-type spliceosomal complex 8.54E-06 7 24 
nuclear speck 1.01E-05 10 67 
ATP metabolic process 1.85E-05 14 158 
rRNA processing 2.44E-05 9 56 
poly(A) binding 3.41E-05 5 10 
rRNA metabolic process 5.12E-05 9 61 
purine nucleoside monophosphate metabolic process 7.13E-05 14 177 
purine ribonucleoside monophosphate metabolic process 7.13E-05 14 177 
single-stranded RNA binding 8.55E-05 7 33 
ribonucleoside monophosphate metabolic process 8.55E-05 14 180 
nucleoside monophosphate metabolic process 1.34E-04 14 187 
ncRNA processing 1.37E-04 11 111 
nucleocytoplasmic transport 1.47E-04 17 278 
poly-purine tract binding 1.52E-04 5 13 
nuclear transport 1.67E-04 17 281 
negative regulation of translational initiation 2.28E-04 5 14 
regulation of DNA-templated transcription, elongation 5.15E-04 6 28 
chaperone binding 7.83E-04 6 30 
DNA conformation change 8.86E-04 11 135 
regulation of RNA splicing 9.63E-04 8 66 
mRNA 3'-end processing 1.02E-03 9 88 
regulation of mRNA stability 1.35E-03 6 33 
ribosomal small subunit biogenesis 1.52E-03 5 20 
positive regulation of DNA-templated transcription, elongation 1.52E-03 5 20 
regulation of transcription elongation from RNA polymerase II 
promoter 1.57E-03 4 10 
regulation of RNA stability 1.57E-03 6 34 
regulation of mRNA splicing, via spliceosome 2.18E-03 6 36 
protein folding 2.38E-03 10 124 
oligodendrocyte development 2.38E-03 4 11 
Cajal body 2.38E-03 5 22 
RNA 3'-end processing 2.87E-03 9 101 
RNA stabilization 2.92E-03 5 23 
mRNA stabilization 2.92E-03 5 23 
DNA replication 3.92E-03 13 222 
ATP-dependent DNA helicase activity 4.42E-03 5 25 
mRNA 3'-UTR binding 5.36E-03 5 26 
translation regulator activity 6.44E-03 5 27 
response to heat 9.17E-03 5 29 
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RNA polymerase binding 1.13E-02 4 16 
positive regulation of type I interferon production 1.60E-02 7 74 
unfolded protein binding 1.66E-02 6 52 
mitochondrial nucleoid 1.96E-02 5 34 
type I interferon production 2.02E-02 8 103 
regulation of type I interferon production 2.02E-02 8 103 
nucleoid 2.19E-02 5 35 
replication fork 2.19E-02 5 35 
oligodendrocyte differentiation 2.67E-02 4 20 
NF-kappaB binding 2.67E-02 4 20 
DNA helicase activity 3.18E-02 5 38 
positive regulation of NF-kappaB transcription factor activity 3.23E-02 8 111 
nuclear export 3.63E-02 8 113 
mRNA polyadenylation 3.82E-02 4 22 
response to temperature stimulus 3.95E-02 5 40 
DNA duplex unwinding 4.41E-02 5 41 
endodermal cell fate commitment 4.83E-02 3 10 
RNA polymerase II core binding 4.83E-02 3 10 
gliogenesis 5.07E-02 6 65 
RNA polyadenylation 5.18E-02 4 24 
DNA geometric change 5.34E-02 5 43 
mitochondrial matrix 5.47E-02 12 257 
MHC protein complex binding 6.16E-02 3 11 
MHC class II protein complex binding 6.16E-02 3 11 
basal transcription machinery binding 6.16E-02 3 11 
basal RNA polymerase II transcription machinery binding 6.16E-02 3 11 
small nucleolar ribonucleoprotein complex 6.16E-02 3 11 
termination of RNA polymerase II transcription 6.29E-02 5 45 
alternative mRNA splicing, via spliceosome 6.69E-02 4 26 
regulation of cysteine-type endopeptidase activity 7.03E-02 9 159 
mRNA cleavage factor complex 7.85E-02 3 12 
RNA polymerase core enzyme binding 7.85E-02 3 12 
positive regulation of cysteine-type endopeptidase activity 8.20E-02 7 100 




Table A-5: GO functional enrichment analysis of 110 human host proteins that are common to 
DENV1 and 2 NS3 and NS5. The Benjamini-Hochberg procedure was used to calculate the q-value 
(false discovery rate adjusted p-value) of each enriched GO feature. For each enriched GO feature that 
is associated with the generated interaction network, the number of proteins in the interaction network 
listed in that group, as well as the number of total proteins in the Homo sapiens proteome associated 
with the same GO feature. The table is arranged in order of increasing q-value. 
 
GO feature q-value Genes in network 
Genes in 
genome 
translational initiation 2.75E-41 35 150 
cytosolic ribosome 1.88E-34 27 90 
ribosomal subunit 2.99E-34 29 121 
protein localization to endoplasmic reticulum 4.17E-31 27 120 
ribosome 4.17E-31 29 155 
translational termination 4.17E-31 25 89 
SRP-dependent cotranslational protein targeting to membrane 7.27E-31 26 107 
protein targeting to ER 7.41E-31 26 108 
cotranslational protein targeting to membrane 7.41E-31 26 108 
establishment of protein localization to endoplasmic reticulum 7.92E-31 26 109 
viral gene expression 7.92E-31 25 94 
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 3.75E-30 26 116 
cytosolic part 3.75E-30 28 151 
RNA catabolic process 3.75E-30 31 215 
translational elongation 5.42E-30 25 102 
multi-organism metabolic process 8.74E-30 25 104 
mRNA catabolic process 2.60E-27 28 190 
cellular protein complex disassembly 9.79E-27 25 135 
protein targeting to membrane 1.37E-26 26 157 
establishment of protein localization to membrane 3.35E-25 29 253 
protein complex disassembly 3.93E-25 25 156 
nuclear-transcribed mRNA catabolic process 4.25E-25 26 179 
viral transcription 5.68E-25 25 159 
viral life cycle 5.68E-25 25 159 
macromolecular complex disassembly 1.05E-24 25 163 
protein localization to membrane 8.03E-24 27 227 
single-organism cellular localization 1.04E-21 27 272 
single-organism localization 1.04E-21 27 272 
protein targeting 1.28E-20 27 299 
structural constituent of ribosome 1.82E-20 19 97 
cytosolic small ribosomal subunit 2.33E-17 13 36 
cytosolic large ribosomal subunit 6.79E-17 14 51 
large ribosomal subunit 9.36E-17 15 67 
small ribosomal subunit 2.11E-16 14 55 
ribonucleoprotein complex biogenesis 2.57E-16 19 158 
RNA splicing 3.66E-14 21 274 
ribosome biogenesis 4.02E-14 14 78 
RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile 4.35E-14 19 208 
mRNA splicing, via spliceosome 4.35E-14 19 208 
RNA splicing, via transesterification reactions 7.24E-14 19 214 
spliceosomal complex 5.99E-13 15 118 
mRNA processing 1.23E-12 20 288 
regulation of translation 2.63E-11 15 152 
posttranscriptional regulation of gene expression 2.89E-11 19 298 
translation initiation factor activity 1.14E-10 9 31 
eukaryotic translation initiation factor 3 complex 1.04E-09 7 15 
ribonucleoprotein complex assembly 1.07E-09 12 102 
cytoplasmic stress granule 1.40E-09 8 26 
catalytic step 2 spliceosome 1.51E-09 11 80 
ribonucleoprotein complex subunit organization 2.24E-09 12 109 
mRNA binding 2.57E-08 10 77 
translation factor activity, nucleic acid binding 3.82E-08 9 57 
ribosome assembly 1.13E-07 6 15 
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ncRNA metabolic process 1.44E-07 13 194 
ribonucleoprotein granule 5.16E-07 9 76 
ribosomal small subunit biogenesis 8.07E-07 6 20 
rRNA processing 8.93E-07 8 56 
ncRNA processing 8.93E-07 10 111 
rRNA metabolic process 1.77E-06 8 61 
U12-type spliceosomal complex 2.53E-06 6 24 
helicase activity 2.53E-06 8 64 
positive regulation of translation 3.92E-06 7 44 
double-stranded RNA binding 4.54E-06 7 45 
RNA helicase activity 8.25E-06 6 29 
single-stranded RNA binding 1.85E-05 6 33 
ATP catabolic process 7.77E-05 9 137 
ribonucleoside monophosphate catabolic process 8.41E-05 9 139 
purine nucleoside monophosphate catabolic process 8.41E-05 9 139 
purine ribonucleoside monophosphate catabolic process 8.41E-05 9 139 
nucleoside monophosphate catabolic process 8.81E-05 9 140 
poly(A) binding 9.26E-05 4 10 
ribonucleoprotein complex binding 1.16E-04 6 45 
ATPase activity 1.64E-04 10 197 
ATP metabolic process 2.31E-04 9 158 
poly-purine tract binding 2.94E-04 4 13 
regulation of mRNA stability 5.46E-04 5 33 
purine nucleoside monophosphate metabolic process 5.65E-04 9 177 
purine ribonucleoside monophosphate metabolic process 5.65E-04 9 177 
regulation of RNA stability 6.12E-04 5 34 
ribonucleoside monophosphate metabolic process 6.32E-04 9 180 
negative regulation of translation 7.09E-04 6 62 
nucleoside monophosphate metabolic process 8.44E-04 9 187 
ATPase activity, coupled 9.77E-04 8 143 
regulation of RNA splicing 9.89E-04 6 66 
negative regulation of RNA splicing 1.08E-03 4 18 
purine NTP-dependent helicase activity 1.63E-03 5 42 
ATP-dependent helicase activity 1.63E-03 5 42 
RNA-dependent ATPase activity 2.01E-03 4 21 
RNA stabilization 2.89E-03 4 23 
mRNA stabilization 2.89E-03 4 23 
protein folding 3.42E-03 7 124 
ATP-dependent DNA helicase activity 3.99E-03 4 25 
unfolded protein binding 4.43E-03 5 52 
mRNA 3'-UTR binding 4.59E-03 4 26 
translation regulator activity 5.31E-03 4 27 
DNA conformation change 5.63E-03 7 135 
regulation of mRNA processing 7.89E-03 5 59 
MHC protein complex binding 8.20E-03 3 11 
MHC class II protein complex binding 8.20E-03 3 11 
response to unfolded protein 1.26E-02 6 106 
regulation of mRNA splicing, via spliceosome 1.60E-02 4 36 
nuclear body 1.69E-02 7 162 
negative regulation of mRNA splicing, via spliceosome 1.70E-02 3 14 
telomeric DNA binding 1.70E-02 3 14 
response to topologically incorrect protein 1.72E-02 6 113 
DNA helicase activity 1.89E-02 4 38 
DNA duplex unwinding 2.51E-02 4 41 
negative regulation of mRNA processing 2.51E-02 3 16 
DNA geometric change 3.00E-02 4 43 
positive regulation of apoptotic process 3.95E-02 8 250 
ribosome binding 4.13E-02 3 19 
positive regulation of programmed cell death 4.43E-02 8 255 
mRNA 3'-end processing 4.56E-02 5 88 
ATP-dependent RNA helicase activity 4.71E-02 3 20 
regulation of translational initiation 4.74E-02 4 49 
positive regulation of cell death 6.12E-02 8 269 
DNA-dependent ATPase activity 7.81E-02 4 56 
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Table A-6: GO functional enrichment analysis of 52 human host proteins that are unique to 
DENV1/2 NS3. The Benjamini-Hochberg procedure was used to calculate the q-value (false discovery 
rate adjusted p-value) of each enriched GO feature. For each enriched GO feature that is associated 
with the generated interaction network, the number of proteins in the interaction network listed in that 
group, as well as the number of total proteins in the Homo sapiens proteome associated with the same 
GO feature. The table is arranged in order of increasing q-value. 
 
GO feature q-value Genes in network 
Genes in 
genome 
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 1.96E-47 31 116 
translational termination 3.55E-47 29 89 
mRNA catabolic process 1.33E-46 34 190 
translational initiation 2.95E-46 32 150 
nuclear-transcribed mRNA catabolic process 1.05E-45 33 179 
cytosolic ribosome 3.73E-45 28 90 
SRP-dependent cotranslational protein targeting to membrane 4.69E-45 29 107 
RNA catabolic process 4.69E-45 34 215 
protein targeting to ER 5.10E-45 29 108 
cotranslational protein targeting to membrane 5.10E-45 29 108 
establishment of protein localization to endoplasmic reticulum 6.30E-45 29 109 
viral gene expression 7.82E-45 28 94 
translational elongation 1.03E-43 28 102 
protein localization to endoplasmic reticulum 1.19E-43 29 120 
multi-organism metabolic process 1.67E-43 28 104 
cellular protein complex disassembly 4.78E-42 29 135 
ribosomal subunit 1.83E-41 28 121 
protein complex disassembly 4.30E-40 29 156 
protein targeting to membrane 4.98E-40 29 157 
viral transcription 6.73E-40 29 159 
viral life cycle 6.73E-40 29 159 
macromolecular complex disassembly 1.41E-39 29 163 
protein localization to membrane 7.22E-39 31 227 
cytosolic part 1.23E-38 28 151 
ribosome 2.63E-38 28 155 
establishment of protein localization to membrane 2.20E-37 31 253 
single-organism cellular localization 2.14E-36 31 272 
single-organism localization 2.14E-36 31 272 
protein targeting 2.38E-33 30 299 
structural constituent of ribosome 9.25E-32 22 97 
cytosolic small ribosomal subunit 1.59E-25 15 36 
small ribosomal subunit 3.14E-22 15 55 
cytosolic large ribosomal subunit 1.43E-18 13 51 
large ribosomal subunit 7.05E-17 13 67 
ribosomal small subunit biogenesis 1.32E-12 8 20 
ribosome biogenesis 2.14E-12 11 78 
rRNA processing 3.25E-12 10 56 
ncRNA metabolic process 3.96E-12 14 194 
rRNA metabolic process 7.70E-12 10 61 
ncRNA processing 1.07E-10 11 111 
ribonucleoprotein complex biogenesis 1.95E-10 12 158 
maturation of SSU-rRNA 1.50E-05 4 10 
polysome 4.05E-04 4 21 
regulation of translation 5.64E-04 7 152 
RNA 3'-end processing 7.54E-04 6 101 
establishment of RNA localization 5.58E-03 5 85 
nucleic acid transport 5.58E-03 5 85 
RNA transport 5.58E-03 5 85 
RNA localization 5.58E-03 5 84 
ribosome assembly 7.76E-03 3 15 
regulation of translational initiation 1.12E-02 4 49 
ribonucleoprotein complex assembly 1.27E-02 5 102 
nucleobase-containing compound transport 1.50E-02 5 106 
ribonucleoprotein complex subunit organization 1.69E-02 5 109 
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positive regulation of mRNA processing 2.03E-02 3 21 
RNA phosphodiester bond hydrolysis 2.59E-02 4 62 
posttranscriptional regulation of gene expression 3.43E-02 7 298 
RNA phosphodiester bond hydrolysis, endonucleolytic 5.18E-02 3 29 
RNA export from nucleus 5.45E-02 4 76 
translation initiation factor activity 6.13E-02 3 31 
nucleic acid phosphodiester bond hydrolysis 6.95E-02 5 151 
DNA strand elongation involved in DNA replication 7.84E-02 3 34 
mRNA 3'-end processing 8.98E-02 4 88 




Table A-7: GO functional enrichment analysis of 71 human host proteins that are unique to 
DENV1 NS5. The Benjamini-Hochberg procedure was used to calculate the q-value (false discovery 
rate adjusted p-value) of each enriched GO feature. For each enriched GO feature that is associated 
with the generated interaction network, the number of proteins in the interaction network listed in that 
group, as well as the number of total proteins in the Homo sapiens proteome associated with the same 
GO feature. The table is arranged in order of increasing q-value. 
 
GO feature q-value Genes in network 
Genes in 
genome 
ribonucleoprotein complex biogenesis 2.90E-10 14 158 
RNA splicing, via transesterification reactions 5.06E-10 15 214 
RNA splicing 7.77E-10 16 274 
spliceosomal complex 1.17E-09 12 118 
mRNA splicing, via spliceosome 2.19E-09 14 208 
RNA splicing, via transesterification reactions with bulged adenosine as 
nucleophile 2.19E-09 14 208 
mRNA processing 1.51E-07 14 288 
catalytic step 2 spliceosome 7.86E-06 8 80 
ribonucleoprotein complex assembly 4.38E-05 8 102 
ncRNA metabolic process 4.38E-05 10 194 
ribonucleoprotein complex subunit organization 6.72E-05 8 109 
ncRNA processing 7.11E-05 8 111 
ribosome biogenesis 1.04E-04 7 78 
maturation of 5.8S rRNA 2.79E-04 4 12 
rRNA processing 2.80E-04 6 56 
rRNA metabolic process 4.41E-04 6 61 
nucleolar part 1.37E-02 4 31 
preribosome 1.63E-02 3 11 
small nuclear ribonucleoprotein complex 1.95E-02 4 35 
ribosomal large subunit biogenesis 1.95E-02 3 12 
COPII vesicle coating 2.20E-02 3 13 
vesicle targeting, rough ER to cis-Golgi 2.20E-02 3 13 
COPII-coated vesicle budding 2.20E-02 3 13 





Table A-8: GO functional enrichment analysis of 41 human host proteins that are unique to 
DENV2 NS5. The Benjamini-Hochberg procedure was used to calculate the q-value (false discovery 
rate adjusted p-value) of each enriched GO feature. For each enriched GO feature that is associated 
with the generated interaction network, the number of proteins in the interaction network listed in that 
group, as well as the number of total proteins in the Homo sapiens proteome associated with the same 
GO feature. The table is arranged in order of increasing q-value. 
 
GO feature q-value Genes in network 
Genes in 
genome 
establishment of organelle localization 2.83E-14 14 136 
Golgi transport vesicle coating 2.83E-14 8 13 
COPI-coated vesicle budding 2.83E-14 8 13 
COPI coating of Golgi vesicle 2.83E-14 8 13 
organelle localization 9.32E-14 14 160 
vesicle targeting, to, from or within Golgi 9.32E-14 9 26 
single-organism membrane budding 9.32E-14 9 26 
Golgi vesicle budding 9.32E-14 8 15 
establishment of vesicle localization 1.69E-13 12 94 
vesicle localization 3.31E-13 12 100 
vesicle coating 5.69E-13 9 32 
vesicle targeting 9.70E-13 9 34 
COPI-coated vesicle membrane 3.94E-12 7 13 
COPI vesicle coat 3.94E-12 7 13 
retrograde vesicle-mediated transport, Golgi to ER 3.94E-12 8 24 
membrane budding 3.94E-12 9 40 
COPI-coated vesicle 2.18E-11 7 16 
Golgi-associated vesicle membrane 3.70E-11 8 31 
vesicle organization 2.96E-10 10 96 
membrane coat 8.38E-10 8 45 
coated membrane 8.38E-10 8 45 
Golgi-associated vesicle 1.39E-09 8 48 
vesicle coat 2.77E-09 7 30 
coated vesicle membrane 5.56E-07 8 100 
Golgi vesicle transport 7.96E-07 9 156 
cytoplasmic vesicle membrane 1.37E-06 10 231 
vesicle membrane 1.76E-06 10 238 
coated vesicle 3.48E-05 8 172 
intra-Golgi vesicle-mediated transport 9.25E-05 4 16 
Golgi membrane 1.31E-04 9 287 
protein N-linked glycosylation via asparagine 2.92E-04 6 96 
peptidyl-asparagine modification 3.01E-04 6 97 
protein N-linked glycosylation 4.16E-04 6 103 
dolichol-linked oligosaccharide biosynthetic process 1.93E-03 4 34 
nucleotide-sugar biosynthetic process 6.43E-03 3 15 
anterograde synaptic vesicle transport 6.43E-03 3 15 
microtubule-based transport 1.16E-02 4 54 
cytoskeleton-dependent intracellular transport 1.60E-02 4 59 
anterograde axon cargo transport 1.71E-02 3 21 
protein glycosylation 1.87E-02 6 208 
nucleotide-sugar metabolic process 1.87E-02 3 22 
macromolecule glycosylation 1.87E-02 6 209 
post-translational protein modification 1.87E-02 6 209 
glycosylation 2.20E-02 6 216 
axon cargo transport 3.22E-02 3 27 
translation initiation factor activity 4.81E-02 3 31 
glycoprotein biosynthetic process 5.96E-02 6 262 
mitotic nuclear envelope disassembly 7.54E-02 3 37 
membrane disassembly 7.54E-02 3 37 
nuclear envelope disassembly 7.54E-02 3 37 
microtubule-based movement 7.71E-02 4 96 
synaptic vesicle transport 7.71E-02 3 38 
establishment of synaptic vesicle localization 7.71E-02 3 38 
synaptic vesicle localization 9.50E-02 3 41 
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Table A-9: GO functional enrichment analysis of 9 human host proteins that are common to 
GFP-NS3 interaction networks of our and Carpp et al (Carpp et al., 2014). The Benjamini-
Hochberg procedure was used to calculate the q-value (false discovery rate adjusted p-value) of each 
enriched GO feature. For each enriched GO feature that is associated with the generated interaction 
network, the number of proteins in the interaction network listed in that group, as well as the number of 
total proteins in the Homo sapiens proteome associated with the same GO feature. The table is arranged 
in order of increasing q-value. 
 
GO feature q-value Genes in network 
Genes in 
genome 
protein folding 1.97E-17 13 124 
response to unfolded protein 2.84E-12 10 106 
response to topologically incorrect protein 3.66E-12 10 113 
protein refolding 6.41E-09 5 10 
'de novo' protein folding 1.49E-07 6 43 
unfolded protein binding 4.12E-07 6 52 
'de novo' posttranslational protein folding 7.09E-06 5 38 
microtubule 1.88E-04 6 149 
MHC protein complex binding 9.61E-04 3 11 
MHC class II protein complex binding 9.61E-04 3 11 
double-stranded RNA binding 1.03E-03 4 45 
chaperone-mediated protein complex assembly 1.07E-03 3 12 
chaperone-mediated protein folding 3.63E-03 3 18 
peptidyl-proline modification 1.20E-02 3 27 





Table A-10: Human proteins that were identified to co-elute with GFP-NS3 and GFP-NS5 in our 
study, and were also up- or down-regulated during DENV2 infection in Pando-Robles et al’s 
study (Pando-Robles et al., 2014). GFP and mock are excluded from the table since they were 
negative.   









Up-regulated (4)      
Aspartyl-tRNA synthetase, cytoplasmic  57 kDa 9 0 3 3 
Protein arginine N-methyltransferase 1  42 kDa 7 0 8 2 
Putative RNA-binding protein 3  17 kDa 4 0 3 5 
Matrin-3  95 kDa 19 0 18 10 
Down-regulated (12)      
Nuclease-sensitive element-binding protein 1 (YB-1)  36 kDa 7 0 6 5 
Putative pre-mRNA-splicing factor ATP-dependent RNA 
helicase DHX15  91 kDa 12 0 18 15 
Caprin-1  78 kDa 10 0 5 8 
Heterogeneous nuclear ribonucleoproteins C1/C2  34 kDa 6 0 5 3 
Heat shock 70 kDa protein 1A/1B  70 kDa 14 9 16 14 
Heat shock protein HSP 90-beta  83 kDa 3 3 7 4 
Interleukin enhancer-binding factor 3  95 kDa 25 0 19 17 
Splicing factor 3B subunit 3  136 kDa 2 0 42 21 
Tubulin alpha-1C chain  50 kDa 3 0 3 3 
Polyadenylate-binding protein  71 kDa 11 0 3 6 
Stress-70 protein, mitochondrial  74 kDa 16 4 10 10 





Table A-11: GO functional enrichment analysis of 12 human host proteins that are common to 
GFP-NS3 interaction networks of our and the down-regulated list of proteins during DENV2 
infection in Pando-Robles et al’s study (Pando-Robles et al., 2014). The Benjamini-Hochberg 
procedure was used to calculate the q-value (false discovery rate adjusted p-value) of each enriched GO 
feature. For each enriched GO feature that is associated with the generated interaction network, the 
number of proteins in the interaction network listed in that group, as well as the number of total 
proteins in the Homo sapiens proteome associated with the same GO feature. The table is arranged in 
order of increasing q-value. 
 
GO feature q-value Genes in network 
Genes in 
genome 
cytoplasmic stress granule 9.41E-06 5 26 
double-stranded RNA binding 5.70E-05 5 45 
RNA splicing 5.70E-05 8 274 
RNA splicing, via transesterification reactions 9.65E-05 7 214 
protein folding 9.65E-05 6 124 
RNA splicing, via transesterification reactions with bulged 
adenosine as nucleophile 9.65E-05 7 208 
spliceosomal complex 9.65E-05 6 118 
mRNA splicing, via spliceosome 9.65E-05 7 208 
ribonucleoprotein granule 2.77E-04 5 76 
mRNA processing 5.68E-04 7 288 
poly(A) binding 7.82E-04 3 10 
MHC protein complex binding 9.09E-04 3 11 
MHC class II protein complex binding 9.09E-04 3 11 
poly-purine tract binding 1.46E-03 3 13 
RNA stabilization 7.83E-03 3 23 
mRNA stabilization 7.83E-03 3 23 
U12-type spliceosomal complex 8.41E-03 3 24 
catalytic step 2 spliceosome 8.45E-03 4 80 
translation initiation factor activity 1.66E-02 3 31 
single-stranded RNA binding 1.82E-02 3 33 
regulation of mRNA stability 1.82E-02 3 33 
regulation of RNA stability 1.90E-02 3 34 
response to unfolded protein 2.02E-02 4 106 
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